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ABSTRACT 
PERTURBATIONS IN PROTEIN DYNAMICS ASSOCIATED WITH LIGAND 
BINDING TO THE BLOOD COAGULATION ENZYMES THROMBIN AND 
FACTOR XIII 
 
Thomas M Sabo, II 
 
December 13, 2007 
 
 
In blood coagulation, the serine protease thrombin is a multifaceted enzyme that 
interacts with multiple proteins.  Thrombin utilizes two anion binding exosites (ABE-I 
and II) to supplement binding to fibrinogen and to the platelet receptor GpIbα, two 
proteins instrumental in clot formation.  Approximately 7% to 15% of the fibrinogen γ 
chain exists as the highly anionic γ′ variant (410PEHPAETEYSDSLYSPEDDL427), which 
has been shown to bind ABE-II.  GpIbα possesses a similar anionic stretch of residues 
(269DEGDTDLYSDYSYSPEEDTEG286); however, the exact destination of thrombin 
binding is more ambiguous.  1D and 2D solution NMR have been employed to 
characterize the structural features of the bound γ′ and GpIbα peptides.  The results 
indicate that the γ′ residues A414-L427 make significant contact with the enzyme, a turn is 
present between residues YS422-D425, and there is a hydrophobic cluster involving YS418-
YS422.  For the GpIbα peptide, NMR results suggest the peptide exists in an extended 
conformation with residues D274-E285 contributing to binding.  Hydrogen deuterium 
exchange (HDX) coupled with MALDI-TOF MS indicate that at a 20:1 peptide-enzyme 
ratio both peptides are interacting with residues within ABE-II fragments.  Both peptides 
 vii 
affect the dynamics of HDX for regions not associated with ABE-II including ABE-I, the 
autolysis loop, and the A-chain.  Curiously, at 40:1 GpIbα peptide to thrombin, the 
GpIbα peptide appears to interact with ABE-I, with unique allosteric consequences. 
Thrombin also activates FXIII, and the resultant transglutaminase covalently crosslinks 
fibrin through the formation of isopeptide bonds.  Studies were performed to examine the 
effects of activation and inhibition on the conformational dynamics of FXIII using 
MALDI-TOF MS.  A peptide-based FXIIIa inhibitor has been developed with the 
glutamine isostere 6-diazo-5-oxo-norleucine (DON).  The K9 DON peptide blocks 
chemical modification of C409 within the catalytic core and promotes significant HDX 
protection for the β barrel 1 fragment 526-546.  These results suggest that inhibition of 
FXIIIa leads to local and long-range effects on protein dynamics.  Finally, thrombin 
activation of FXIII appears to influence regions near the activation peptide, and Ca2+-
activated FXIII presents more evidence for the existence of additional Ca2+ binding sites.  
Ultimately, these studies further detail the dynamic nature of thrombin and FXIII.          
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CHAPTER I 
INTRODUCTION 
Overview of Blood Coagulation 
One of the most precious physiological tissues exists in the fluid state.  Blood 
travels throughout the body and is maintained in the vasculature.  A multifaceted 
substance, blood serves as a transport system for cellular components, proteins, nutrients, 
hormones, and waste.  Blood shuttles red blood cells to and from the lungs, where 
hemoglobin loads oxygen for aerobic metabolism in cells and deposits the waste product 
carbon dioxide.  In the case of infection, blood transports white blood cells to the site of 
the foreign invasion.  The white blood cells then attack the threat.  Thus, the vitality of 
life clearly depends on maintaining blood in an unimpeded fluid state and in an enclosed 
network of highways (the blood vessels) that connect even the most distant regions of the 
organism (1, 2).   
When a vascular breach or damaged tissue is present, circulating platelets and 
proteins are ready to quickly seal the leak in a process termed coagulation.  Unchecked 
clotting, however, could potentially lead to a life threatening obstruction of blood flow, 
termed thrombosis.  Through evolutionary processes, life has developed a tightly 
regulated system of clot formation and degradation, involving cells, proteins, sugars, 
electrolytes and other molecules.  Further elucidation into the mechanisms of blood 
coagulation will eventually open new avenues for treatment of hypertension, heart 
disease, and hemophilia (1, 2). 
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The classical view of blood coagulation as a cascade of events separated into two 
pathways that converge with the activation of Factor X (FX) is presented in Figure 1.  
Tissue damage leads to activation of the extrinsic, or tissue factor (TF), pathway (3, 4).  
Physiologically, this pathway is the most prompt route for wound healing.  The 
components of the intrinsic, or contact factor, pathway all reside within the circulating 
plasma (5).  Initiation of this branch of 
coagulation requires more time for full 
activation.  A few perplexing issues 
exist regarding this model of blood 
clotting.  The main quandary deals 
with the absence of any blood clotting 
deficiencies in patients with low levels 
of FXII (6).  However, FVIII and FIX 
from the intrinsic pathway are 
absolutely essential for coagulation, 
since patients lacking sufficient levels 
of these proteins in the plasma suffer 
from hemophilia (7).  Finally, a dearth 
in FVII from the extrinsic pathway also produces severe clotting disorders illustrating 
that the intrinsic pathway alone cannot support effective wound healing (8).  These 
observations exemplify the interrelatedness of both pathways and suggest that 
coagulation should not be thought of as two separate conduits but a more integrated 
process without clear pathway demarcations. 
Figure 1:  Classical view of blood coagulation. 
The cascade is separated into the intrinsic and 
extrinsic pathways.  Adapted from a poster by 
Enzyme Research Laboratories, South Bend, IN. 
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Recent proposals from Hoffman 
and Monroe attempting to rationalize 
the clinical observations 
contradicting the view of coagulation 
as two pathways have developed the 
cell-based model of haemostasis (9, 
10).  In this scheme, coagulation is 
separated into three stages, initiation, 
amplification, and propagation (11).  
Figure 2 presents the extrinsic and 
intrinsic pathways in terms of the 
cell-based model of coagulation.  
Regardless of whether this model or 
the classical views of the coagulation 
cascade are accurate representations 
of blood clotting, the complexity of 
thrombus formation should be readily 
apparent with a cursory glance at 
Figures 1 and 2.  In an effort to present blood coagulation with a fresh perspective, the 
process of clot formation, regulation, and, ultimately, lysis will be discussed in terms of 
the cell-based model of Hoffman and Monroe. 
Proper synthesis of prothrombin, FVII, FIX, and FX calls for vitamin K which is a 
cofactor in the conversion of glutamic acid to γ-carboxyglutamic acid (Gla) (12).  These 
Figure 2:  Blood coagulation according to  
Monroe and Hoffman (9-11).  The classical view of 
blood coagulation separates the process into two distinct 
pathways converging on the activation of FX.  The cell-
based model of blood coagulation emphasizes the 
interrelatedness of both pathways as described in the 
text.  In this figure, procoagulation events are depicted in 
relation to the cell surface on which they occur.   
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proteins’ Gla domains reside at the N-termini and provide the site for interaction with the 
surface of cell membranes involved with blood coagulation.  Binding to the phospholipid 
membranes has the additional requirement of calcium.  Ca2+ serves to stabilize the Gla 
domains of these vitamin K-dependent proteins and to bridge the negatively charged 
phospholipid membrane to the negatively charged Gla domains of the proenzymes (13).  
Without the Gla domains, successful initiation of blood coagulation is significantly 
hindered.  In the following discussion of coagulation, productive activation and/or 
function of prothrombin, FVII, FIX, and FX all require Ca2+ and a cell surface. 
The initiation phase of clotting is characterized by the preparation of extravascular 
cells for an appropriate response to tissue damage.  TF bearing cells typically exist 
outside the vasculature, i.e. subendothelial tissue.  TF is a transmembrane protein 
formally known as FIII.  It should be noted that TF also resides in the blood, although the 
physiological significance of the circulating TF has yet to be determined (3).  Even in the 
absence of vascular injury, several clotting factors are able to diffuse into the 
extravascular space.  Some of the TF forms a complex with the serine protease FVIIa that 
can successfully activate FIX and FX in small quantities (14).   
The low levels of FXa are able to activate FV and FVII present on TF bearing cells 
(15).  The resulting prothrombinase complex (FVa/FXa) can convert prothrombin to 
thrombin (IIa) (3).  Like FXa, IIa also can activate FVII (16).  These events explain the 
basal level of active coagulation factors that are present in normal individuals.  
Fortunately for proper haemostatic balance, once FXa diffuses from the TF bearing cell 
and returns to the blood stream, antithrombin and the TF pathway inhibitor (TFPI) 
inactivate the protease (17).  An explanation for the lack of full blown clotting resides in 
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the sizes of the FVIII/von Willebrand factor (vWF) complex and platelets which 
effectively minimizes the amount of diffusion that can occur, maintaining these 
coagulation factors in the vasculature (18). 
Amplification of clotting commences when damage to the endothelium allows 
platelets, which are circulating in the blood, to contact the exposed tissue.  Platelets 
adhere to collagen and other extracellular matrix components that are available at the site 
of tissue damage (19).  Adhesion of platelets to the damaged tissue only partially 
activates the blood cells.  IIa activated by TF bearing cells during the initiation phase can 
now cleave the protease activated receptors (PARs) leading to the activation of platelets 
(20).  FVIII/vWF binds to the platelet surface and activation of FVIII by IIa releases vWF 
(18, 21).  IIa also activates FV (22) and FXI (23) located on the platelet membrane.  The 
ability of IIa to activate FXI on the activated platelet surface alleviates the requirement 
for FXII, high molecular weight kininogen (HK), and prekallikrein (PK) for FXI 
activation (10).  This point is highlighted because in the classical model of coagulation, 
FXII, HK, and PK initiate intrinsic coagulation through activation of FXI (24).  As 
evident in the amplification phase, the small amount of available IIa primes the system 
for full-blown thrombin activation and clot formation (9-11). 
 In the final phase of coagulation, a burst of IIa generation is evident as well as a 
propagation of procoagulant activities through positive feedback mechanisms.  The low 
levels of FIXa from the initiation phase forms the tenase complex with FVIIIa on the 
platelet surface (25-27).  FXIa bound to the platelet membrane generates additional 
activated FIX (28, 29).  Since FXa produced on TF bearing cells is unable to effectively 
travel to the platelets, the tenase complex activates FX on the platelet surface (9-11).  
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FXa associates with FVa forming the prothrombinase complex, which catalyzes the 
conversion of prothrombin to IIa (3).  Monroe and Hoffman emphasize that the platelet 
surface is the only cell adequately designed to support tenase and prothrombinase 
complex formation concurrently (9-11).  In hemophilia, deficient quantities of FVIII or 
FIX on the platelet surface severely limit that amount of thrombin activated at the site of 
injury (7, 30, 31).  Though TF bearing cells can activate thrombin, this pathway is 
insufficient in alleviating the loss of the tenase complex formation on platelets (9-11).   
 At the nexus of procoagulation and anticoagulation resides the most important 
coagulation protein thrombin (32-34).  The procoagulant activities of thrombin are 
multifaceted and numerous.  Thrombin converts fibrinogen to fibrin which associates 
non-covalently to form the soft clot (35).  Stabilization of the growing fibrin clot is 
provided by IIa-activated FXIII, a transglutaminase that forms covalent linkages between 
neighboring fibrin molecules (36, 37), and thrombin-activatable fibrinolysis inhibitor 
(TAFI), a metalloprotein that protects the growing clot from degradation (38).  In 
addition, thrombin participates in procoagulant positive feedback by activating FV (22), 
FVIII (18), and FXI (39).  Finally as mentioned earlier, several platelet receptors are 
cleaved by this serine protease leading to the activation of platelets (20). 
Obviously, unchecked coagulation would be fatal due to the cessation of blood 
circulation.  The activation of the anticoagulant protein C (PC) by IIa is accelerated when 
IIa encounters the glycoprotein thrombomodulin on the surface of endothelial cells (40).  
Activated PC turns off IIa production by cleaving FVa and FVIIIa disrupting productive 
tenase and prothrombinase complex formation (41).  Inhibition of coagulation proteases 
by the serpin antithrombin is another method for shutting down coagulation (42).  The 
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glycosaminoglycan (GAG) heparin enhances successful inhibition of these proteases with 
antithrombin, with the acceleration of thrombin inhibition augmented up to 1000-fold 
(43).  Heparin cofactor II is another serpin that specifically targets IIa, with inactivation 
improved in the presence of GAGs (44). 
Clots exist as temporary solutions to repairing wounds and eventually degradation 
occurs by the fibrinolytic system.  Tissue-type plasminogen activator (tPA) and 
plasminogen are the major players in this process.  Activation of plasminogen to plasmin 
results from ternary complex formation between tPA, plasminogen, and fibrin (45).  
Active plasmin proceeds to hydrolyze fibrin at specific sites within the clot, ultimately 
leading to the dissolution of the clot (35).  To prevent premature clot lysis, several 
proteins inhibit the protease plasmin.  α2-antiplasmin not only acts as an inhibitor of 
plasmin, the protein also blocks the binding of plasminogen to the fibrin clot preventing 
activation of the fibrinolytic protease (46).  FXIIIa acts to covalently crosslink α2-
antiplasmin into the growing clot another preventive measure against unwarranted 
fibrinolysis (36).  The serine protease plasminogen activator inhibitor type 1, when bound 
to fibrin, inhibits tPA and thus plasminogen activation (47).  As mentioned previously, 
TAFI activated by the thrombin/thrombomodulin complex serves as another mechanism 
for the prevention of clot lysis (38).   
Only a brief summary has been presented of the processes that encompass blood 
coagulation.  The majority of the projects described in this dissertation focus on the 
proteins located at the end of coagulation, specifically thrombin and FXIII.  A more 
detailed analysis of the relevant features associated with these proteins will be discussed 
in the following sections.  With regard to thrombin, the research undertaken has 
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examined peptide interactions at anion binding exosite II of this serine protease.  These 
peptides are derived from sequences that exist in fibrinogen and GpIbα.  Therefore, a 
more in depth view of these proteins will be presented in context to interactions with IIa.  
The Most Important Coagulation Protease:  Thrombin 
Circulating in the blood stream and awaiting activation by the prothrombinase 
complex is the 579-residue zymogen 
prothrombin (48, 49).  Prothrombin is a 
glycoprotein that is synthesized in the liver 
and circulates in the blood stream at ~1.2 
µM.  The zymogen possesses several 
domains including an N-terminal Gla 
domain, two kringle domains, and a 
proteolytic domain that is dormant until 
activation.  Within the Gla domain, 10 
glutamic acids residues are converted to γ-
carboxyglutamic acid through vitamin K-
dependent mechanisms.  Kringle domains 
are so named due to their resemblance to 
the Danish pastry.  These structures form 
large loops that are stabilized by three 
disulfide bonds.   
Conversion of prothrombin to α-thrombin (IIa) proceeds through several proteolytic 
steps (see Figure 3) catalyzed by the prothrombinase complex (FXa/FVa) in the presence 
Figure 3:  Schematic of the conversion of 
prothrombin to thrombin.  Depicted are the 
various IIa precursors and autolytic products. 
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of Ca2+ on either the platelet surface or on a TF bearing cell (reviewed in 49).  FXa 
hydrolyzes two peptide bonds, though the order of cleavage has yet to be established.  
Proteolysis at R320-I321 results in meziothrombin with fragment 1.2 and the A-chain 
associated to IIa’s proteolytic domain through a disulfide bond (C1-C122 in chymotrypsin 
numbering, see below).  Prethrombin 2 is formed when FXa first hydrolyzes R271-T272 
leading to dissociation of fragment 1.2.  When FXa cleaves the second bond, α-IIa is 
produced with the A-chain associated to the B-chain through a disulfide linkage.  Once 
α-IIa possesses catalytic activity, autolysis of the A-chain residues R284-T285 yields 
mature α-IIa.  α-IIa is 37.5 kDa with six α-helices, two β-sheets, and four disulfide 
bonds (50).  One of the disulfide linkages is between the A and B-chains, while the 
remaining disulfide bonds are all within the B-chain. 
For ease of comparison to other members of the serine protease family, α-IIa 
residue numbering is referenced relative to chymotrypsin (51).  When describing residues 
in loops that are unique to IIa or just single amino acid insertions that are not present in 
chymotrypsin, a letter follows the number of the last common residue.  For example, two 
important loops are specific to IIa and begin from the last common residue shared 
between the two proteases.  The β insertion loop begins at 60 and continues with 60A, 
60B, etc.  The autolysis loop starts from 149, and continues from 149A, 149B, and so on.  
The N-terminus of IIa’s A-chain possesses eight additional residues when compared to 
chymotrypsin.  Thus, A-chain numbering begins at 1H and continues 1G, 1F, etc.  It 
should be noted that bovine α-IIa lacks an autolytic site within the A-chain.  Therefore, 
bovine α-IIa possesses an additional 22 residues at the N-terminus when compared to 
chymotrypsin and 13 residues when compared to human α-IIa. 
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The primary catalytic machinery of all serine proteases is conserved in the catalytic 
triad of residues H57, D102, and S195 (Figure 4A) (52).  With IIa, the promiscuity observed 
with trypsin hydrolysis of anything containing an R or K at P1 (as long as a proline is not 
present at P1′) is not evident.  The P nomenclature system assigns P1-P1′ as the 
Figure 4:  Structure of the serine protease thrombin (1PPB) (51).  A. Location of the relevant features 
of thrombin described in the text.  The catalytic triad is in yellow, the 60 loop is in light brown, the 
residues involved in the S4 site are orange, the autolysis loop is red, the Na+ binding loop is pink and 
the A-chain is cyan.  B. Location of ABE-I and ABE-II in relation to Y60a-Y60d (yellow).  ABE-I is 
orange and ABE-II is red. 
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hydrolyzable bond.  Residues N-terminal to P1 are designated P2, P3, etc. and residues C-
terminal to P1′ are P2′, P3′, etc.  Sites within the enzyme that interact with substrate are 
given the corresponding number, i.e. P2 binds to the S2 site in IIa.   
IIa’s specificity is a result of the loops and residues that surround the catalytic triad 
(reviewed in 48).  IIa hydrolyzes the protein backbone primarily after R, although K and 
F at the P1 position can also act as less efficient substrates.  At the P2 position, IIa prefers 
small and hydrophobic residues that can interact effectively with the 60-loop defined by 
Y60A, P60B, P60C, and W60D (S2 site).  The P3 position is not a determinant for specificity 
since this residue does not interact with the IIa surface.  The aryl binding site (S4 site) is 
created by L99, I174, and W215 leading to a preference for hydrophobic, aromatic residues.  
The γ-loop, or autolysis loop (149-149E), is a flexible, hydrophilic surface loop that is 
involved in determining substrate specificity C-terminally to the scissile bond. 
To this point, the discussion has focused on α-IIa, but several autolytic sites exist in 
IIa (Figure 3) (reviewed in 49).  Since α-IIa in vivo is rapidly inhibited by a multitude of 
serpins, these forms of IIa probably do not have physiologic significance.  α-IIa that is 
isolated in solution over time will hydrolyze several bonds.  The first such proteolytic 
event leads to the generation of β-IIa.  Cleavage of R77A-N78 exposes the peptide bond 
R67-I68 to IIa hydrolysis resulting in the excision of the peptide I68-R77A.  Further catalysis 
of K149E-G150 in the flexible autolysis loop produces γ-IIa.  It should be noted that bovine 
β-IIa can be produced by autolysis; however, a non-conservative substitution of E for K 
at position 149E prevents formation of bovine γ-IIa (51).  These autolytic events do not 
affect catalysis of small chromogenic substrates, but significantly reduces the amount of 
fibrinogen that is converted to fibrin due to the disruption of fibrinogen binding (53).  
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An important allosteric activator of IIa is sodium (54).  The binding loop is located 
near the S1 pocket (see Figure 4A).  Na+ coordination involves the carbonyl groups of 
R221A and K224 as well as four water molecules and the bound cation is situated 15 Å from 
the active site (55).  Additional stabilization of Na+ is provided by D221 and D222.  When 
Na+ is bound to IIa, the protease is referred to as being in the fast form defined by a more 
open and rigid structure, while IIa lacking coordinated Na+ is in the slow form 
characterized by a more closed and flexible structure (56).  Procoagulation is favored by 
the fast form, where cleavage of fibrinogen and PAR-1 are significantly enhanced in the 
presence of Na+ (57).  Cleavage of PC with thrombomodulin as a cofactor occurs with 
greater ease in the slow form (58).  Since the concentration of Na+ remains tightly 
regulated at 140 mM in the blood circulation, the partition of fast and slow form IIa in 
vivo will not deviate from a ratio of 3:2 based on the KD of 110 mM (54).  Whether Na+ 
acts as an allosteric regulator physiologically is an open debate; however, bound Na+ 
does result in conformational and catalytic changes for IIa (54, 59). 
Thrombin contains two exosites that are located on opposing faces of the serine 
protease flanking the catalytic site (51) (Figure 4B).  These highly electropositive patches 
are termed anion binding exosites I and II (ABE-I and ABE-II).  An exosite is a ligand-
protein interface that is distinct from the residues involved in catalysis.  Exosite functions 
include guiding substrate orientation for catalysis that is more efficient and/or providing a 
separate cofactor interaction site that either enhances or dampens enzyme reactivity.  
Selected residues from ABE-I include K36, R67, R73, R75, R77A, K81, K109, K110, and K149E.  
ABE-I aides in the activation of fibrinogen, PAR-1, FV, FVIII, and FXI, binds the 
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inhibitors hirudin and heparin cofactor II, and interacts with thrombomodulin which 
switches thrombin’s specificity toward the anticoagulant PC (34, 48).   
Table 1:  Sequences of Selected ABE-II Binding Sitesa,b 
Fibrinogen γ′            408VRPEHPAETEYSDSLYSPEDDL427                 
GpIbα                269DEGDTDLYSDYSYSPEEDTEG286                   
FVIII                         341EEAEDYSDDDLTDSEM355               
aAnionic residues are in bold. 
bThese human ABE-II binding sequences were taken from the following sources:  
fibrinogen γ′ (60, 61), GpIbα (62), and factor VIII (63). 
 
ABE-II is more electropositive than ABE-I and encompasses R93, R97, R101, R126, 
R173, R175, R233, K235, K236, and K240.  The glycosaminoglycan heparin interacts with 
ABE-II and plays an important role in inhibition of thrombin by the serpins antithrombin 
(64) and heparin cofactor II through ternary complex formation.  FV and FVIII binding to 
both ABE-I and ABE-II may serve to further enhance activation of these two cofactors 
(65).  A recent crystal structure of haemadin and thrombin demonstrates the necessity of 
both ABE-II and the active site for this inhibitory interaction (66).  On the surface of 
platelets, the association of GpIbα with ABE-II accelerates thrombin activation of PAR-1 
and FXI, while reducing the rate of fibrinopeptide A release from fibrin (67, 68).    
Finally, a C-terminal variant of the fibrinogen γ chain (termed the γ′ chain) has been 
demonstrated to bind to ABE-II (69, 70).  Table 1 shows a selection of sequences from 
proteins that interact with ABE-II. 
In a significant number of the previously described ABE interactions, sulfonation 
appears to be an important element in ligand binding to IIa.  In 1954, Bettelheim first 
reported the presence of sulfonation in a blood coagulant protein at Y6 of the bovine 
fibrinogen Bβ chain (71).  This modified residue probably aids in interaction of the Bβ 
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chain with the extended active site region, and possibly ABE-II.  Other well known 
sulfonated ligands are the ABE-I binding active site inhibitor hirudin (72) and the ABE-II 
targeting heparin sulfate (73).  The ABE-II binding sequences of γ′ chain (60, 61), GpIbα 
(62), and FVIII (63) all display an intense clustering of YS, D, and E (Table 1). 
The conformational features associated with the interaction of the acidic C-terminal 
tails of fibrinogen and GpIbα with ABE-II are described in later chapters.  Both of these 
proteins utilize ABE-II for recruitment of IIa to the site of vascular injury and clot 
formation.  In addition, the proteins may play a role as cofactors in the cleavage of IIa’s 
target proteins.  The following sections describe these two proteins in further depth.  
Glycoprotein Ibα 
Residing on the surface of platelets is the transmembrane receptor complex 
GpIbα/β-GpIX-GpV (74-77).  The importance of this protein complex in blood 
coagulation is highlighted in Bernard-Soulier syndrome, a bleeding disorder resulting 
from either dysfunctional or low levels of GpIbα/β-GpIX-GpV.  Disulfide bonds 
covalently link GpIbα (140 kDa) to GpIbβ (27 kDa) recently discovered to exist at a 1:2 
ratio (78).  GpIX (22 kDa) is non-covalently associated with GpIbα/β.  The final 
component of the receptor complex is GpV (82 kDa), which forms a 1:2 complex with 
GpIbα/β-GpIX.  GpIbα is a member of the leucine rich repeat (LRR) family (Figure 5).  
The receptor also has the following structural components C-terminally to the LRR 
domain:  a couple of loop structures linked by a disulfide bond, a highly glycosylated 
mucin-like stem, a transmembrane domain, and a cytoplasmic region (79, 80).   
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Within the platelet receptor complex, the N-terminal region (1-290) of GpIbα is the 
major site of ligand binding.  The macrophage antigen-I (Mac-I) (81) and the cell 
adhesion molecule P-selectin (82) bind GpIbα leading to the recruitment of leukocytes to 
a site of infection resulting in vascular inflammation.  GpIbα interacts with FXI (83), 
FXII (84), and HK (85, 86), bringing these proteins to the platelet surface and amplifying 
coagulation.  Adhesion of platelets to sites of damaged tissue is the primary role for 
GpIbα binding to vWF under high-shear.  When vWF interacts with GpIbα, the 
transmembrane complex is primed to begin intracellular signaling achieving an increase 
in Ca2+ in the cytosol, degranulation, rearrangement of the cytoskeleton, and activation of 
the platelet aggregating integrin αIIbβ3 (75, 77).  GpIbα assists thrombin in the 
activation of PAR-1 (67) and FXI (83).  GpIbα may also aid cleavage of GpV by 
thrombin, though the exact function of GpV proteolysis has yet to be established.  GpV 
could sterically hinder thrombin binding to and activation of platelets (87, 88) and/or be 
involved in the adhesion of platelets to collagen (89). 
Figure 5:  Structure of glycoprotein Ibα (1-266) (1P9A) (96).  The highly anionic C-terminal tail 
(269-286) is not modeled in this structure.  The most prominent feature of the structure is the leucine 
rich repeat domain that forms the curvature of the protein.   
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Considerable interest has been directed toward understanding in more detail the 
nature of the GpIbα-IIa interaction in solution (90).  The sequence within GpIbα that is 
responsible for binding thrombin has been localized to the C-terminus of the N-terminal 
fragment (1-290) between residues (269DEGDTDLYSDYSYSPEEDTEGD287)  (Table 1) 
(91).  Mutagenesis studies have identified the ABE-II residues R93, R97, R101, R233, K236 
and K240 as playing a role in binding, while the ABE-I residues R67, R73, R75, R76, and 
R77A did not appear to be involved in the interaction (23, 68, 92).  In the mutagenesis 
work, the indicated residues were usually mutated to alanine and the effect of the 
mutation on the KD was determined. 
Though the evidence for ABE-II as the primary destination for GpIbα is strong, 
others have identified ABE-I as the site of interaction through competitive inhibition with 
hirudin but not with heparin (93-95).  Yet, heparin inhibits GpIbα binding to IIa’s ABE-
II and not hirudin (68).  Adding to the confusion, two independent crystal structures of 
IIa-GpIbα (residues 1-279/284) were published in Science (96, 97).  The Dumas structure 
displays GpIbα residues 269-279 exclusively interacting with ABE-II, while the Celikel 
structure illustrates residues 269-284 binding to both ABE-II and ABE-I through IIa 
dimerization.  The reasons for the discrepancies in results have yet to be resolved. 
The KD values calculated for this interaction are highly salt dependent, which is 
characteristic of ABE-II binding.  At 100 mM Na+, the KD ranges from 102 nM to 187 
nM, while at 150 mM Na+ this value increases to 1 µM (68, 92).  Li et al. calculated a salt 
dependence of Γsalt = -4.2, which indicates at least 4 salt bridges for GpIbα-IIa (68).  This 
value is in good agreement with an independent assessment of the salt dependence for 
GpIbα-IIa (98), as well as for the nonspecific ABE-II ligand heparin (99).   
 17 
The efficiency of thrombin catalysis is affected by GpIbα exosites binding.  Release 
of fibrinopeptide A (FpA) is noncompetitively inhibited by GpIbα (68), while PAR-1 
hydrolysis is enhanced by GpIbα binding to IIa (67).  Curiously, other groups have 
attributed GpIbα inhibition of FpA hydrolysis to competitive inhibition at ABE-I (100, 
101).  Based on recent mutagenesis data involving IIa, it seems more likely that inhibition 
is occurring through ABE-II and not ABE-I (68, 92).  GpIbα leads to decreased catalysis 
at R372 in FVIII presumably due to competition for binding at ABE-II (65).  These 
examples emphasize the importance of ligand binding to ABE-II on catalytic activity and 
the allosteric nature of the interaction.            
Though GpIbα plays an important role in platelet aggregation, the protein 
fibrinogen provides an equally important function in clot formation.  Like GpIbα, 
fibrinogen has been demonstrated to bind ABE-I and ABE-II.  In this instance, solid data 
exists illustrating that fibrinogen interacts with both exosites, perhaps simultaneously.     
Fibrinogen 
The large soluble glycoprotein fibrinogen (340 kDa) is a dimer comprised of three 
domains (AαBβγA)2 existing as coiled coils in the shape of a dumbbell (35, 102) (Figure 
6).  The N-termini of all six polypeptide chains are located in the central E-region of 
fibrinogen, supplying a low affinity binding site for thrombin via ABE-I (103).  The C-
termini of the polypeptide chains reach laterally from the E-region to form the flanking D 
regions.  During coagulation, thrombin cleaves fibrinopeptides A and B from the N-
terminus of α and β chains, respectively.  This action converts fibrinogen to fibrin 
(αβγA)2, initiating formation of the noncovalently associated soft clot. 
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There are two variants of the γ chain C-terminus extending outward from the D 
regions (104, 105).  The γA chain terminates with four amino acids (408AGDV411) and 
interacts with platelets through residues 400-411 (106).  The γ′ chain results from a 
mRNA splice variant due to alternative processing and replaces the last four residues of 
the γA chain with an insertion of 20 amino acids (408VRPEHPAETEYSDSLYSPEDDL427) 
(107, 108) (Table 1). About 7% to 15% of all fibrinogen exist as the γA/γ′ heterodimer as 
opposed to the γA/γA homodimer (109, 110).  
Meh et al. demonstrated that the D-region of fibrinogen γA/γ′ contained a high 
affinity binding site for thrombin with a KD of 0.26 µM (111).  Further work implicated 
the γ′ residues A414-L427 as essential to the high affinity interaction, although the exact 
Figure 6:  Schematic diagram depicting the structure of fibrinogen and clot formation.  Thrombin 
cleavage of fibrinopeptides A and B (orange and green) lead to soft clot formation and FXIIIa 
catalyzes covalent intermolecular crosslinks making the clot more resistant to fibrinolysis. 
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location of the γ′ chain interface on thrombin was unclear (60).  Subsequent competitive 
fluorescent binding studies localized γ′ peptide binding to ABE-II with a KD in the 0.63–
2.2 µM range for residues V408-L427 (69, 70).  Replacement of the YS with F in the γ′ 
region of fibrin abolishes IIa binding (69).  A combination of heparin, hirudin fragments, 
and DNA aptamers targeting ABE-I and II were employed to verify the site of interaction 
(69, 70).  An aptamer is a short oligonucleotide sequence (20-30 bases) that has been 
selected to bind a target protein with high affinity (112).  
The presence of elevated levels of the heterodimer γA/γ′ has been linked to 
increased incidence of cardiovascular diseases.  As with GpIbα, the γ′ chain decreases the 
rate of FpA hydrolysis (113) in this case leading to a fibrin network that possesses many 
more offshoots with thinner fibers (113, 114).  Fibrin clots formed in this manner are less 
susceptible to fibrinolysis (110, 113).  Fibrin enhanced FXIII activation is slightly slower 
when the γ′ chain binds to ABE-II (113) suggesting that the levels of  γ′ chain variant 
present in fibrinogen has a significant impact on the regulation of coagulation (115). 
The γ′ chain of fibrinogen has also been demonstrated to be a carrier of plasma 
Factor XIII (A2B2) via the FXIII B2-subunits (116).  Like fibrinogen, IIa also activates 
FXIII at the conclusion of procoagulation.  Several issues have yet to be resolved 
regarding FXIII activation and substrate recognition.  For instance, a high degree of 
similarity exists between the structures of FXIII and FXIIIa (117-119).  Therefore, the 
conformational transition resulting from activation that enables FXIIIa to perform 
catalysis is unclear.  In the following section, the role FXIII plays in blood coagulation is 
described in more detail, as well as some of the questions that need to be addressed in 
relation to this transglutaminase. 
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The Transglutaminase Factor XIII 
FXIII (83 kDa) shares the same primarily β sheet architecture of the other known 
transglutaminases (TGases) (119).  The five principal structural elements of the TGase 
family are depicted in Figure 7A:  the activation peptide (1-37), the β sandwich (residues 
38-183), the catalytic core (residues 184-515), and the β barrel 1 (residues 516-627) and 
β barrel 2 (residues 628-731) domains.  The active site architecture for both cysteine 
proteases and TGases are quite similar, consisting of the catalytic triad C314, H373, and 
D396 (FXIII numbering) (Figure 7B); however, the proposed mechanism of TGases is the 
reverse of cysteine proteases (119, 120).  The only TGase to exist as a dimer is FXIII, 
with key interchain interactions between K113-D367′, K257-E401′, and R260-D404′ (Figure 7B). 
FXIII circulating in the plasma possesses an additional dimer that serves a 
regulatory function.  Upon activation of FXIII by thrombin, the regulatory B2 subunits 
dissociate from the catalytic A2 subunits in the presence of 1 mM Ca2+ (121).  In the 
platelets and the placenta, FXIII lacks the B2 subunits and is termed cellular FXIII (122).   
The A2 dimer from plasma and cellular FXIII is equivalent in structure and function. 
Catalytically competent FXIIIa is achieved when IIa cleaves the N-terminal 
activation peptide at R37-G38 and at least 1 mM Ca2+ is present (referred to as FXIIIaIIa) 
(123, 124).  FXIIIa catalyzes the formation of isopeptide bonds between Q and K 
residues and the catalytic mechanism is illustrated in Figure 8 (125).  These covalent 
bonds act to stabilize the growing fibrin clot.  Furthermore, FXIIIa aids in protecting the 
clot from plasmin degradation through the incorporation of substrates, like α2 antiplasmin 
(126), to the fibrin matrix.  After proteolysis by IIa, the activation peptide remains non-
covalently associated with FXIIIa and transverses both monomers (Figure 7A) (118).  A 
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secondary thrombin cleavage site is located near the division of the catalytic core and β 
barrel 1 (127).  Proteolysis of K513-S514 reduces the affinity of FXIIIa for Q and K 
containing substrates, however the catalytic machinery of the TGase is not perturbed 
(128).  Curiously this cleavage has no effect on FXIIIa binding to fibrin (128). 
Figure 7:  Structure of the transglutaminase Factor XIII (1FIE) (118).  A. FXIII depicted as the A2 
dimer.  Regions include the activation peptide (red), β sandwich (blue), catalytic core (green), β 
barrel 1 (cyan), and β barrel 2 (orange).  The catalytic triad (C314, H373, and D396) is in pink.  The two 
Q substrate recognition sites peptide 4 (β sandwich) and peptide 7 (catalytic core) are purple and 
yellow respectively.  The potential K substrate recognition site in β barrel 2 is light green.  B. 
Expanded view of the catalytic core and the dimer interface.  Depicted in the figure are the active site 
(violet), the Ca2+ binding site (yellow), and key interactions at the dimer interface (orange).    
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Alternatively, high concentrations of Ca2+ (>50 mM) or of monovalent cations 
(>150 mM) with 1 mM Ca2+ can non-proteolytically activate FXIII (referred to as 
FXIIIaCa) (129, 130).  Only one Ca2+ binding site (Figure 7B) has been observed (N436, 
D438, A457, E485, and E490) with a KD of ~100 µM (117), though the existence of several 
more low affinity sites has been supported by equilibrium dialysis (131) and 43Ca NMR 
(132).  In addition, several other cations have been demonstrated to interact with FXIII, 
including magnesium, strontium, manganese, ytterbium, terbium, and zinc (117, 133, 
134).  In fact, Fox et al. solved a structure of FXIII with ytterbium bound at the dimer 
interface chelated by D270 and E272 from both monomers (117). 
Pinpointing FXIIIa substrate specificity remains an elusive goal.  Investigations in 
the past have focused on primary sequence specificity (135-137) and substrate access to 
the active site for the Q-containing substrate (138).  As far as the K containing substrate, 
some work has examined sequence specificity surrounding the reactive lysine residue 
Figure 8:  Proposed catalytic 
mechanism of transglutaminases 
(125).  A. The active site thiol 
attacks the side chain carbonyl of 
the acyl donor glutamine.  B. 
Formation of the first tetrahedral 
intermediate. The primary amine 
abstracts a proton from histidine 
and leaves as ammonia.  C. 
Formation of the acyl-enzyme 
intermediate.  D. The active site 
histidine pulls a proton from the 
donor lysine substrate, which then 
attacks the carbonyl of the acyl-
enzyme intermediate.  E. Formation 
of the second tetrahedral 
intermediate.  In this case, the thiol 
group leaves regenerating the 
active site for the next crosslinking 
reaction.  F. The product of a 
transglutaminase reaction is an ε(γ-
glutamyl)lysyl crosslink. 
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(139, 140).  In addition to the primary amine in the side chain of K, most other primary 
amines will complete the TGase reaction (141).  The absence of a primary amine will 
lead to deamidation in the presence of water (137, 142, 143).  These studies have 
ultimately reached the conclusion that determinants for substrate specificity not only exist 
near the reactive residues, but also further away from the catalytic triad in potential 
exosites.  An ideal substrate for FXIIIa, or any TGase, would probably be located within 
a pliable region of a protein, such as surface loops or sequences near the N- or C- 
terminus that can reach into the deeply buried catalytic core (138, 144).   
Several prospective FXIIIa exosites have been proposed.  Two potential Q substrate 
exosites named peptides 4 (72-97) and 7 (190-230) are located within the β sandwich and 
the catalytic core, respectively (Figure 7A) (145).  Peptides derived from these sequences 
competitively inhibit Q substrate catalysis.  Within the β barrel 2, the antibody 5A2 
targets residues 646-658 and acts as a competitive inhibitor of K substrate incorporation.  
Such β barrel 2 residues may thus be part of a K substrate exosite (146).   
Interestingly, alkylation of C314 by a small molecule like iodoacetamide (IAA) 
occurs only after activation (124, 147-149).  Yet, the X-ray structures of the zymogen 
(119), FXIIIaIIa (118), and FXIIIaCa (117) are lacking in significant RMSD deviations 
(118).  These observations led Yee et al. to hypothesize that the inactive and active 
conformers exist in equilibrium (117).  Since the inactive conformer is favored during 
crystallization, FXIIIa interaction with a substrate or inhibitor may favor crystallization 
of the active conformer (117).   
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Research Goals 
A common thread is shared by all projects described in the following chapters.  
Specifically, the research focuses on the implementation of solution-based methods to 
better characterize the conformational features associated with ligand binding to the 
proteins thrombin and FXIIIa.  With that in mind, these investigations can be segmented 
into two separate projects.  The first endeavor examines peptide binding to thrombin’s 
ABE-II, which can be further broken down into studies involving the complexes γ′ chain 
(410-427)-IIa and GpIbα (269-286)-IIa.  The second project aims to explore the 
inhibition of FXIIIa with a newly developed peptide based inhibitor, perhaps yielding 
new insight into FXIIIa substrate recognition. 
Rationale for Studying Peptide Binding to Thrombin’s ABE-II 
One of the original treatments to promote anticoagulation is the administration of 
heparin, which interacts at ABE-II (73, 150-152) and enhances antithrombin (AT) (64) 
and heparin cofactor II (153) inactivation of thrombin.  Heparin is used clinically to treat 
myocardial infarction, atrial fibrillation, and deep-vein thrombosis.  Unfortunately, the 
presence of heparin can lead to inhibition of a multitude of other coagulation proteins 
including FXa (which is also a therapeutic target of heparin) (154), FIXa (155), FXIa 
(156), FXIIa (157) and vWF (158).  In addition to anti-coagulation activities, heparin also 
binds to circulating plasma proteins (159) and endothelial cells (160).  Furthermore, 
heparin has been shown to promote bone loss (161) and induce thrombocytopenia (low 
levels of circulating platelets) (162).  These heparin side effects vary from individual to 
individual; therefore levels of heparin dosage must be carefully monitored during 
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treatment (163).  The difficulties in administrating heparin have led to the development of 
several heparin-derived drugs and other anticoagulants (164).    
Peptides provide a potential route for specifically targeted therapeutic utility.  Drugs 
designed from naturally occurring protein ligands of thrombin could avoid many of the 
side effects resulting from heparin treatment (163).  The efficacy of peptide-based 
anticoagulants has been demonstrated with the ABE-I binding inhibitors hirudin and 
bivalirudin (165, 166).  At the present time, a peptide-based anticoagulant that targets 
ABE-II has not been developed.  By examining the conformational features associated 
with γ′ peptide (410-427) and GpIbα (269-286) binding to ABE-II, an ABE-II targeting 
peptide with anticoagulant properties may be developed employing the unique structural 
elements characteristic of these complexes.   
The work described in Chapter IV details the γ′ peptide (410-427)-IIa interaction 
utilizing NMR and MALDI-TOF MS (167).  At the time this research was initiated, a 
crystal structure demonstrating the interaction of the γ′ peptide with IIa had not been 
reported, though the binding site was localized to ABE-II (69, 70).  The length of the γ′ 
peptide substitution for γA in fibrinogen is twenty amino acids.  Therefore, once bound to 
thrombin, the γ′ peptide may potentially adopt secondary structural elements, i.e. helix 
formation, turn structures etc., not favored when the peptide is free in solution.   
From thrombin’s perspective, the residues within ABE-II that provide the γ′ peptide 
interface had not been elucidated.  Crystal structures of heparin (168), prothrombin 
fragment II (169), GpIbα (96, 97), and haemadin (66) binding to ABE-II provide an 
important starting point for predicting where the γ′ peptide interacts at ABE-II.  All 
structures highlight R93, R101, and K240 as essential ABE-II binding residues, suggesting 
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that the γ′ peptide also utilizes these positively charged residues when binding to 
thrombin.  Another aspect of ABE-II binding that remains to be further explored is 
whether an allosteric connection exists from ABE-II to ABE-I.  Some reports suggest 
such a pathway is present in thrombin (70, 170), while other work appears to dismiss 
such a possibility (171).  Since thrombomodulin binding to ABE-I has been demonstrated 
to perturb the dynamics of deuterium incorporation at ABE-II (172, 173), perhaps the 
reverse is true for ligand binding to ABE-II.  
With those questions in mind, research was initiated to further explore the γ′ 
peptide-IIa relationship.  The project implemented 1D line broadening NMR and 2D 
transferred NOESY NMR (detailed in Chapter II) to describe the ligand protein 
interaction from the γ′ peptide’s perspective.  Using these techniques, the important 
protons that contact thrombin’s surface were identified in addition to several key 
secondary conformational features associated with γ′ chain binding to IIa.  By using 
MALDI-TOF MS and hydrogen deuterium exchange (HDX) (discussed in Chapter III), 
the effects of the γ′ peptide on the dynamics of HDX for IIa were examined.  These 
experiments were performed to more accurately localize γ′ peptide binding within ABE-
II and to observe potential allostery associated with ligand binding to ABE-II.   
Chapter V focuses on the interaction between GpIbα and IIa.  Two crystal 
structures of GpIbα bound to IIa were solved simultaneously (96, 97).  As discussed 
earlier in the chapter, thrombin’s interaction with ABE-II appears to be similar in both 
structures, while the second IIa binds at differing interfaces on GpIbα.  The anionic C-
terminal tail in the Dumas et al. structure ended at YS279 due to insufficient electron 
density to model these residues (96).  Conversely, the Celikel et al. structure terminates at 
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T284, with the C-terminus spanning both thrombin molecules and interacting with ABE-II 
and ABE-I in an extended conformation (97).  The Celikel structure suggests that the C-
terminal fragment of GpIbα may induce dimerization of thrombin.  Due to the high 
degree of similarity between the ABE-II binding sequences of GpIbα and the γ′ peptide 
(see Table 1), perhaps these anionic, sulfonated regions share conformational elements 
that direct these residues to interact with ABE-II.   
As with the γ′ peptide, research was performed to study the GpIbα (269-286)-IIa 
interaction in further detail utilizing NMR and HDX coupled with MALDI-TOF MS.  1D 
and 2D NMR work demonstrate that GpIbα (269-286) and the γ′ peptide adopt differing 
conformations when bound to ABE-II.  HDX coupled with MALDI-TOF MS was 
performed in order to distinguish between ABE-II versus ABE-I binding of the GpIbα 
peptide, as well as to characterize allostery associated with GpIbα interactions with IIa.  
Finally, further work was then carried out with analytical ultracentrifugation to observe 
whether the γ′ peptide or the GpIbα peptide could dimerize IIa in solution. 
Rationale for Studying Peptide Inhibition of Factor XIIIa 
Examining FXIIIa in solution is a difficult task, since the active TGase is mostly 
insoluble by nature (as is the soft clot that FXIIIa covalently crosslinks).  This 
insolubility perhaps explains the difficulties in obtaining a structure of the active FXIIIa 
(117). As mentioned earlier in the chapter, structures have been solved for FXIIIaIIa (118) 
and FXIIIaCa (117), though without significant RMSD deviations from the zymogen 
(119).  Many studies have demonstrated that activation of FXIII must lead to a 
conformational change that has been undetected in the reported X-ray structures (124, 
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147-149).  Fortunately, sufficient quantities of FXIIIaIIa and FXIIIaCa remain in solution 
in order to probe the conformational changes associated with activation (174, 175).   
These observations have led to the hypothesis that irreversible inhibitor binding to 
FXIIIa may capture the TGase in an active conformation (117).  Inhibited FXIIIa could 
potentially be utilized to detail previously unobserved features of FXIIIa substrate 
recognition and, indirectly, activation.  Recently, irreversible inhibitors have been 
developed for TGase 2 based on natural Q-containing substrate sequences for the enzyme 
(176).  One of the reported peptide inhibitors of the TGase incorporated a glutamine 
isostere 6-diazo-5-oxo-norleucine (DON) in place of the reactive glutamine.  A well-
characterized substrate for FXIIIa is the K9 peptide (177).  The DON moiety has been 
incorporated into the K9 peptide in order to study the conformational features resulting 
from inhibitor binding to FXIIIa.    
Perturbations in FXIIIa dynamics were further explored by inhibition with K9 DON 
or iodoacetamide (IAA) (Chapter VI) (178).  The investigations rely primarily on 
MALDI-TOF MS methodology (Chapter III).  HDX, limited proteolysis, and differential 
chemical modification were the strategies used to study the conformational changes 
associated with FXIIIa inhibition, as well as build upon the earlier work investigating 
FXIII activation (174, 175).  The FXIIIa inhibitors K9 DON and IAA both displayed 
similar perturbations in protein dynamics for regions distant from the active site, perhaps 
indicating the location of exosites within the TGase.  These experiments may also have 
provided evidence for a potential interaction site for K9 DON within the catalytic core.  
Though these are low-resolution studies, highly valuable glimpses are being provided on 
FXIIIa allostery and the presence of putative FXIIIa exosites. 
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CHAPTER II 
NUCLEAR MAGNETIC RESONANCE TECHNIQUES: 
1D LINE BROADENING AND 2D TRANSFERRED NOESY 
One of the most powerful tools to study molecular structure and dynamics, ligand-
receptor interactions, and chemical kinetics is nuclear magnetic resonance spectroscopy 
(reviewed in 179).  Through the application of an external magnetic field, a nuclear spin 
becomes excited, ultimately allowing the detection of perturbations in electronic 
environment that are quite subtle.  In order to achieve an excited state, radio waves 
irradiate the sample indicating that excitation requires small amounts of energy.  
Consequently, the signal to noise in an NMR spectrum is low, thus requiring an 
abundance of material and multiple scans to enhance resolution.  One beneficial aspect of 
the low energy transition is the long lifetime of nuclear spin excitation, which ranges 
from msec to sec.  It is this feature of an NMR experiment that produces very narrow 
spectral signals and permits the observance of molecular motion over a large time scale.  
Most importantly, the long lifetime of nuclear spin excitation confers the ability to 
transfer resonance energy from one spin to another spin.  As relaxation occurs, the energy 
released by the nuclear spin is measured as a free induction decay (FID), which is 
converted to a plot of intensity versus frequency by Fourier transform. 
The magnetization that is experienced by the nucleus is primarily affected by the 
density of electrons surrounding the nuclear spin (reviewed in 179).  Application of an 
external magnetic field also causes electrons to precess resulting in the creation of a 
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magnetic field that opposes the applied field.  This phenomenon leads to shielding of the 
nuclear spin and is termed chemical shift.  Larger electron density equates to lower 
resonance frequencies of the observed nuclear spin.  Therefore, the measured frequency 
of a nuclear spin not only depends on the type of nuclei studied, but the electronic 
environment in which the nuclear spin resides, whether due to bonding or proximity.   
For amino acids, typical chemical shifts for the observed protons depend on the 
atom and position of the group within the residue.  Since nitrogen is more electronegative 
than carbon, a backbone amide proton will possess a chemical shift at ≈ 8 ppm.  The 
proximity of Hα to the backbone nitrogen results in a resonance at ≈ 4 ppm, while Hδ 
from leucine resonates further upfield at ≈ 1 ppm.  This example illustrates the 
fundamental complexity of 1D spectra for peptides and proteins due to overlap of 
multiple resonances for similar protons.  In order to resolve the spectra of larger 
polypeptides, NMR experiments are performed in multiple dimensions, where multiple 
chemical shifts aide in assigning the resonances for the observed peaks.        
As with any transition from a ground state to an excited state, energy is eventually 
released as the system reestablishes equilibrium (reviewed in 179).  In NMR, the nuclear 
spins that are excited experience two types of relaxation.  The first relaxation process is 
termed spin-lattice relaxation, whose time constant is T1.  As energy transfers from the 
excited nuclear spin to the environment, or lattice, the original Boltzman population 
distribution is regenerated as the magnetic moment of the spins are realigned along the 
static magnetic field.  For proteins, the time scale for T1 relaxation is around a second, 
while for smaller molecules, like peptides, T1 times range from 10 to 100 seconds.   
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Transverse relaxation, with a time constant of T2, does not involve reestablishing 
thermal equilibrium or demoting excited spins to the ground state (reviewed in 179).  T2 
relaxation describes the agitation of nuclear spin phase coherence.  Three processes 
dephase transverse magnetization.  First, inhomogeneity of the magnetic field within the 
sample affects the precessional frequency of the excited spins depending on the spatial 
position of the spin within the inhomogeneous field.  To minimize inhomogeneity, 
modern instruments possess shim coils that serve to increase the homogeneity of the 
magnetic field.  The second way for transverse relaxation to occur is due to the existence 
of anisotropic electron density that envelops the nucleus (Chemical Shift Anisotropy).  
Thus, the alignment of the nuclear spin within the magnetic field will actually determine 
the actual field that is experienced by the spin due to variations in electron shielding.  The 
final type of transverse relaxation is spin-spin relaxation, which describes dipolar 
coupling between two magnetic dipoles in close proximity.  
For protons, dipolar coupling is the primary means for transverse relaxation 
(reviewed in 179).  Thus, molecular motion and, subsequently, molecular weight play an 
important role in dipolar coupling.  The rotational correlation time (τc) refers to the 
average time a molecule in solution rotates 1 radian, which is about 1 nsec/2.6 kDa.  
When the resonance frequency (ω) associated with the coupled spins is much slower than 
τc (ωτc<<1), isotropic tumbling is observed, the dipolar coupling contribution to the spin 
energy is zero, and splitting of resonance lines are not observed.  This situation is 
observed for small molecules in solution.  For larger molecules, like proteins, the time 
required to rotate 1 radian is much longer, resulting in shorter T2 lifetimes (ωτc>>1) and 
presenting a serious impediment for the transfer of magnetization between spins.  Despite 
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the longer τc, proteins tend to possess rotational frequencies on the order of 108 Hz, thus, 
tumbling in solution is sufficiently fast to subvert the splitting of the resonance lines 
(dipolar coupling is averaged). 
Differences in rotational correlation times (τc) between proteins and peptides can be 
exploited to obtain structural information regarding peptide interactions with a protein 
(reviewed in 180, 181-184).  In the 1D spectrum of a peptide interaction with a protein, 
line broadening of the spectral signal for the nuclei being observed is an indication of 
contact between that atom and the protein surface.  Conformational information can be 
obtained by performing a 2D transferred NOESY experiment where 2 protons within 5Å 
display a cross peak which can then be employed to determine structural features of the 
bound peptide.  A majority of the NMR work described in the subsequent chapters deals 
with implementing these two techniques to describe the conformational features 
associated with two peptides interacting with thrombin’s anion binding exosite II.   
Protons (or 31P nuclei of phosphorylated peptides) that contact the protein surface 
(and thus contribute to the binding interface) can be discerned by comparing the 1D 
spectra of the free peptide versus the bound peptide.  Equation 1 illustrates the 
relationship between T2, ωτc, and the difference in resonance linewidth (πΔvi) (180).  
Within Equation 1, g = 0.1γi2γj2(h/2π)2(µ0/4π)2 and the distance between protons is rij.  
Peptides with less than 18 amino acids lack significant secondary structure and tumble 
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rapidly when free in solution (ωτc approaches 1).  In the 1D 1H or 31P spectra of the free 
peptide, well-defined, narrow spectral peaks result from a longer T2 time (180, 184).  
When examining the bound state, the peptide concentration is in molar excess to the 
protein and the koff has to be sufficiently fast to allow the peptides with secondary 
structural information to rejoin the free peptides in solution.  Upon interacting with the 
surface of an enzyme, the peptide now adopts a conformation with distinct secondary 
structural features.  Nuclei that interact with the enzyme surface experience an increase in 
τc leading to ωτc >> 1.  The decrease in the T2, coupled to differences in chemical shift 
arising from the nuclei experiencing a new magnetic environment, lead to line 
broadening of the peaks in the 1D spectra.   Nuclei that do not interact with the surface of 
the protein display similar spectral linewidths as observed with the free peptide (185). 
Figure 9 presents an example of a 1D 
1H line broadening experiment.   Protons 
that contact the protein surface are 
broadened relative to the spectra of the free 
peptide.  In this example, several residues 
are not involved in the binding interface, 
particularly the G (~8.65 ppm) and T (~8.2 
ppm) residues, and are illustrated by peaks 
that remain sharp and well resolved in the 
absence and presence of the protein.  
Conversely, the Y (~7.83 ppm) residue is 
broadened in the presence of the protein. 
Figure 9:  Example of line broadening in 1D 
NMR spectra.  The top spectrum is free 
unphosphorylated GpIbα (269-286) and the 
bottom spectrum is of the peptide bound to IIa. 
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Due to the overlapping resonances of protons in a 1D spectrum, 2D TOtal 
Correlation SpectroscopY (TOCSY) NMR is performed in order to assign chemical shifts 
of similar protons within a peptide.  TOCSY NMR takes advantage of a spin lock pulse, 
which enables the connectivity for 
an entire spin system to be 
visualized within the 2D spectrum.  
Carbonyls within amide bonds 
demarcate the spin systems of 
amino acids in a peptide.  
Therefore, each residue will have a 
unique set of proton-proton 
correlations flowing from the 
backbone amide proton to the side 
chain protons.  Figure 10 displays 
the amide to aliphatic proton region frequently referred to as the “fingerprint” region.  
Cross-peaks representing protons with unique chemical shifts yet are neighbors due to 
scaler coupling (through bond interactions) appear on opposite sides of the diagonal (for 
an example of an entire spectrum see Figure 11, which is similar to the layout of a 
TOCSY spectrum).  By assigning the resonances in the 2D TOCSY, the 1D spectrum (the 
diagonal) becomes rather straightforward to identify.   
In addition to line broadening, another NMR technique provides information 
concerning the conformational features associated with peptide binding: 2D transferred 
Nuclear Overhauser Effect SpectroscopY (trNOESY).  A typical spectrum obtained 
Figure 10:  Fingerprint region from a 2D TOCSY 
spectrum.  The spectrum is of unphosphorylated GpIbα 
(269-286) interacting with bovine IIa.  On the far left of 
the spectrum is an example of a spin system for an E 
residue (9 ppm).  The backbone amide’s spin is 
correlated with the α (4.4 ppm), β (2.0 ppm), and γ (2.4 
ppm) proton resonances for this particular E residue. 
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during a 2D experiment is 
illustrated in Figure 11.   Along 
the diagonal is the 1D spectrum of 
the peptide, while crosspeaks 
representing NOEs between 
protons flank the diagonal.  An 
NOE develops due to a transfer of 
magnetization between two 
protons through space, resulting in 
cross-relaxation.  Since dipolar coupling depends on the distance between the protons 
(relaxation rates are proportional to 1/r6), only protons within 5Å will result in a NOE 
peak.  Equation 2 relates the relaxation rate between protons (σ) to the interproton 
distance (r).  Thus, NOE intensity can be implemented to calculate a structure for the 
peptide interacting with a protein (186). 
The 2D trNOESY NMR experiment also profits from the variations in τc resulting 
from molecular weight between a peptide and a protein.  Once again, a free peptide (of 
less than 18 residues) possesses τc values of approximately 10-10 sec leading to ωτc ≤ 1.  
This situation equates to NOEs that are both small and positive or approach zero.  The 
binding of the peptide to a larger protein (τc > 10-8 sec) means ωτc >> 1 and the NOEs are 
large and negative, dominating the 2D spectrum.  Interaction of the peptide with the 
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Figure 11:  2D transferred NOESY spectrum.  The 
spectrum is of the γ′ peptide interacting with bovine IIa. 
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protein surface may result in a defined conformation for the peptide.  For a successful 
experiment, the peptide must be in molar excess to the protein (~10:1).  The koff should 
be sufficiently quick for the peptide to rejoin the free peptide population, allowing 
another peptide to bind to the protein.  If these conditions are met, then reliable 
information regarding the bound state of the peptide will be obtained (Figure 12).   
In instances where the peptide binds too tightly to the enzyme, line broadening and 
NOEs will not be observed in the spectra.  This situation results in less buildup of 
magnetization intensity within the free peptide population since the peptide remains 
Figure 12:  Summary of the 1D line broadening and 2D transferred NOESY techniques.  When free 
in solution, a peptide possesses very little secondary structural features due to lack of constraining 
factors, such as a protein in which to interact.  This situation results in ωτ c ≤ 1 and longer transverse 
relaxation (T2) times.  The 1D spectrum will display very sharp peaks and the 2D trNOESY will lack 
the presence of many discernable NOEs.  Introduction of the binding partner, in this case a larger 
protein, leads to the peptide interacting with protein.  Thus, those protons that contact the protein 
surface adopt the solution characteristics of the larger macromolecule, i.e. ωτ c >> 1, shorter T2 times, 
and large negative NOEs.  The peptide now assumes the secondary characteristics associated with 
binding to the protein.  If the koff for the peptide is sufficiently fast, then the peptide will take a 
“memory” of the bound conformation to the free peptide population.  This rejoining with the free 
peptide population results in 1D line broadening for protons that contact the protein surface and a 
weighted average of the NOES of the free and bound ligands in the 2D trNOESY spectrum. 
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bound to the protein.  A variety of measures can be implemented to circumvent these 
situations (reviewed in 184).  First, since koff is dependent on temperature, raising the 
temperature may weaken the interaction enough for the bound peptide to dissociate from 
the protein and retain the characteristics of the bound conformation.   Another method 
involves manipulating the ionic strength or the pH of the solution, which could interfere 
with binding to protein enough to increase koff.  Larger ratios of peptide to enzyme (up to 
50:1) create a situation where more peptide is competing for the protein-binding site, thus 
increasing dissociation.  Finally, modifying the residues within the peptide, such as 
removing phosphorylation from a phosphotyrosine or substituting an F for a Y, may 
achieve a similar effect as raising the temperature.  Increasing koff too much may result in 
the disappearance of NOEs and line broadening as well, because the rate of interaction 
with the protein is now faster than the detection limits of the NMR experiment.   
Spin diffusion resulting from intermolecular relaxation with the protein can 
interfere with interpretation of NOEs.  In this case, distances between protons appear to 
be shorter due to dipolar coupling with protein protons leading to spin diffusion across 
the protein surface.  A direct outcome of spin diffusion is a peptide structure that is quite 
compact when compared to the actual conformation of the ligand.  Increasing the peptide 
to protein ratio may circumvent this situation.  Another way around this potential 
problem is by decreasing the mixing time for the NMR experiment, which discourages 
indirect transfer of magnetization from the protein to the peptide and thus the appearance 
of an artificial NOE or an increase in NOE intensity.   A comparison of NOEs from 
spectra acquired at a range of mixing times should display a linear dependence for NOE 
intensity with mixing time length (184).   
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The ultimate advantage of these two NMR techniques, 1D line broadening and 2D 
trNOESY, rests in the ability to observe, in solution, the conformational characteristics of 
a ligand bound to a protein.  In X-ray crystallography, a static snapshot of a system is 
captured which could potentially be deceptive with regard to structural information.  
Crystal packing effects within a lattice, or between neighboring protein molecules, could 
potentially influence the solved structure and constrain the conformation of a bound 
ligand.  These techniques can observe transient interactions that may not be able to be 
crystallized due to weak KD values. 
As of this writing, NMR structures of IIa and FXIII have not been published.  The 
most probable reason for this absence is due to the need of large amounts of isotopically 
labeled protein, which are required to obtain the NMR structure.  Without a reliable 
E.coli expression system, trNOESY NMR experiments provide a means to observe IIa-
ligand or FXIIIa-substrate interactions in solution with no requirement for large amounts 
of protein.  A glance at the literature reveals that these NMR techniques have been 
employed to gather an extensive amount of information regarding ligand interactions 
with IIa’s active site and anion binding exosite I (185, 187-199).  As for FXIIIa, NMR 
work has focused on examining the interaction of the FXIIIa substrates K9 and α2-
antiplasmin binding to the active site (137, 200).  For the first time, the conformational 
features associated with peptide binding to IIa’s anion binding exosite II have been 
elucidated in solution and are described in the subsequent chapters (167).   
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CHAPTER III 
MATRIX ASSISTED LASER DESORPTION IONIZATION TIME-OF-FLIGHT MASS 
SPECTROMETRY AND HYDROGEN DEUTERIUM EXCHANGE 
 
As discussed in the previous chapter, NMR is a powerful tool for high-resolution 
structural analysis.  However, serious drawbacks to this technique include the 
requirement for large amounts of material and the potential for macromolecules to 
possess poor solubility in solution.  A typical 2D trNOESY experiment may take upwards 
of 24 hours to complete and demand a sample prepared to the highest degree of purity.  
An important complementary method for the characterization of protein structure and 
dynamics that alleviates many of the prerequisites for a successful NMR experiment is 
Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry 
(MALDI-TOF MS).  Whereas in NMR µM to mM concentrations of material are needed 
to collect a spectrum, MALDI-TOF MS proves to be a much more sensitive technique 
with detection limits reaching pM levels.  MALDI-TOF MS tolerates small amounts of 
impurities, has short preparation/analysis times, and detects large macromolecules (>300 
kDa).  In this chapter, the basics of the MALDI-TOF MS experiment will be detailed 
from the preparation of a sample to the acquisition of a spectrum, followed by a 
discussion of how hydrogen deuterium exchange (HDX) can be monitored with MALDI-
TOF MS. 
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MALDI-TOF MS Theory and Instrumentation 
As the name implies, mass spectrometry detects molecules based on molecular 
mass.  More precisely, the signal obtained reflects the mass to charge ratio (m/z) of the 
observed ion.  A typical MS experiment is broken down into three parts:  ion production, 
ion transmission, and ion detection (201).  Figure 13 depicts a schematic of a Voyager 
DE (Delayed Extraction)-PRO MALDI-TOF MS instrument (Applied Biosystems).  The 
following description pertaining to the theory and operation of the Voyager DE-PRO 
MALDI-TOF MS is adapted from the Voyager Biospectrometry Workstation User Guide 
provided by Applied Biosystems, unless referenced otherwise. 
Preparation of the sample is the first step in performing a MALDI-TOF MS 
experiment.  Sample ionization proceeds with the assistance of the matrix.  The choice of 
matrix depends on the composition of the material, i.e. protein, nucleic acid, or lipid, and 
the molecular weight of the substance studied.  The Voyager DE PRO is equipped with a 
Figure 13:  Schematic of a MALDI-TOF mass spectrometer.  The red line is the path of the laser beam 
and the blue line is the path of the ions traveling in reflector mode.  The figure is adapted from the 
Voyager Biospectrometry Workstation User Guide (Applied Biosystems). 
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N2 laser with a wavelength of 337 nm, therefore the matrix must absorb at 337 nm.  Table 
2 presents a list of matrices most frequently employed in the projects described in this 
dissertation.  These compounds are dissolved in a volatile, acidic solvent.  A typical 
solution for α-CHCA consists of 1:1:1 acetonitrile:0.1 % trifluoroacetic acid:ethanol at a 
concentration of 10 mg/mL.  Sample is mixed with matrix at a 1:1 ratio and allowed to 
dry on a stainless steel plate.  After the matrix and sample co-crystallize, the plate is 
inserted into the mass spectrometer. 
MALDI-TOF MS acquisition consists of the laser firing, the matrix absorbing the 
laser’s energy, the sample ionizing, the ions traveling to the detector, and the instrument 
Table 2:  Common Matrices Used with MALDI-TOF MS 
Matrix Structure Application 
3,5-Dimethoxy-4-hydroxy 
cinnamic acid (Sinapinic 
Acid) 
HC
OCH3
OH
H3CO
CH
C O
HO
 
Peptides and Proteins  
>10 kDa 
α-cyano-4-
hydroxycinnamic acid  
(α-CHCA) 
HC
OH
C
C O
HO
CN
 
Peptides and Proteins  
< 10 kDa 
trans-4-hydroxy-3-
methoxycinnamic acid 
(Ferulic Acid) 
HC
OH
CH
C
O
OH
O
CH3
 
Peptides and Proteins  
3-10 kDa 
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displaying the molecular mass of the ions in a spectrum (202).  The laser fires coherent, 
high-density energy (337 nm) at a rate of 3 nsec per pulse.  An attenuator controls laser 
intensity, with a prism directing the beam to the sample plate.  An excess of matrix over 
sample facilitates efficient sample ionization and desorption, as well as dissuades 
decomposition of the sample due to radiation, thus the process is termed “soft” ionization 
(203).  It should be noted that ionization refers to the transfer of a proton from the matrix 
to the sample (204).  Hence, analytes are recorded as m/z values and not mass.   
Once irradiated, a plume of gaseous material is ejected (desorption) from the 
surface of the sample plate (204, 205).  Within this plume, a mixture of matrix, sample 
ions, and buffer components are in a dense cloud.  The next step is to apply a potential 
(20 kV) between the sample chamber and the variable voltage grid.  Ions accelerate 
through the field-free flight tube, desirably with the same kinetic energy and in a straight 
path.  Since KE=1/2mv2, smaller ions will reach the detector before larger species.  A 
guide wire within the flight tube possesses a potential of ~1% of the accelerating 
potential and serves to focus the ions into a more coherent path to the detector.  
The system is maintained under a high vacuum (10-6-10-8 torr) for a few reasons.  
At atmospheric pressure, gaseous molecules will collide with the ions produced from 
desorption.  Collisions of this nature result in the ions experiencing decreases in the 
kinetic energy and deviating from a straight path to the detector.  These molecular 
interactions ultimately lead to errors in m/z determinations.  Another consideration is that 
constant bombardment of the ion detectors with molecules from the atmosphere will 
reduce sensitivity.  Finally, the possibility exists for electrical arcing within the source 
chamber since the high voltages required for ion transmission to the detector could cause 
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molecules within the air to momentarily conduct current.  Therefore, after inserting the 
sample plate into the instrument, the sample chambers must be evacuated of nearly all 
gaseous molecules for proper instrument functioning and maintenance.  Located at the 
opposite end of the instrument is the linear detector.  The purpose of this device is to 
count the number of ions (intensity) that reach the detector and the time the ions arrive 
(drift time) at the detector.  Signals recorded by the detector are sent to a digitizer for 
conversion to a mass spectrum displaying a plot of the intensity versus m/z (206, 207).   
The drift time (t) is converted to m/z using Equation 3, where KE is kinetic energy, s is 
drift distance, and z is ionic charge.   
Equation 3 highlights the necessity of similar KE and drift distance values for 
accurate m/z determinations.  An initial delay in the application of the accelerating 
potential is quite important for a few reasons (208).  If the potential is not immediately 
applied, these plume components will drift apart and the initial ionization energy within 
the sample molecules will dissipate to the surroundings.  Therefore, introduction of 20 
kV to the system will be less likely to induce fragmentation within the less dense plume.  
Second, initial ionization will randomly impart varying degrees of energy to the ejected 
species.  Acceleration of the ions immediately following ionization yields an uneven 
distribution of KE, skewing the detected m/z values for the observed species (209).   In 
order to avoid these issues, a delay of 100-200 nsec is implemented before engaging the 
accelerating potential (delayed extraction) (210, 211).  This delay ensures that the ions 
will traverse the field free tube at the same time and with the same KE. 
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Within the Voyager DE PRO, another type of detection involves ion reflection.  
Before reaching the linear detector, the ions are reflected by a single-stage gridded mirror 
(evenly spaced electrodes) that uses a uniform electric field to direct the ions to the 
reflector mode detector (212).  In conjunction with delayed extraction, this process serves 
to minimize initial differences in KE (213).  Ions with higher KE will penetrate deeper 
into the ion mirror, while ions with the same m/z but lower KE will not travel as far 
within the ion mirror.  Thus, variations in m/z due to KE are minimized.  Reflector mode 
significantly improves mass accuracy and signal resolution when compared to linear 
detection.  The upper limit for reflector mode ion detection is 10,000 m/z.  The reason for 
this threshold is related to peak broadening resulting from the metastable decay of higher 
MW ions (214).  This type of broadening is greater than broadening associated with KE 
variation, thus resolution is not enhanced in reflector mode.   
Applications of MALDI-TOF MS 
As previously described, MALDI-TOF MS primarily measures the mass of 
molecules.  This technique has been utilized to observe conformational changes in 
protein dynamics that result from conversion of a zymogen to an active enzyme or of a 
ligand binding to a protein.  The three principal methods for probing variations in protein 
dynamics with MALDI-TOF MS are chemical modification, limited proteolysis, and 
hydrogen deuterium exchange (HDX).  
Differential chemical modification of specific amino acid residues was first 
implemented in our laboratory as a valuable tool for observing FXIII dynamics in 2004 
(175).  In this method, the protein is exposed to an amino acid modifying reagent, 
digested with a protease, and analyzed with MALDI-TOF MS.  For example, unactivated 
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and activated FXIII are both introduced to N-ethylmaleimide (NEM), which specifically 
modifies cysteine residues (215).  FXIII possesses nine cysteines and once labeled, 
increases the m/z value of the monitored digest fragment by 125.1 Da (Figure 14).  By 
comparing the reaction of NEM with cysteine in zymogenic versus activated FXIII, 
information is obtained about the solvent accessibility of cysteine, which is then 
extrapolated to deduce conformational changes within the transglutaminase.  Similarly, 
acetic anhydride reacts with available lysine residues providing complementary structural 
information (216, 217).  An increase of 42 Da is observed in the mass spectrum (Figure 
15).  Further detail concerning this methodology will be discussed in chapter VI.   
Conformational changes can also be detected by proteolytically digesting the 
protein for only 30 minutes and recording the appearance and abundance of ions in the 
mass spectra (218).  Such limited proteolysis provides a glimpse of peptide bond 
accessibility for the proteases chymotrypsin and trypsin.  If one fragment appears in the 
Unmodified Fragment NEM Modified  
Cysteine Fragment 
Figure 14:  NEM modification of cysteine as detected by MALDI-TOF MS.  FXIIIa is treated with 
NEM for 60 minutes, digested with trypsin, and analyzed with MALDI-TOF MS.  The unmodified 
fragment represents 327-333 (729.39 m/z).  C327 is modified with NEM adding 125.1 m/z to the tryptic 
peptide (854.45 m/z) 
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digest of the zymogen and is absent in the digest of the activated form of the enzyme, 
then it is inferred that a conformational change has rendered this peptide bond less 
accessible to hydrolysis in the active form.  Once again, the utility and implementation of 
this technique is presented in chapter VI. 
An important technique for observing perturbations in protein dynamics that does 
not rely on chemical modification of amino acids is hydrogen deuterium exchange 
(HDX).  HDX within proteins has been studied for nearly a half a century (219).  The 
method exploits differences in the rate of chemical exchange for backbone amide protons 
in proteins.  Half-lives ranging from milliseconds to years is possible for amide protons 
in proteins due to secondary and tertiary structure, protein flexibility, and protein 
mobility (220-223).  Equation 4 relates the rate of chemical exchange to the concentration 
Figure 15:  Acetic Anhydride modification of lysine as detected by MALDI-TOF MS.  FXIIIa is 
treated with AA for 60 minutes, digested with trypsin, and analyzed with MALDI-TOF MS.  The 
unmodified fragment represents 704-715 (1307.69 m/z).  K704 is modified with AA adding 42 m/z to 
the tryptic peptide (1349.69 m/z) 
 
Unmodified 
Fragment 
AA Modified  
Lysine 
Fragment 
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of acid and base present in solution (224).  Typical rate constants for polyalanine are kH = 
41.7 M-1 min-1, kOH = 1.12 x 1010 M-1 min-1, and kH2O = 3.16 x 10-2 M-1 min-1 (224). 
The rate of chemical exchange is highly dependent on pH and temperature.  At a pH 
of 2.5, the rate of proton exchange is at a minimum.  More acidic conditions (pH < 2.5) 
lead to catalysis occurring through proton addition and a more basic environment (pH > 
2.5) promotes proton abstraction (220).  In addition, exchange is much slower at 0 °C 
than at 25 °C.  Therefore, HDX quench conditions refer to dropping the pH to 2.5 at 0 °C 
where the exchange rate for backbone amide protons ranges from 30-120 minutes (225).  
A few factors influence the rate of backbone amide proton exchange that are 
intrinsic to the protein (220-223).  First, the degree of solvent accessibility for the proton 
is an important consideration.  Surface-exposed amides are more available for deuterium 
exchange than protons buried within the interior of the protein.  Hydrogen bonding, along 
with secondary and tertiary structural elements, involving the proton will provide 
stabilization against exchange, further slowing the rate of deuterium incorporation.  
Protein dynamics influence deuterium exchange to a high degree (Figure 16) (226-
228).  Through fluctuations in protein structure (temporary protein unfolding), a deeply 
buried proton may become briefly exposed to solvent.  Therefore, the rate of protein 
unfolding (ku) and refolding (kf) will play a role in proton solvent accessibility.  A 
smaller fluctuation event could be the momentary disruption of a H-bond leading to 
deuterium exchange.  In this instance, the rate of opening (kop) and closing (kcl) of local 
protein structure need to be considered when following deuterium exchange (229). 
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Two different types of deuterium exchange regimes describe the kinetic extremes of 
the HDX continuum (221, 228).  In EX1 exchange, once the proton becomes solvent 
exposed, deuterium exchange immediately occurs.  The observed rate of exchange is 
equal to the rate describing the opening of the particular structural element within the 
protein (kobs = kop).  The time for the protein to reversibly refold, or close, (kcl) is slower 
than deuterium exchange.  At the other extreme, EX2 exchange refers to the situation 
where protein refolding after solvent exposure is faster than the rate of deuterium 
exchange.  Thus, an equilibrium exists between the solvent accessible and properly 
folded protein states (kobs = kop/kcl*kex).  Since the observed rate is proportional to the rate 
of exchange, the EX2 regime is sensitive to pH changes.  Unless the rate of protein 
unfolding is dependent on pH, the EX1 regime is independent of pH.  Most protons 
within a protein reside somewhere between the two exchange states.     
Figure 16:  Pathways of protein backbone amide proton exposure (229).  The top route 
illustrates a local unfolding event, whereas the bottom pathway depicts complete unfolding of the 
protein followed by deuterium exchange. 
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The Komives laboratory described the first applications of HDX with MALDI-TOF 
MS in 1998 (230, 231).  Figure 17 illustrates the general protocol for the technique.  
Since all three projects described in this dissertation employ HDX methodology, the 
general protocol will be discussed in this chapter with the relevant features associated 
with each specific project detailed in the following chapters. 
HDX can be utilized to examine conformational changes associated with the 
conversion of a zymogen to an activated state.  Additionally, the technique may be 
applied to study the consequences of ligand binding to a protein.  The Komives 
laboratory was the first to implement HDX to study solvent accessibility at a protein-
protein interface (231).  With such an HDX experiment, the ligand should be bound to 
the protein, ideally, for the entire course of the deuterium exchange (173, 231).  Thus, the 
KD describing the strength of the ligand-protein interaction, as well as, the concentration 
Figure 17:  Protocol for the hydrogen deuterium exchange experiment.  In this schematic, a protein 
and peptide interact leading to protection from deuterium at the peptide-protein interface.  After 
binding, a conformational change occurs at the purple fragment blocking exchange for several 
interior protons.  The exchange is quenched by acidification and a decrease in temperature.  
Disulfides within a protein can be reduced with TCEP at the quench conditions.  The protein is 
hydrolyzed with pepsin and then analyzed with MALDI-TOF MS. 
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of the binding partners, will determine the lifetime of the complex.  In other words, the 
more time the ligand and protein spends apart directly affects protein deuterium 
incorporation at the binding interface.  Equation 5 illustrates the equation that calculates 
the percentage of ligand (L) bound to protein (R) given the molar concentrations of both 
components and the KD are known (173, 231).   
For a typical HDX experiment, the protein is exchanged into the desired buffer and 
lyophilized.  Initiation of deuterium exchange occurs when the protein is reconstituted in 
D2O.  Next, the samples are incubated in a desiccator at room temperature for 1 minute or 
10 minutes. The exchange is quenched by lowering the temperature to 0 °C and 
acidification to pH 2.5.  Under the quench conditions, immobilized pepsin is introduced 
to the sample and digested for 10 minutes.  Unlike the proteases chymotrypsin and 
trypsin, pepsin is most active at acidic pH conditions.  Also, pepsin’s specificity 
determinants differ from chymotrypsin and trypsin (232).  Whereas chymotrypsin and 
trypsin hydrolyze peptide bonds after specific residues, pepsin relies on secondary and 
tertiary structural elements when cleaving proteins (223).  Though predicting where 
pepsin cleaves proteins is a difficult prospect, proteolysis always yields the same 
fragments from digest to digest, even with similar proteins from different species (233).  
At this point, it should be noted that others have employed a range of time points 
from 30 seconds to 10 minutes when studying HDX (172-174, 230, 231, 233, 234).  The 
data were then fitted to an exponential equation that classifies protons as either fast or 
slow exchangers.  The fitted equation yields values for the rate of proton exchange and 
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the maximum amount of deuterium incorporation for the particular class of protons (fast 
or slow).  Since the peptides examined in this HDX method consist of a multitude of 
backbone amide protons, assigning rate constants for individual amide protons is a 
difficult task.  Furthermore, classifying protons as either fast or slow exchangers does not 
serve to advance a clearer understanding of the differences between protein states.  
Therefore, the HDX technique may be considered as more of a qualitative method to 
determine variations amongst several unique protein states.  Observing differences in 
HDX for a protein at an initial time point (1 minute) and a longer time point (10 minutes) 
enables ligand binding interfaces to be deduced, as well as more transient deviations in 
HDX resulting from allostery due to ligand binding or activation of the protein. 
Since thrombin possesses four disulfide bonds (51), both a reducing and non-
reducing digest was necessary to produce maximal sequence coverage.  Tris (2-
carboxyethyl) phosphine hydrochloride (TCEP HCl) can efficiently reduce disulfide 
bonds in acidic conditions on ice (235) and does not interfere with pepsin hydrolysis of 
the protein (167, 234).  Once pepsin hydrolysis has proceeded for 10 minutes, 
centrifugation at 4 °C separates the digest from the immobilized pepsin.  Finally, 10 µL 
aliquots are immediately frozen in liquid nitrogen and are stored at –70 °C.  
MALDI-TOF MS analysis of the digested protein is the next step.  A frozen HDX 
aliquot of the protein is thawed, immediately mixed with an equal volume of 10 mg/mL 
α-CHCA matrix and then 0.5 µL spotted onto a chilled stainless steel MALDI plate.  The 
spotted MALDI plate is dried under a moderate vacuum and is inserted into the MALDI-
TOF MS.  The amount of time required for the plate to dry is roughly equivalent to the 
time needed for the MALDI-TOF MS to cycle through the eject protocol and accept the 
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plate for analysis.  The entire procedure takes about five minutes of time, limiting the 
amount of hydrogen back exchange.   
The spectra are collected in the reflector mode with 256 laser shots per spectrum to 
maximize signal to noise ratios.  Since pepsin’s cleavage patterns are difficult to predict, 
peptide fragments within a mass spectrum require identification, primarily through post 
source decay (PSD) sequencing (236).  Briefly, PSD is a technique that leads to peptide 
fragmentation within the MS through ionization with higher laser intensity and collisions 
with gas molecules introduced into the ion source.  The resulting fragments are detected 
by the MS.  By matching the m/z values to theoretical fragments obtained from a known 
potential peptide sequence, identification of a particular peptide is achieved and 
differences in deuteration states can be localized to specific regions within the protein.  
Thrombin peptides derived from a peptic digest without TCEP treatment were 
previously identified by Croy and co-workers (233).  These assignments were verified in 
the current studies by in-house PSD sequencing.  Peptides obtained from the reduction of 
IIa by TCEP were also identified in-house with additional assistance from Julia Koeppe 
(University of California at San Diego) (167, 234).  Brian T. Turner, Jr. identified peptic 
fragments from the digest of FXIII (174).  The program Data Explorer (Applied 
Biosystems) was used to analyze the spectra.  Calibration of the spectra involved two 
reference peptides produced from the digest with pepsin.   
Within the mass spectrum, compounds appear as an isotopic cluster.  The first peak 
in the envelope represents the compound with only the dominant isotopes 12C, 16O, and 
14N.  Since the natural abundance of 13C is 1.1% (237), the next peak in the cluster 
correlates to the probability of the compound possessing a single 13C.  The third peak in 
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the cluster is the compound with two 13C atoms.  The monoisotopic peak will dominate 
the cluster, until analyzing a compound with at least 100 carbon atoms, at which point the 
likelihood of the presence of a 13C atom is greater than the molecule without 13C.  The 
atoms oxygen and nitrogen also possess naturally 
occurring isotopes; however, 18O (0.2%) and 15N 
(0.4%) have lower abundances than 13C (1.1%) (237).  
Since oxygen and nitrogen do not appear as frequently 
in peptides as carbon, these O and N isotopes will not 
contribute to the isotopic profile as visibly as 13C.   
Introducing a peptide to deuterium will also serve 
to increase the m/z by the amount of deuterium 
incorporated into the peptide.  Deuterium is 1 Da 
heavier than hydrogen, which is reflected in the shift of 
the isotopic cluster to the right.  Figure 18 displays 
three time points from zero to ten minutes of 
deuterium incorporation.  As longer time points are observed, the peptide will incorporate 
more deuterium, eventually reaching a plateau.  
Once the spectra are collected, the amount of deuterium incorporation must be 
calculated.  Equation 6 has been developed to quantify the amount of deuterium uptake 
for each peptide observed in the spectra, where Im represents the average mass of the 
isotopic cluster (also termed centroid), xi is the intensity and mi is the mass of peak i.  The 
summation encompasses all peaks in a cluster that have signal to noise ratios of at least 
two.  By subtracting the undeuterated centroid from each deuterated centroid, the amount 
Figure 18:  Isotopic envelope for a 
peptide after 0, 1, and 10 minutes of 
deuteration.  Mass spectra 
representing residues 85-99 of 
bovine thrombin (1317.73).  A.  
Undeuterated fragment.  B.  One 
minute of deuteration.  C.  Ten 
minutes of deuteration. 
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of deuterium incorporated into the peptide is quantified.  At least three spectra were 
collected per trial and three trials were run for each time point under each condition. 
Quantification of differences in deuteration between different protein states was 
calculated with Equation 7, where D is the amount of deuterium incorporated in the 
different protein state, Dref is the amount of deuterium incorporated for reference protein 
state, and Hex is the theoretical maximum number of exchangeable protons within the 
indicated peptide, assuming 100% deuteration.  Only % differences more than ±4.5% are 
considered significant (174, 238, 239).   
Hex can be divided into three categories.  The first type is backbone NHs, calculated 
by subtracting the number of prolines and the N-terminal residue from the total amino 
acids in the peptide.  The next two types rely on the final % of D2O in solution under 
quench conditions (~4.5%).  The N-terminus and C-terminus possess four exchangeable 
protons.  Finally, 12 residues contain side chain protons that can exchange for deuterium:  
R(5), K(3), H(2), N(2), Q(2), C(1), S(1), T(1), Y(1), W(1), E(1), and D(1).  The 
following is an example for calculating Hex for the IIa fragment 173-181 (RIRITDNMF).  
The total number of NHs is nine.  From this, the N-terminal residue is subtracted, leaving 
8 exchangeable backbone protons.  At the termini reside four protons.  To these protons 
are added the amount of exchangeable side chain protons:  2R (10 Hs), 1T (1 H), 1D (1 
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H), and 1N (2 H).  The termini plus side chain Hs equal 18, which is multiplied by the 
residual % of deuterium in solution under quench conditions:  18 x 0.045 = 0.8.  Add 0.8 
and 8 to arrive at Hex = 8.8 for 173-181 of IIa.  
Back exchange from deuterium to hydrogen resulting from humidity, temperature, 
quench solutions, and matrix accounted for a 50% loss of deuterium during analysis.  
This percentage was determined by performing the HDX protocol on a small model 
peptide.  Experiments were performed within the same week to minimize HDX variations 
resulting from temperature and humidity fluctuations.  In addition, a dehumidifier has 
been installed in the MALDI-TOF MS room.  Thus, the amount of back exchange is 
essentially constant for each individual peptide, verified by the low standard deviation for 
three independent trials.  Only differences in HDX between two states of the protein are 
desired, therefore a correction for deuterium loss was not necessary. 
Mass spectrometry provides an important tool for studying protein structure.  In the 
case of FXIII, MALDI-TOF MS probes conformational changes that result from 
activation and inhibition that otherwise would have gone undetected in the absence of the 
corresponding crystal structures.  The difficulties in crystallizing FXIIIa are detailed in 
Chapter I.  As for thrombin, HDX coupled with MALDI-TOF MS has identified sites of 
peptide interaction at ABE-II and variations in protein dynamics independent of the 
ligand interaction site.  These variations in protein dynamics that occur due to peptide-
protein interactions may go undetected in crystal structures. The relative ease in sample 
preparation, instrument operation, and data analysis further enhances the accessibility of 
this technique to researchers around the world.  MALDI-TOF MS will continue to be an 
essential method in detailing protein structure and dynamics for years to come. 
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CHAPTER IV 
CONFORMATIONAL ANALYSIS OF γ′ PEPTIDE (410-427) INTERACTIONS WITH 
THROMBIN ANION BINDING EXOSITE-II 
 
Introduction 
The thrombin anion binding exosites are highly electropositive patches that flank 
the catalytic triad of this serine protease (Figure 4B) (51).  Binding to these exosites can 
modulate thrombin specificity or act in the recruitment of inhibitors (34, 240).  At the 
time this research was undertaken, a crystal structure illustrating γ′ peptide binding to 
thrombin’s ABE-II had not been solved.  As a result, the conformation the peptide 
adopted upon binding to thrombin and the exact ligand interface on the surface of 
thrombin were unknown.   
X-ray structures of ligands interacting with ABE-II have been reported in the 
literature (66, 96, 97, 168, 169).  Figure 19 displays the residues that form ABE-II and 
some of ligands bound to ABE-II (it should be noted that the views of IIa are different 
than Figure 4.  The structures are flipped 90° on the z-axis and rotated 180° relative to the 
horizontal plane for a head on view of ABE-II).  The structures illustrate two unique 
modes of ABE-II interactions.  In the first set of structures, prothrombin fragment II 
(169) and haemadin (66) are illustrated reaching toward R97, R173, and R175.  Both of 
these proteins utilize secondary structural elements while binding to IIa.  Alternatively, 
GpIbα (96, 97) and heparin (168) bind to a groove formed by R93, R101, K236, and K240 in 
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an extended conformation.  Due to the high degree of sequence similarity to GpIbα, 
perhaps the γ′ peptide binds to ABE-II in a similar fashion (Table 1).   
Differing perspectives exist regarding the transmission of allostery resulting from 
ABE-II binding.  Though allosteric communication from ABE-II to the active site is a 
fairly well accepted concept (67, 68, 113), more ambiguous is the linkage amongst ABE-I 
and ABE-II (70, 170, 171).  Hydrogen deuterium exchange (HDX) experiments provide a 
method to observe the regions of thrombin influenced by ligand binding and enhance the 
understanding of how allosteric changes are transmitted from ABE-II throughout the 
protease.  Previous HDX work with the ABE-I binding protein thrombomodulin 
demonstrated that deuterium exchange for several regions within thrombin is affected, 
suggesting allostery from ABE-I to ABE-II (172, 173).  With γ′ peptide binding to ABE-
II, maybe HDX could detect a reverse pathway from ABE-II to ABE-I. 
The research described in this chapter examines the γ′ peptide’s interaction with 
IIa’s ABE-II.  1D and 2D NMR experiments were carried out to observe, in solution, the 
structural features the γ′ peptide adopts upon interacting with IIa’s ABE-II.  Furthermore, 
the individual residues within the γ′ peptide that contact the enzyme’s surface could be 
detected.  In another series of studies, HDX monitored by matrix-assisted laser desorption 
time-of-flight mass spectrometry (MALDI-TOF MS) was used to characterize the effects 
of γ′ peptide binding on the solvent accessibility of IIa’s surface.  Additional coverage of 
IIa was obtained through the use of the reducing agent TCEP, which enabled the 
monitoring of previously unseen regions of thrombin.  In these NMR and MS studies, 
phosphotyrosines, which do not sacrifice binding affinity, were prepared instead of the 
acid labile sulfotyrosines present in the fibrinogen γ′ chains (69, 241).   
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Figure 19:  Modes of ligand binding to ABE-II.  In the 1PPB structure, key ABE-II residues 
are labeled and color-coded.  The orange residues interact with all ligands depicted in this 
figure.  The blue residues form a groove that is utilized by heparin and GpIbα.  The 
polypeptides prothrombin fragment 2 and haemadin reach toward the yellow residues, skirting 
the ABE-II binding groove formed by the blue residues. 
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Our findings describe the γ′ peptide-thrombin relationship from the perspective of 
both the peptide and the enzyme.  γ′ peptide binding to ABE-II causes the ligand to adopt 
significant secondary structure when compared to free peptide in solution.  Interactions at 
ABE-II also have allosteric consequences on the rate of deuterium exchange for regions 
unaffiliated with the ligand-protease interface.  Fresh analysis of the results obtained in 
this investigation (167) will be compared to the crystal structure recently published by the 
Di Cera lab (242).  
Materials and Methods 
 Synthetic Peptides.  SynPep (Dublin, Ca) and Research Genetics, Inc (Huntsville, 
Al) synthesized peptides based on residues 410-427 (PEHPAETEYDSLYPEDDL) of the 
human fibrinogen γ′ chain.  Four variants of this sequence were prepared (Table 3).  
MALDI-TOF measurements on an Applied Biosystems Voyager DE-Pro mass 
spectrometer were used to verify the peptide m/z values.  The concentrations of the 
peptides in solution were determined by quantitative amino acid analysis (AAA Service 
Laboratory, Boring, OR).  
 
 
 
 
Thrombin Preparation.  The isolation and purification of thrombin from bovine 
plasma barium sulfate eluate (BSE) (Sigma) was performed as previously described by 
Trumbo and Maurer (243).  The purified thrombin solution was concentrated with 
Amicon Ultra-15 centrifugal filter units (Millipore) in an Allegra 21R Centrifuge 
Table 3: γ′ Peptides Used in IIa Binding Studies 
YP418 YP422 410PEHPAETEYPDSLYPPEDDL427 
YP418 Y422 410PEHPAETEYPDSLYPEDDL427 
Y418 YP422 410PEHPAETEYDSLYPPEDDL427 
Y418 Y422 410PEHPAETEYDSLYPEDDL427 
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(Beckman Coulter) run at 4000 rpm and 4 °C.  The concentration of the activated 
thrombin was determined using the extinction coefficient of E1% = 19.5 (244), then 
aliquoted and frozen at –70 °C for future use. 
Bovine IIa was used as the enzyme during the course of this work, while peptides 
derived from the fibrinogen γ′ chain were based on the human sequence.  Human and 
bovine IIa exhibit a high degree of sequence conservation (87% identical) (51).  
Important regions where there are no differences include the active site, the Na+ binding 
site, the β-insertion (Trp60D) loop, ABE-I, and ABE-II.  As for the γ′ chain, the bovine γ′ 
sequence terminates at residue 419 (111), while the human sequence possesses an 
additional eight residues (60, 61).  In this case, a peptide derived from the bovine γ′ chain 
may not accurately portray human γ′ chain binding to IIa.  The interaction of the human γ′ 
peptide with bovine IIa should not be influenced by the minor differences between the 
species.  Supporting this statement is an HDX study, where PPACK inhibition of human 
and bovine IIa affected HDX in a similar manner for analogous peptides from both types 
of IIa (233).  In addition, 2D trNOESY NMR examining the structural features adopted 
by fibrinopeptide A (193, 196, 245, 246) and a PAR1 peptide (185) bound to bovine IIa 
were in agreement with the corresponding human IIa X-ray structures (247, 248).   
1H and 31P NMR Sample Preparation and Analysis.  Approximately a 1:10 ratio of 
IIa to peptide was maintained for each complex studied.  Sample preparation and analysis 
procedures similar to those of Trumbo and Maurer were employed (190).  Selective 
features are summarized here.  Each 400 µl NMR sample contained 1.5 mM peptide and 
either zero or 151-162 µM IIa.  The samples were buffered in 25 mM H3PO4, 150 mM 
NaCl, 0.2 mM EDTA, pH 5.6 and 10% D2O (NMR buffer).  Human gamma-IIa 
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(Haematologic Technologies, Inc.) at 56 µM was buffer exchanged into the NMR buffer 
and concentrated to 153 µM via ultracentrifugation.  With addition of the YP418YP422 
peptide, the final ratio of gamma-IIa to peptide was 11:1 in 10% D2O.   
All 1H NMR experiments were performed on either a Varian Inova 800 MHz 
spectrometer equipped with a triple resonance probe and pulsed-field triple axis gradients 
or a Varian Inova 500 MHz equipped with a triple resonance probe and pulsed-field z-
axis gradients. 2D transferred NOESY experiments of the enzyme-peptide complexes 
were run at 15 or 17 °C with 32 transients, 512 t1 increments, a mixing time of 400 ms, 
and a spectral width of 8006 Hz or 5006 Hz.  Spectra were processed using FELIX2000 
software (Accelerys, San Diego, CA) on a Silicon Graphics Octane workstation.  For 31P 
NMR, spectra were recorded on a Varian Inova 500 MHz equipped with a 5 mm 
broadband probe tuned to 202.4 MHz.  The spectra were referenced to the peak 
corresponding to H3PO4 (0.00 ppm). 
HDX Sample Preparation.  Aliquots of 100 µL, 142-150 µM IIa were buffer 
exchanged with Amicon-Ultra 4 units (10,000 MWCO) and diluted into 75 mM NaCl, 
12.5 mM NaH2PO4, pH 6.5 (HDX Buffer).  The final target concentration of IIa for all 
HDX preparations was from 20-25 µM.  D-Phe-Pro-Arg-chloromethyl ketone (PPACK) 
inhibited IIa was prepared by adding 5 µL of 11 mM PPACK to a thawed IIa sample 
diluted to 545 µL with the HDX buffer (resulting in a 4:1 ratio of PPACK to IIa).  The 
PPACK-IIa solution was incubated at 37 °C for at least 30 minutes.  An assay involving 
the chromogenic substrate S2238 was employed to establish that IIa was inactivated by 
PPACK.  Following inactivation, PPACK-IIa was buffer exchanged in the same manner 
as active IIa.  For samples containing the γ′ peptide, 25 µL of 480 µM γ′ peptide in dI 
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H2O was added to 24 µL of the buffer exchanged IIa (20-25 µM).  The aliquots of the 
buffer-exchanged IIa, with and without the peptide, were evaporated to dryness using a 
SpeedVac unit (Savant).  The dry aliquots were stored at -70°C. 
HDX Experiments.  Dry aliquots of IIa or YP418YP422 peptide-IIa were allowed to 
come to room temperature before beginning the experiment.  12 µL of 99.996% D2O 
(Cambridge Isotope Laboratories) were added to the aliquot yielding the final 
concentrations:  40-50 µM IIa/PPACK-IIa, with or without 1000 µM γ′ peptide, in 150 
mM NaCl, 25 mM NaH2PO4, pH 6.5.  The samples were incubated in a desiccator at 
room temperature for 1 minute or 10 minutes.  An initial set of HDX experiments were 
performed with varying concentrations of the γ′ peptide (150-1500 µM) to determine the 
target peptide concentration and to address potential non-specific binding interactions.   
Since IIa possesses four disulfide bonds, both a reducing and non-reducing digest 
was necessary to produce maximal sequence coverage.  Adding 114 µL of 0.1% 
trifluoroacetic acid (TFA) (on ice) acted to acidify (pH 2.5) the solution and quench 
HDX.  Immediately, 66 µL was transferred to a tube of activated pepsin bound to 6% 
agarose (Pierce Chemical).  To the remaining quenched IIa, 6µL of 1 M TCEP (Tris (2-
carboxyethyl) phosphine hydrochloride, Pierce Chemical) was introduced, quickly 
vortexed, and the entire solution added to another tube of activated pepsin.  After 
deuteration was quenched, the entire process of splitting IIa into a non-reducing and 
reducing pepsin digest took 30-40 seconds.  Digestion occurred on ice for 10 minutes.  
Centrifugation at 4 °C separated the digest from the pepsin and 10 µL aliquots were 
immediately frozen in liquid nitrogen and stored at -70 °C.  
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HDX Analysis.  A frozen HDX aliquot of IIa, with or without peptide, was thawed, 
immediately mixed with an equal volume of 10 mg/mL α-cyano-hydroxycinnamic acid 
matrix (Aldrich) in 1:1:1 ethanol/acetonitrile/0.1% TFA, pH 2.2, and then 0.5 µL spotted 
onto a chilled stainless steel MALDI plate.  The spotted MALDI plate was dried within a 
SpeedVac unit (Savant) and inserted into the MALDI-TOF MS.  The amount of time 
required for the plate to dry was roughly equivalent to the time needed for the MALDI-
TOF MS to cycle through the eject protocol and accept the plate for analysis.  The entire 
procedure took about five minutes of time, limiting the amount of hydrogen back 
exchange.  The spectra were collected in the reflector mode over a mass range of 800-
3500 m/z with 256 laser shots per spectrum.  Peptides obtained from the peptic digest of 
IIa were previously identified.  New coverage obtained by reducing the disulfides in IIa 
with TCEP was identified in-house and independently verified.   
The program Data Explorer (Applied Biosystems) was used to analyze the spectra.  
Calibration of the spectra involved two reference peptides, one with the singly protonated 
monoisotopic mass of 888.4943 Da (residues 46-52) and the other with the singly 
protonated pentaisotopic mass of 2106.1505 Da (residues 85-99).  The amount of 
deuterium uptake by each peptide and the % difference in deuteration relative to IIa was 
quantified as described by Sabo et al. (167) and discussed in Chapter III. 
Results 
One-Dimensional Line Broadening NMR.  One-dimensional proton NMR spectra of 
the different fibrinogen γ′ peptides were obtained in the absence and presence of IIa.  The 
appearance of resonance broadening in the spectra is indicative of peptide protons 
coming in direct contact with the IIa surface.  Figure 20 illustrates the extensive binding 
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interactions observed for the YP418YP422 peptide.  Widespread line broadening is observed 
for the entire 1D spectrum, including the NHs spanning residues H412 to L427, the β, δ, and 
ε protons of YP418 and YP422, the β protons of D419, D425, and D426, and the β, γ, and δ 
protons of residues L421 and L427.  Only three observable proton resonances in Figure 20 
remain unchanged with the addition of the enzyme:  P410 β, E411 NH, and H412 δ.   
  
 To assess the contributions that each YP makes to the interaction with IIa, singly 
phosphorylated peptides were also analyzed.  The spectrum for the YP422 peptide 
indicates broadened peaks for several residues (Figure 21).  These spectra provide 
evidence that phosphorylation at a single Y is sufficient to promote binding of the γ′ 
Figure 20:  Line broadening for the γ′ (YP418YP422) peptide in the presence of thrombin.  A. 1D NMR 
spectrum for 1.5 mM peptide in solution.  B. 1D NMR spectrum for 1.5 mM peptide in the presence of 
0.162 mM thrombin.  All NMR samples are in 25 mM H3PO4, 150 mM NaCl, 200 µM EDTA, and 10% 
D2O, pH 5.6 (NMR Buffer).  All observable protons make extensive contact with the surface of 
thrombin except P410 β, E411 NH, and H412 δ. 
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peptide to IIa.  The absence of the phosphate at Y418, however, abrogates enzyme contact 
for at the least the protons:  H412 NH, A414 NH and β, T416 γ, Y418 ε, and L421 γ and δs. 
With the YP418 peptide, the appearance of much weaker enzyme binding is evident 
when examining the spectra in Figure 22, suggesting that most protons are not contacting 
the surface of the enzyme.  The only significant amount of line broadening that can 
unambiguously be assigned is observed for the following protons:  A414 β, E417 NH and 
β′, Y418 δ and ε, and D419, D425, and D426 βs.  The amide region of the YP418 spectra also 
displays broadening for a peak that includes the NH of H412, A414, and E424, indicating 
that all three of these amide protons are contacting the surface of thrombin.  To complete 
Figure 21:  Line broadening for the γ′ (YP422) peptide in the presence of thrombin.  A. 1D NMR 
spectrum for 1.5 mM peptide in solution.  B. 1D NMR spectrum for 1.2 mM peptide in the 
presence of 0.122 mM thrombin.  The experimental conditions are the same as in Figure 27.  In 
contrast to the previous figure, several residues experience a decrease in line broadening including 
the observable protons of H412, A414, T416, Y418, and L421. 
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the series, 1D spectra of the unphosphorylated peptide were obtained which lacked any 
line broadening in the presence of thrombin (data not shown).  
Two-Dimensional Transferred Nuclear Overhauser Effect NMR.  For the γ′ peptides 
representing YP418YP422, YP418, and YP422, between 135-155 inter-residue NOEs were 
observed in the presence of IIa displaying similar structural features.  Appendix A lists 
the chemical shifts associated with each residue in all four γ′ peptides.  In addition, inter-
residue NOEs for the YP418YP422, YP418, and YP422 peptides are compiled in Appendix B.  
By removing both phosphates from the peptide, 26 inter-residue, nearest neighbor NOEs 
were identified in the presence of IIa, which is quite similar to the NOESY of the free 
Figure 22:  Line broadening for the γ′ (YP418) peptide in the presence of thrombin.  A. 1D NMR 
spectrum for 1.5 mM peptide in solution.  B.  1D NMR spectrum for 1.5 mM peptide in the presence of 
0.151 mM thrombin.  The experimental conditions are the same as in Figure 27.  A significant reduction 
in line broadening occurs in the absence of phosphorylation at Y422.  Residues displaying contact with 
the enzyme include H412, A414, E417, Y418, E424, L427, and the aspartate βs. 
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phosphorylated peptides (data not shown).  This significant decrease in NOEs suggests 
that phosphorylation of at least one Y residue is required for interacting effectively with 
IIa.  Such an effect is in agreement with the 1D line broadening studies.   
Important structural information related to the conformation of all three 
phosphorylated peptides bound to IIa are obtained through analysis of the trNOESY 
spectra.  Key through space interactions occurs between the H412 α-P413 δs protons, as 
Figure 23:  Representative spectra of key γ′ peptide NOEs in the presence of thrombin.  A. β-
turn between residues Y422-D425 from 2D trNOESY spectrum of the YP418 peptide (1.5 mM) in 
the presence of IIa (0.151 mM).  All three phosphorylated peptides exhibit this conformational 
feature, while the turn is absent when analyzing spectra involving the unphosphorylated peptide.  
B. The intense clustering of NOEs centered at the aromatic protons of both tyrosine residues.  
The spectrum is from the 2D trNOESY of YP418YP422 peptide (1.5 mM) in the presence of IIa 
(0.162 mM).  The aromatic protons of Y418 are in close proximity to aliphatic protons from T416, 
E417, D419, and L421, while the Y422 ring protons display NOEs with residues S420, L421, P423, E424, 
and D425.  When the unphosphorylated peptide is observed, the NOEs are no longer present.   
  
 
A 
B 
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well as the Y422β-P423δs protons (see Appendix B).  These NOEs are indicative of an 
Xxx-Pro bond in the trans conformation (249).  Figure 23A from the trNOESY spectrum 
of YP418 displays a β-turn formed by residues Y422-E425.  The principal NOEs for this turn 
are between the P423α-E424NH, the P423α-D425NH, and the NHs of E424 and D425 (249).  
The NOEs for the β-turn and the proline trans bonds were also present in the 2D 
spectrum of the YP418YP422 peptide binding to γ-IIa (a form of IIa with an impaired ABE-
I, see Chapter I) (data not shown).  Examining the trNOESY spectrum for the 
unphosphorylated peptide with native IIa reveals the existence of trans H412-P413, but the 
absence of the required NOEs for the β-turn and the C-terminal trans bond.   
A region displaying numerous proton interactions in the trNOESY spectra of the 
three phosphorylated peptides is centered on the two aromatic Y residues (Figure 23B 
and Appendix B).  A hydrophobic cluster, or an intense grouping of aliphatic protons, is 
present encompassing T416-D425.  By including through space interactions between E424 α 
and the aliphatic chain of L427, this cluster extends to the C-terminus of the peptide.   
31P NMR Studies.  Phosphorous NMR spectra were collected for the YP418YP422, 
YP418, and YP422 peptides with and without IIa in solution.  These experiments were 
performed to monitor the effects of peptide-IIa interaction on line broadening.  The 
YP418YP422 peptide displayed two resonances at -3.06 ppm and -3.14 ppm (Figure 24).  
Addition of IIa resulted in a merging of both phosphorous signals into one peak with a 
significant amount of line broadening.  The singly phosphorylated peptides were also 
analyzed to assess the contribution each individual YP makes to the 31P NMR spectrum.  
The YP418 and YP422 peptide signals shift upfield and become slightly broader with the 
introduction of IIa (data not shown). 
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HDX Experiments:  Examining the Influence of the γ′ Peptide on the Solvent 
Accessibility of Thrombin.  Peptic digests of thrombin, with and without the reducing 
agent TCEP, yielded fourteen quantifiable isotopic clusters encompassing 44% of 
thrombin’s sequence (Figure 25).  The presence of four disulfide bonds (C1-C122, C42-C58, 
C168-C182, and C191-C220) limits the amount of sequence coverage attainable without 
introducing a reducing agent.  Peptides spanning ABE-1 (65-84), ABE-2 (85-99), the 
autolysis loop (135-149D), and several residues involved in substrate specificity (L99 and 
I174) are represented in the peptic digests.  TCEP allowed additional coverage to be 
obtained in the A-chain (-3 to 7), as well as a region encompassing W215 and the Na+ 
binding site (212-227).  Appendix C lists the m/z values for the fragments obtained from 
a peptic digest of thrombin. 
Figure 24:  31P 1D NMR spectra for 
the γ′ YP418YP422 peptide in the 
presence of thrombin.  A. Spectrum for 
1.5 mM peptide in solution.  B. 
Spectrum for 1.5 mM peptide in the 
presence of 0.162 mM IIa.  Both 
phosphotyrosines are contacting the 
enzyme surface resulting in a slight 
downfield shift of the broadened peak.   
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IIa with or without the addition of 1 mM γ′ peptide was exposed to 100% D2O for 
either 1 or 10 minutes.  The concentration of 1 mM γ′ peptide provided at least 99.93% 
occupancy of 40-50 µM IIa (KD = 0.68 µM) (69).  Table 4 and Figure 26 present the raw 
data representing total deuterium incorporation for IIa.  The fourteen quantifiable 
peptides represent ten distinct regions within IIa (Figure 25).  When analyzing IIa alone, 
five of these regions were continuing to exchange for deuterium after 10 minutes:  85-99, 
106-116, 173-181, 202-207, and 212-227.  These residues span ABE-II, the Na+ binding 
site, and the substrate specificity residues L99, I174, and W215.  The other five segments, 
representing ABE-I, the A-chain, and the autolysis loop, became saturated with 
deuterium at 1 minute:  -13 to -4, -3 to 7, 46-52, 65-84, and 135-149D.  The continued 
uptake of deuterium over the entire observed time range is specific to amide protons more 
protected from the solvent, or partially solvent exposed.  Conversely, almost complete 
initial saturation of the peptide indicates a more solvent exposed region (229).   
Figure 25: Sequence coverage from the peptic digest of bovine thrombin. The solid 
black lines indicate quantifiable peptide clusters obtained without a reducing agent, 
while dashed lines refer to peptides acquired in the presence of TCEP.  This coverage 
represents 44% of the total sequence and includes residues from both anion binding 
exosites, the W148 loop, the Na+ binding site, and several residues involved in substrate 
specificity (L99, I174, and W215).  Residues in the catalytic triad are green.  ABE-I 
amino acids are blue and ABE-II residues are red. 
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 Differences in Deuteration for Thrombin versus γ′ Peptide-Thrombin.  The γ′ 
peptide imparts a significant amount of solvent protection (Table 5; Figure 26) in five IIa 
peptides representing two regions within ABE-II.  Peptides 85-94, 85-96, and 85-99 are 
situated in the center of ABE-II.  Peptides 173-180 and 173-181 involve peripheral ABE-
II residues and the substrate specificity residue I174.  After ten minutes, differences in 
HDX for these ABE-II regions significantly increase when compared to one minute 
Figure 26: Graphs of deuterium incorporation for IIa, PPACK-IIa, γ′-IIa, and γ′ PPACK-IIa.  A. one minute 
and B. ten minutes of HDX for IIa in the absence or presence of ligands.  The bars in the graph correspond 
to:  IIa (purple), PPACK-IIa (magenta), γ′ peptide-IIa (green), and γ′ peptide PPACK-IIa (orange).  The 
asterisk symbol (*) located after 6 fragments on the x-axis refers to data obtained in the absence of TCEP 
for fragments.  Errors correspond to standard deviation of the mean for three independent experiments. 
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(Table 5).  For example, γ′ peptide binding within 85-94 leads to HDX protection of 0.5 
deuterons at 1 minute (-5.6%), which increases to 1.6 deuterons at 10 minutes (-17.7%) 
(Figure 27).   
Table 4:  Deuterium Incorporation for IIa, PPACK-IIa, γ′-IIa, and γ′ PPACK-IIa at 
One and Ten Minutes 
1 Minute Residues Theo. Dmaxa IIa P-IIa γ′ IIa γ′ P-IIa 
-13 to -4b 
-3 to 7 
46-52 
65-84 
85-94 
85-96 
85-99 
106-113b 
106-116b 
135-149D 
173-180b 
173-181b 
202-207b 
212-227 
8.5 
16.9 
6.6 
21.8 
8.8 
10.9 
15.2 
6.7 
9.8 
19.4 
7.8 
8.8 
6.8 
15.9 
3.7 ± 0.1 
5.3 ± 0.1 
0.4 ± 0.0 
   10.5 ± 0.1 
1.4 ± 0.0 
2.2 ± 0.1 
4.4 ± 0.0 
1.6 ± 0.0 
2.0 ± 0.1 
7.8 ± 0.1 
1.7 ± 0.1 
1.7 ± 0.1 
2.3 ± 0.0 
3.4 ± 0.1 
3.4 ± 0.1 
5.0 ± 0.1 
0.4 ± 0.0 
  10.1 ± 0.2 
1.5 ± 0.1 
1.8 ± 0.1 
3.4 ± 0.1 
1.5 ± 0.1 
1.8 ± 0.1 
6.8 ± 0.1 
1.1 ± 0.1 
1.1 ± 0.1 
2.3 ± 0.0 
2.5 ± 0.1 
2.7 ± 0.1 
2.8 ± 0.1 
0.3 ± 0.0 
7.2 ± 0.1 
0.9 ± 0.0 
0.9 ± 0.1 
1.9 ± 0.1 
0.9 ± 0.1 
1.3 ± 0.1 
6.9 ± 0.0 
1.1 ± 0.1 
1.2 ± 0.1 
1.4 ± 0.1 
2.4 ± 0.1 
2.3 ± 0.0 
2.3 ± 0.0 
0.4 ± 0.0 
5.0 ± 0.1 
0.8 ± 0.1 
0.7 ± 0.0 
1.2 ± 0.0 
0.9 ± 0.0 
1.2 ± 0.1 
4.9 ± 0.1 
1.0 ± 0.1 
1.1 ± 0.1 
1.2 ± 0.1 
1.5 ± 0.1 
10 Minutes Residues Theo. Dmax IIa P-IIa γ′ IIa γ′ P-IIa 
-13 to -4b 
-3 to 7 
46-52 
65-84 
85-94 
85-96 
85-99 
106-113b 
106-116b 
135-149D 
173-180b 
173-181b 
202-207b 
212-227 
8.5 
16.9 
6.6 
21.8 
8.8 
10.9 
15.2 
6.7 
9.8 
19.4 
7.8 
8.8 
6.8 
15.9 
     3.6 ± 0.1 
5.3 ± 0.1 
0.4 ± 0.0 
   10.4 ± 0.2 
2.6 ± 0.1 
3.7 ± 0.1 
6.4 ± 0.1 
2.3 ± 0.0 
2.8 ± 0.1 
7.7 ± 0.1 
2.6 ± 0.1 
2.7 ± 0.1 
2.6 ± 0.1 
4.0 ± 0.1 
3.7 ± 0.1 
5.3 ± 0.1 
0.4 ± 0.0 
  10.5 ± 0.1 
2.7 ± 0.1 
3.4 ± 0.2 
5.5 ± 0.1 
2.3 ± 0.1 
2.8 ± 0.1 
7.3 ± 0.1 
2.1 ± 0.1 
2.1 ± 0.1 
2.8 ± 0.1 
2.7 ± 0.1 
3.2 ± 0.2 
4.3 ± 0.1 
0.4 ± 0.0 
9.7 ± 0.2 
1.0 ± 0.1 
0.9 ± 0.1 
3.0 ± 0.2 
1.4 ± 0.2 
1.8 ± 0.2 
7.8 ± 0.1 
1.2 ± 0.1 
1.2 ± 0.1 
2.2 ± 0.1 
3.7 ± 0.2 
     3.1 ± 0.2 
4.4 ± 0.1 
0.4 ± 0.1 
8.7 ± 0.2 
1.0 ± 0.1 
1.0 ± 0.1 
2.3 ± 0.1 
1.3 ± 0.1 
1.7 ± 0.1 
6.4 ± 0.1 
1.0 ± 0.1 
1.0 ± 0.1 
2.1 ± 0.1 
2.4 ± 0.1 
aThe maximum number of exchangeable protons within the indicated peptide, 
assuming 100% deuteration.  This value accounts for all exchangeable backbone 
amide protons and a slight fraction of N-terminal, C-terminal, and side chain 
exchangeable protons that are dependent on the final percentage of D2O in solution 
under quench conditions (approximately 4.5%).  A fully deuterated peptide would 
theoretically have acquired this amount of deuterons.  bThe deuterium uptake for these 
peptides was quantified from the non-reducing digests.  All other peptides are from 
the digests with TCEP.  When isotopic clusters appear in both the TCEP and non-
TCEP digests, the differences in deuteration are negligible when comparing similar 
peptides.  Certain peptides appear exclusively under non-reducing or reducing 
conditions, hence the necessity of performing both types of peptic digests. 
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In addition to the noted protection within the vicinity of ABE-II, the γ′ peptide also 
shielded regions distant from ABE-II.  Unlike the ABE-II fragments, these thrombin 
segments lost some of their degree of protection as the incubation with D2O was 
increased from 1 to 10 minutes.  Such thrombin segments are likely not becoming 
completely solvent excluded in the presence of the γ′ peptide.  The regions affected 
include ABE-I (65-84 and 106-116), the A-chain (-13 to -4 and -3 to 7) and a nearby B-
chain loop (202-207), the W215 region (212-227), and the autolysis loop (135-149D).  See 
Table 5 and also Figure 26.  Figures 28B and 28D illustrate that within one minute the 
isotopic cluster representing residues within ABE-I (65-84) underwent a -15.1% 
difference in deuteration relative to free thrombin whereas the cluster for residues within 
the W215 region (212-227) underwent a -6.3% difference.  Fragment 46-52 of thrombin 
remained insensitive to the γ′ peptide binding to ABE-II.   
Figure 27: Mass spectra of IIa 
residues 85-94 after one and ten 
minutes of HDX.  All D-on 
experiments are in 150 mM NaCl, 
25 mM NaH2PO3, pH 6.5 (HDX 
buffer). A and F: the undeuterated 
peak cluster, B and G:  thrombin 
spectrum in the absence of 
ligands, C and H: PPACK 
inhibited thrombin, D and I: γ′ 
peptide bound to thrombin, and E 
and J: γ′ peptide bound to PPACK 
inhibited thrombin.  This peak 
cluster contains the ABE-II 
residue R93 and experiences a 
significant degree of protection 
from deuterium in the presence of 
the γ′ peptide.  This protection 
from solvent is maintained over 
the course of ten minutes. 
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Differences in Deuteration Between PPACK-Thrombin and the γ′ Peptide-PPACK-
Thrombin Complex.  γ′ peptide binding to PPACK-IIa resulted in significant protection 
from HDX for almost every IIa region (Tables 4 and 5; Figure 26).  After 10 minutes of 
HDX, the peptide 85-99 (2102.12 m/z) experiences a decrease in deuteration of -21.8% in 
the presence of the γ′ peptide, a decrease of -5.5% with PPACK inhibition, and both 
interacting together with IIa result in a decrease of -26.6% (Table 5).  These additive 
shifts lead to lower m/z values for the peptide as can be seen by comparing the isotopic 
clusters of PPACK-IIa, γ′ peptide-IIa, and γ′ peptide-PPACK IIa (Figures 27 and 28).   
Located adjacent to this ABE-II region is the fragment 173-181.  This segment 
encompasses several residues involved in substrate specificity (R173 and I174) and some 
peripheral ABE-II residues (R173 and R175).  When examining the results for one minute 
of HDX, the binary and ternary complexes with IIa offer similar degrees of protection 
Figure 28: Mass spectra of IIa 
residues 65-84 and 212-227 after one 
minute of HDX.  All D-on 
experiments are in 150 mM NaCl, 25 
mM NaH2PO3, pH 6.5 (HDX buffer). 
A: the undeuterated peak cluster, B: 
thrombin spectrum in the absence of 
ligands, C: PPACK inhibited 
thrombin, D: γ′ peptide bound to 
thrombin, and E:  γ′ peptide bound to 
PPACK inhibited thrombin. 
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(between -5.9% and -7.1%) (Table 5).  After ten minutes of HDX, differences are more 
apparent.  The γ′ peptide (-16.9%) appears capable of imparting an increasing degree of 
protection over 10 minutes whereas PPACK’s affect remains at similar levels (-6.6%).   
Another region of thrombin for which there are some time dependent trends in 
deuteration involves residues 212-227 (Table 5).  Shifts to this peptide’s isotopic cluster 
can be followed in Figure 28.  After one minute of HDX, both PPACK and the γ′ peptide 
impart a similar degree of protection from solvent (-6.0% and -6.3%).  Protection of the 
ternary γ′-PPACK-IIa complex appears additive at (-12.1%).  Similarities in protection 
for the binary complexes, however, are lost within 10 minutes of HDX.  PPACK-IIa now 
exhibits protection of (-7.9%), whereas γ′ peptide binding no longer significantly affects 
this region (-1.5%).  Interestingly, the degree of protection of the ternary complex is still 
roughly additive (-10.0%).  Contrary to results for segment 173-181, it is the PPACK, not 
the γ′ peptide, which dominates in hindering exchange for segment 212-227.  
Two solvent exposed regions encompassing ABE-I (65-84) and the autolysis loop 
(135-149D) present evidence of a synergistic effect involving the interactions of both 
ligands (Table 5).  After one minute of HDX, the presence of PPACK affords very little 
HDX protection for 65-84 (-1.6%) (Figure 28C), whereas the γ′ peptide provides 
significant protection (-15.1%) (Figure 28B).  Interestingly, both ligands together offer 
even more protection from solvent than an additive effect would suggest (-25.1%) 
(Figure 28D).  The same is true for the segment spanning 135-149D.  The presence of 
both these ligands appears to stabilize these surface regions of IIa, protecting the 
backbone amides from exchange more effectively than either ligand acting alone.   
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The peptides spanning residues -13 to 7, 106-116, and 202-207 experienced roughly 
similar protection when the γ′ peptide bound to ABE-II in the presence or absence of 
PPACK (Tables 4 and 5).  PPACK’s sphere of influences must not extend to these 
fragments.  The A-chain peptides -13 to -4 and -3 to 7 incorporate an almost identical 
amount of deuterium at one minute and after ten minutes display similar % differences 
(ranging from -5.1% to -6.1%).  Located in close proximity to the A-chain, the fragment 
202-207 was also protected from solvent within ten minutes of deuteration by a 
comparable amount to the A-chain (-6.1%).  Finally, peptides 106-113 and 106-116, 
containing several peripheral ABE-I residues, incorporated virtually identical amounts of 
deuterium regardless of the presence of PPACK.  
 
 
 
 
 
 
 
 
  
Table 5:  Changes in % Deuteration for IIa, PPACK-IIa, γ′-IIa, and γ′ PPACK-IIa 
Complexes at One and Ten Minutes Relative to Free IIaa 
P-IIa γ′ IIa γ′ P-IIa Residues Theo. Dmax b 1 min 10 min 1 min 10 min 1 min 10 min 
-13 to -4c 
-3 to 7 
46-52 
65-84 
85-94 
85-96 
85-99 
106-113c 
106-116c 
135-149D 
173-180c 
173-181c 
202-207c 
212-227 
8.5 
16.9 
6.6 
21.8 
8.8 
10.9 
15.2 
6.7 
9.8 
19.4 
7.8 
8.8 
6.8 
15.9 
-3.6 
-2.0 
0.0 
-1.6 
1.1 
-3.9 
-6.3d 
-1.6 
-2.1 
-5.5 
-7.7 
-6.6 
0.5 
-6.0 
0.8 
0.0 
0.0 
0.4 
1.2 
-2.5 
-5.5 
-0.5 
-0.6 
-2.2 
-7.0 
-6.6 
2.9 
-7.9 
-11.3 
-15.0 
-0.2 
-15.1 
-5.6 
-12.3 
-16.4 
-10.0 
-6.9 
-4.6 
-7.3 
-5.9 
-13.2 
-6.3 
-5.1 
-6.1 
-0.7 
-3.3 
-17.7 
-25.9 
-21.8 
-13.1 
-10.0 
-0.5 
-18.6 
-16.9 
-6.1 
-1.5 
-15.9 
-18.2 
0.1 
-25.1 
-6.2 
-13.4 
-20.9 
-10.8 
-8.3 
-15.2 
-8.7 
-7.1 
-15.8 
-12.1 
-5.8 
-5.6 
-0.6 
-7.9 
-17.6 
-25.2 
-26.6 
-13.9 
-11.2 
-6.9 
-21.3 
-19.3 
-6.1 
-10.0 
aThe % change for a particular peptide is calculated by Equation 7 (Chapter III).  bThe 
maximum number of exchangeable protons within the indicated peptide, assuming 
100% deuteration (Chapter III).  A fully deuterated peptide would theoretically have 
acquired this amount of deuterons.  cThe deuterium uptake for these peptides was 
quantified from the non-reducing digests.  All other peptides are from the digests with 
TCEP.  When isotopic clusters appear in both the TCEP and non-TCEP digests, the 
differences in deuteration are negligible when comparing similar peptides.  Certain 
peptides appear exclusively under non-reducing or reducing conditions, hence the 
necessity of performing both types of peptic digests.  dThe values in bold represent 
significant changes in deuteration of greater than -4.5%. 
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Discussion 
The binding interface for the γ′ peptide has been localized to thrombin anion-
binding exosite II through fluorescence studies (69, 70).  Additional information is 
needed on the conformational features the peptide adopts upon binding and the 
contribution each sulfotyrosine makes toward the thrombin interaction.  There is also 
interest in determining the residues within thrombin ABE-II that make contact with the 
peptide and the possible long range effects associated with a binding event at this exosite.  
The current work employs solution NMR methods and HDX coupled with MALDI-TOF 
mass spectrometry to further describe the γ′ peptide-thrombin relationship (167).  Since 
the γ′ peptide-thrombin structure has been recently crystallized (242), the data in this 
chapter will be compared to the X-ray structure when relevant to the discussion.  
Analysis of NMR Data:  Insight into the Structural Requirements for the γ′ Peptide 
Interaction with Thrombin’s ABE-II.  One-dimensional (1D) 1H and 31P NMR 
demonstrate that the YP418YP422 peptide makes significant contact with the IIa surface 
(Figures 20 and 24).  The NMR broadening effects are in agreement with observations 
that truncation of the γ′ peptide from E411-L427 to A414-L427 decreases binding affinity 
almost 4-fold whereas peptides lacking the N-terminal residues P410-T416 demonstrate no 
observable binding to ABE-II (60, 69).  The current work makes it possible to identify 
individual protons on amino acids that participate in this binding.  The consequences of 
removing the phosphates were also screened using 1D 1H and 31P NMR line broadening.  
Figures 21 and 22 demonstrate that both the YP418 and YP422 peptides are interacting with 
IIa.  The binding segment of the YP422 peptide exhibits more extensive contact with IIa 
than the YP418 peptide, suggesting a more instrumental role for YP422 in anchoring the γ′ 
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peptide segment to thrombin.  Although phosphorylation at either position is enough to 
support the ABE-II interaction, the presence of both phosphates in the γ′ peptide 
promotes more effective binding to IIa as evidenced by the increased line broadening.   
Two-Dimensional (2D) trNOESY spectra supply critical information regarding the 
conformational features the peptides adopt when interacting with thrombin.  All three 
phosphorylated peptides generate similar spectra illustrating that IIa-bound structural 
characteristics are preserved as long as one YP is present.  Key conformational features 
for the bound γ′ peptides include a turn between residues Y422-D425 (Figure 23A), a trans 
conformation adopted by both Xxx-Pro bonds, and a cluster of NOEs centered around the 
aromatic rings of both Y residues (Figure 23B).  The Y residues and their neighbors are 
major contributors to establishing the bound structure. The results demonstrate the 
requirement of at least one YP in the interaction of the γ′ chain and ABE-II.   
2D NMR with Gamma-Thrombin:  The γ′ Peptide Targets ABE-II.  Previous 
solution studies have demonstrated that the primary binding site for the γ′ peptide is 
ABE-II (69, 70).  Recent crystal structures of GpIbα and thrombin display interactions 
occurring with both ABE-II and ABE-I (96, 97).  GpIbα and the γ′ peptide have quite a 
comparable clustering of YS, E, and D residues (Table 1).  Therefore, 2D trNOESY NMR 
spectra were obtained for the γ′ peptide in the presence of gamma-thrombin to address if 
the peptide is interacting with ABE-I or influenced by this exosite.  The gamma variant of 
thrombin retains catalytic activity while possessing an impaired ABE-I due to cleavages 
after residues R75/R77A and K149E (53).  The spectra obtained were remarkably similar to 
the spectra obtained for wild type thrombin, suggesting that the structural information 
results from interactions at ABE-II (data not shown).   
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Comparing the NMR data with the X-ray Crystal Structure.  Before the X-ray 
structure for this complex was solved, the NMR data predicted several conformational 
features adopted by the bound peptide.  One of these structural elements was a turn 
conformation at the peptide’s C-terminus (YP422-D425) (167).  The NMR work suggested 
extensive interactions with every residue within the peptide with the exception of the first 
three residues (P410, E411, and H412) (167).  Figure 29 depicts the crystal structure of the γ′ 
peptide-IIa (242).  The structure was reported at 2.4Å and is lacking sufficient electron 
density to model residues P410, E411, H412, and L427 (242).  The 1D NMR results (Figure 
20) predicted a limited role for the γ′ peptide’s N-terminus in binding to IIa (167), which 
is in agreement with the X-ray structure (242) and solution studies with truncated γ′ 
peptides (60, 69).  As for L427, the NMR study suggests that this residue does contribute 
to IIa binding (167), even though L427 is not modeled in the structure (242). 
The 2D trNOESY experiments provided evidence for a trans configuration for the 
two P amide bonds in the peptide (167).  As mentioned, H412 was not modeled in the X-
ray structure, thus the H412-P413 bond is not present (242).  However, the YP422-P423 bond 
is in the trans configuration, forming the beginning of the turn structure that was also 
predicted by the NMR data (Figures 23A and 29) (242).  An additional feature of the 2D 
trNOESY spectra was the presence of significant C-terminal interactions with the protons 
spanning residues YP418-L427 (Figures 23B and 29; Appendix B) (167).  The C-terminal 
turn amongst residues YP422-D425 enables the peptide to bend back on itself, supporting 
the extensive amount of NOEs observed for the aromatic ring of YP422 (242).  
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Analysis of HDX Results (I): Comparing the HDX data with the X-ray Crystal 
Structure.  HDX coupled with the MALDI-TOF MS was performed to gain further 
insight on the location of the γ′ peptide interface with IIa.  Observed decreases in 
deuteration could be the product of a restricted ensemble of conformations (protein 
stabilization), a conformational change, or a ligand-protein interface.  When examining 
the HDX results, differences in deuteration at sites located within ABE-II are due 
primarily to the shielding of backbone amides from solvent by the γ′ peptide.  Regions 
Figure 29:  Crystallographic views of the γ′ peptide bound to thrombin (I) (2HWL).  A. The γ′ peptide 
isolated from thrombin.  The individual amino acids are labeled.  YP418 is yellow.  The trans bond between 
YP422-P423 is light blue and the turn structure YP422-D425 is blue.  B. Illustration of γ′ peptide induced 
dimerization of IIa.  The turn conformation is situated between the two symmetry related IIa monomers. 
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distant from the γ′ peptide-IIa interface that display protection from the solvent are 
probably experiencing a change in dynamics due to binding at ABE-II.  
A number of mutagenesis studies and crystallographic structures have demonstrated 
the importance of IIa residues R93, R101, and K240 in the binding of ligands to ABE-II (66, 
73, 96, 97, 168, 169, 250) (Figure 19).  As described in the introduction, ligand binding 
to IIa appears to involve two separate ABE-II interfaces that both utilize residues R93, 
R101, and K240 (Figure 19).  The HDX data present evidence that the γ′ peptide is 
interacting with ABE-II residues within the fragments 85-99 and 173-181 (Table 5).  
These results compare extremely well to the γ′ peptide-IIa X-ray structure, which 
illustrates an ABE-II interaction similar to heparin and GpIbα (Figures 19 and 30A).  
Specifically, the HDX data supports the observed electrostatic interactions between R93T- 
S420γ′ and N179T-D419γ′ (Figure 30B).  In addition, the residue R93 from a symmetry related 
IIa interacts with both D425 and D426 (Figure 30B).   The authors also describe a 
hydrophobic pocket formed by I162, V163, R165, F181 (part of peptide 173-181), A183, and 
the disulfide C168-C182 into which the residues P413 and A414 insert (Figure 30B).  
Unfortunately, lack of peptic digest coverage for many of the residues that bind the γ′ 
peptide prevented analysis of their contribution to the interaction, including the C-
terminal helix 233-240. 
There is evidence that binding of the γ′ peptide to IIa ABE-II reduces the rate at 
which fibrinopeptide A (FpA) is released from fibrinogen and the chromogenic substrate 
S2238 is hydrolyzed (113).  Contact of the γ′ peptide with the thrombin regions 85-99 
and 173-181 could explain the hindered release of FpA.  Crystal structures of FpA (7-16) 
and IIa demonstrate the importance of R97, E97A and I174 in orienting FpA in the active 
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site (248).  HDX results indicate that regions containing these residues are protected from 
deuteration in the presence of γ′ peptide.  Since the crystal structure has identified the 
residues R93, N179, and F181 as being involved in binding, perhaps the γ′ chain could be 
Figure 30:  Crystallographic views of the γ′ peptide bound to IIa (II) (2HWL).  A. View of the γ′ peptide 
binding into the groove formed by ABE-II residues in a similar manner as heparin and GpIbα.  B. Depiction 
of key interactions detected by HDX and illustrated in the crystal structure.  The orange fragment is 85-99 
and the yellow fragment is 173-181.  The catalytic triad is pink.  The text contains descriptions of the 
relevant features highlighted in this figure including the hydrophobic pocket (green) and the γ′ peptide (red). 
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hindering the helical turn of FpA from optimally accessing the active site region through 
an allosteric mechanism.  The conformation of R97, E97A and I174 may be perturbed due to 
allostery resulting from γ′ peptide binding, ultimately reducing the rate of catalysis (70, 
170) (Figure 30B).  A similar suggestion has been offered for the inhibition of fibrinogen 
clotting activity by the chondroitin sulfate moiety of thrombomodulin (250). 
Analysis of HDX Results (II):  Determining the Consequences of Ligand Binding to 
ABE-II on Several Key Regions of Thrombin.  Binding of ligands (fibrinogen Aα, PAR-1, 
thrombomodulin, and hirudin) to ABE-I has clearly been shown to affect reactivity 
within the thrombin active site region (240).  The reduced release of FpA from fibrinogen 
in the presence of γ′ peptide-IIa (113) supports a linkage from ABE-II to the active site.  
Conflicting reports address the existence of an allosteric linkage between ABE-I and 
ABE-II (170, 171).  The current studies provide evidence that ligand binding to ABE-II is 
perturbing the rate of HDX at other distant sites.  The HDX results suggest lines of 
communication from ABE-II to ABE-I (Figure 31C), from ABE-II to a segment 
containing W215 (Figure 31D), and from ABE-II to a region of the A-chain (Figure 31D). 
Interaction of the γ′ peptide with ABE-II resulted in a segment of ABE-I 
representing residues 65-84 to become more protected from solvent.  A pathway from 
ABE-II to ABE-I can be traced from L99 back toward residue L65 as seen in Figure 31B.  
Electrostatic interactions between two anti-parallel β-strands, including contacts between 
the residues E86-K107, K87-K107, and M84-K109 explain how an ABE-II binding event could 
be relayed to the peripheral ABE-I region involving residues 106-113 (51) (Figure 31C).  
A similar line of communication has been reported in a prior (233) and in our own HDX 
study of PPACK inhibited thrombin.  PPACK alone offers little protection for residues 
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85-96 (Table 5), while the observed protection within 97-99 is in part attributable to 
contacts with L99.  These PPACK interactions are proposed to be transmitted to ABE-I 
via the β-strand formed by residues 85-96 (233) 
Examining the γ′ peptide-PPACK-IIa complex reveals more information about sites 
of distant influence.  The ternary interactions resulted in a synergistic effect on the rate of 
deuterium exchange for the solvent exposed regions 65-84 (ABE-I) and 135-149D 
(autolysis loop) (Figure 31B).  This suggests that simultaneous binding of γ′ peptide and 
Figure 31: Correlating HDX results with X-ray structure of PPACK-IIa (1PPB).  W60D is yellow.  A.  
ABE-II region 85-99 blue and 173-181 green.  The additional ABE-II region not observed in the 
present HDX study, 233-240, is in pink.  B.  The flexible solvent exposed regions 65-84 red and 135-
149D brown.  Both PPACK and the γ′ peptide significantly stabilize the segments upon ternary 
complex formation with thrombin.  C.  Line of communication from ABE-II, 85-99 blue, to ABE-I, 
65-84 red and 106-116 purple.  D.  The A-chain.  There are several electrostatic contacts between the 
A-chain residues 1H -7 red and the B chain residues 202 -207 teal.  Also represented are 85 -99 blue 
and 212-227 green.  The β-strand connecting 202-207 to 212-227 is orange.  
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PPACK to thrombin significantly stabilizes these portions of the protease.  Effects on the 
environment of 212-227 are also important to consider.  The additive effect observed for 
the ternary complex suggests that the two ligands may be independently influencing the 
solvent accessibility of 212-227.  The γ′ peptide could be affecting residues near W215 
and/or other regions within the residues 212-227, while the D-Phe of PPACK is known to 
exhibit beneficial interactions with W215 via a perpendicular aryl-aryl arrangement (51).  
In addition to altering the deuterium exchange dynamics for regions involving 
ABE-II, ABE-I, and the active site region, the γ' peptide also exhibits effects on a portion 
of the thrombin A chain and a nearby B-chain fragment 202-207 (Figure 31D).  As can 
be seen in Figure 31D, a direct connection cannot be made from ABE-II to the A-chain.  
Deletion of K9 from the A-chain has recently been shown to perturb the pKa of the 
catalytic residue H57 slowing the catalytic activity of IIa (251).  K9 contacts D1A which is 
part of a segment that undergoes protection from solvent in the presence of the γ' peptide.  
The γ' peptide decreases kcat values for the hydrolysis of the small chromogenic substrate 
S2238 (113).  Perhaps γ' peptide binding to ABE-II leads to a line of communication to 
the A-chain and the nearby B-chain segment 202-207 through the active site.   
HDX studies on the binding of ligands to thrombin have revealed both local and 
long range effects (172, 173, 230, 233).  The current work with the γ' peptide illustrate 
lines of communication from ABE-II to ABE-I and from ABE-II to regions of the 
extended active site.  Studies with PPACK-IIa display connections from the active site to 
similar regions of ABE-I and the edge of ABE-II (233).  Binding of the thrombomodulin 
fragment TMEGF45 to thrombin ABE-I has led to perturbations in deuterium exchange 
within the 90s loop of ABE II (172, 173).  A distinct linkage between ABE-I and ABE-II 
 86 
may also have been demonstrated in earlier work involving a mixture of γ' peptide, IIa, 
and Fibrin 1 (fibrinogen lacking the γ' extension) (60).  These different observations 
support the concept of an inter-exosite linkage reported between the two ABE-II binding 
ligands prothrombin fragment 2 and γ' peptide and the ABE-I (70, 170).  On the contrary, 
another study with hirudin and heparin ligands did not observe as significant a negative 
allostery for the ABE-I/ABE-II connections (171).  The HDX studies presented here 
cannot evaluate the extent to which inter-exosite linkages affect enzyme function but they 
can establish potential lines of communication between the sites.   
Conclusions.  In this investigation, interactions between a series of γ′ peptides and 
thrombin were characterized using solution NMR and HDX coupled with MALDI-TOF 
MS.  1D NMR results indicate that residues H412-L427 of the YP418YP422 peptide are 
responsible for the primary sites of contact with the thrombin surface and illustrate the 
importance of sulfonation at the Y422 position.  Data from the 2D trNOESY spectra 
demonstrate that the ABE-II bound γ′ peptide adopts significant secondary structure in 
the presence of at least one phosphotyrosine.  HDX results suggest that the γ′ peptide 
interacts with thrombin ABE-II.  In response to this binding, other regions of thrombin 
also experience protection from deuteration including ABE-I, regions near the active site, 
and a portion of the A-chain.  Finally, thrombin can form a ternary complex with the γ′ 
peptide and PPACK generating an enzyme that is further stabilized from HDX.    
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CHAPTER V 
STUDYING GPIBα (269-286) PEPTIDE INTERACTIONS WITH THE THROMBIN 
ANION BINDING EXOSITES 
 
Introduction 
GpIbα is part of a transmembrane receptor complex of glycoproteins on the surface 
of platelets (74-77).  GpIbα serves a multitude of functions that include binding 
coagulation proteins, adhering platelets to the site of damaged tissue, and aiding in the 
recruitment of leukocytes to combat infection.  IIa interacts with GpIbα leading to 
enhancements in the activation of PAR-1, FXI, and GpV (67, 83, 87).  As mentioned in 
Chapter I, GpIbα residues 269-286 share a similar clustering of anionic residues as found 
in the γ′ peptide (410-427) (Table 1).  The studies on γ′ peptide binding to IIa described 
in Chapter IV were originally conducted due to the absence of a reported crystal structure 
illustrating this interaction (167).  In the case of GpIbα-IIa, two independent crystal 
structures have been published pertaining to the binding of these proteins (96, 97).  An 
unresolved issue is why independent groups attribute GpIbα binding either to ABE-II 
(68, 92) or to ABE-I (93, 101), while the γ′ peptide targets ABE-II (69, 70, 167, 242). 
The X-ray structures involving GpIbα possess important similarities and 
differences regarding the mode of IIa interaction (96, 97) (Figure 32).  In the reported 
structures, insufficient electron density prevented the modeling of GpIbα’s C-terminus.  
The Dumas structure (1P8V) ends at Y279 (96), while the Celikel structure (1OOK) 
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includes 5 additional residues (P280-T284) at the C-terminus (97).  The N-terminus of 
residues 269-286 appears to be rather flexible, adopting a turn conformation in 1P8V (96) 
and a fully extended structure in 1OOK (97).  Though both groups report a 1:1 
asymmetric unit, the proteins in symmetry related molecules display unique binding 
interfaces.  Both structures illustrate similar GpIbα interactions with ABE-II, but differ in 
regard to the depiction of GpIbα binding to ABE-I.  1OOK shows the C-terminal tail of 
GpIbα potentially dimerizing IIa through interactions with both exosites (97).  In 1P8V, 
the second IIa molecule binds to GpIbα at the C-terminal end of the leucine rich repeat 
domain (in blue) through ABE-I (96). 
The focus of this chapter is to further characterize the GpIbα-IIa interaction by 
using peptides based on the sequence 269-286 (Table 6), perhaps the γ′ peptide and the 
GpIbα peptide share similar characteristics when binding thrombin.  For example, the C-
terminal turn structure observed for the γ′ peptide (167, 242) is not being modeled in the 
Dumas structure (1P8V), which ends at residue Y279 (96).  The sequence of the γ′ peptide 
Figure 32:  Two views of GpIbα binding to thrombin.  The crystal structures depict similar ABE-II 
interactions but differ in the depiction of thrombin dimerization.  In blue is GpIbα and the anionic C-
terminal tail is in red.  Thrombin in gold binds to the C-terminal tail, while thrombin in green binds at 
different interfaces.  The structure on the left is 1P8V (96), the structure on the right 1OOK (97). 
1P8V 1OOK 
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turn (422YSPED425), however, is very similar to the comparable C-terminal stretch of 
residues in GpIbα (279YSPEE282) (Table 1).  In addition, when the GpIbα peptide binds to 
IIa there are comparable long-range allosteric effects observed as with the γ′ peptide.  For 
the GpIbα studies (as with the γ′ peptide), phosphotyrosines were substituted for the 
naturally occurring sulfotyrosines without sacrificing binding affinity.  This type of 
substitution has been reported to have a minimal effect on binding affinity (69, 241). 
1D and 2D NMR experiments demonstrate that the GpIbα peptide binds to IIa in an 
extended conformation, with a majority of the residues contacting IIa’s surface.  
Additional work with HDX coupled with MALDI-TOF MS suggests a concentration 
dependence in regard to the GpIbα binding interface on IIa.  In addition, the HDX results 
display allostery related to GpIbα interactions with IIa.  GpIbα peptide binding to IIa 
alters the dynamics of deuterium incorporation at sites unaffiliated with the binding 
interface. Finally, analytical ultracentrifugation (AUC) was performed to observe the 
behavior of thrombin when binding the GpIbα peptide or the γ′ peptide in solution.   
Materials and Methods 
Synthetic Peptides and Thrombin Purification.  Bachem (King of Prussia, PA) 
synthesized peptides based on residues 269-286 of GpIbα (Table 6).  SynPep (Dublin, 
CA) synthesized a peptide based on residues 410-427 of the human fibrinogen γ′ chain 
variant (Table 3 in Chapter IV, only the YP418YP422 peptide).  MALDI-TOF MS 
measurements on an Applied Biosystems Voyager DE-Pro mass spectrometer were used 
to verify peptide m/z values.  The concentrations of the peptide in solution were 
determined by quantitative amino acid analysis (AAA Service Laboratory, Boring, OR).  
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Bovine IIa was purified as described by Trumbo and Maurer (243).  The use of bovine IIa 
in place of human IIa is justified in the Material and Methods of Chapter IV. 
Table 6:  GpIbα Peptides Used in IIa Binding Studies 
YP276 YP278 YP279 269DEGDTDLYPDYPYPEEDTEG286 
YP276 Y278 YP279 269DEGDTDLYPDYYPEEDTEG286 
Y276 Y278 Y279 269DEGDTDLYDYYEEDTEG286 
 
1H and 31P NMR Sample Preparation and Analysis.  Approximately a 1:10 ratio of 
enzyme to peptide was maintained for the complex studied.  Sample preparation and 
analysis were similar to those described by Trumbo and Maurer (190).  Selective features 
are summarized here.  Each 400 µl NMR sample contained 1.5 mM peptide and either 
zero or 150 µM bovine IIa.  The samples were buffered in 25 mM H3PO4, 150 mM NaCl, 
0.2 mM EDTA, pH 5.6 and 10% D2O.  1H NMR experiments were performed on a 
Varian Inova 500 MHz equipped with a triple resonance probe and pulsed-field z-axis 
gradients.  2D transferred NOESY experiments of the enzyme-peptide complexes were 
run at 17 °C with 32 transients, 512 t1 increments, mixing time of 400 ms, and a spectral 
width of 5006 Hz.  Spectra were processed using FELIX2000 software (Accelerys, San 
Diego, CA) on a Silicon Graphics O2 workstation.  For 31P NMR, spectra were recorded 
on a Varian Inova 500 MHz equipped with a 5 mm broadband probe tuned to 202.4 MHz.  
The spectra were referenced to the peak corresponding to H3PO4 (0.00 ppm). 
HDX Sample Preparation.  Thrombin was buffer exchanged into 75mM NaCl, 
12.5mM NaH2PO4, pH 6.5 with an Amicon-Ultra 4 unit (10 kDa MWCO).  The 
concentration of IIa for all HDX preparations varied between 20-25 µM.  Enough GpIbα 
peptide was added to achieve a 20:1 or 40:1 ratio during the HDX experiments.  For the 
γ′ peptide, only 40:1 ratios were examined during this investigation.  The data reported 
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for IIa alone and γ′ peptide-IIa (20:1) was previously published and discussed in Chapter 
IV (167); inclusion in this chapter is purely for comparison to GpIbα results.  The 
aliquots of buffer-exchanged IIa with peptide were evaporated to dryness using a 
SpeedVac unit (Savant).  The dry aliquots were stored at -70°C.  
HDX Experiments.  Dry aliquots of γ′ peptide-IIa (40:1) or GpIbα-IIa (20:1 and 
40:1) were allowed to come to room temperature before beginning the experiment.  First, 
12µL of D2O was added to the dry aliquot yielding the final concentrations:  40-50 µM 
IIa, 1 mM or 2 mM GpIbα/γ′ peptide, 150 mM NaCl, 25 mM NaH2PO4, pH 6.5.  The 
samples were incubated in a desiccator at room temperature for 1 minute or 10 minutes.  
After incubation, 114 µL of 0.1% TFA pH 2.5 (on ice) was added to quench the solution.  
Next, 66 µL of the quenched solution was transferred to a tube of activated pepsin bound 
to agarose.  To the remaining 60 µL, 6 µL of 1 M TCEP-HCl in 0.1% TFA was added to 
reduce the disulfides bonds of IIa and then immediately added to another tube of pepsin.  
Digestion occurred on ice for 10 minutes.  Centrifugation at 4°C separated the digest 
from the pepsin and 8.2 µL aliquots were immediately frozen in liquid N2.  
HDX Analysis.  A frozen aliquot was thawed, immediately mixed with an equal 
volume of 10 mg/mL α-CHCA matrix in 1:1:1 ethanol/acetonitrile/0.1% TFA, pH 2.2 
and 0.5 µL spotted onto a chilled stainless steel MALDI plate.  The plate was dried with 
the SpeedVac (Savant) and inserted into the MALDI-TOF MS.  This procedure should 
consume around five minutes of time, limiting the amount of hydrogen back exchange.  
The spectra were collected in the reflector mode over a mass range of 800-3500 m/z with 
256 laser shots per spectrum.  Peptides obtained from the peptic digest of thrombin were 
previously identified (167, 233, 234).  
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The spectra were collected and analyzed using Data Explorer (Applied Biosystems). 
Calibration of the spectra involved two reference peptides, one with the singly protonated 
monoisotopic mass of 888.4943 Da (46-52) and the other with the singly protonated 
pentaisotopic mass of 2106.1505 Da (85-99).  The amount of deuterium uptake by each 
peptide and the % difference relative to IIa alone was quantified as described by Sabo et 
al. and in Chapter III (167).  At least three spectra were collected during each trial and 
three trials were run for each time point under each condition. 
Analytical Ultracentrifugation.  IIa was inhibited with a two-fold excess of PPACK 
for 30 min.  An assay involving the chromogenic substrate S2238 was employed to 
ensure that IIa was inactive.  PPACK-IIa was then subjected to overnight dialysis with 
150mM NaCl, 25mM phosphate, pH 7.4.  The γ′ or GpIbα peptide was lyophilized and 
reconstituted in the same buffer.  A series of sedimentation velocity AUC experiments 
ranging from 1, 2, 5, 10, and 20 times peptide to IIa (4.5-7.0 µM) in duplicate was 
performed in a XL-A AUC (Beckman-Coulter).  The parameters for each run were 
60,000 rpm, 25°C, and 280nm.  The data was analyzed with the program DC-DT+.  
Results 
1H and 31P One-Dimensional Line Broadening NMR.  1D NMR experiments were 
performed to determine which proton or phosphorous nuclei within the GpIbα (269-286) 
peptide interact with IIa.  The first set of spectra collected examined GpIbα 
(YP276YP278YP279) and displayed the absence of significant line broadening for the 1H 1D 
NMR spectra of the peptide in the presence of IIa (data not shown).  Similar results were 
obtained when performing 31P 1D NMR (data not shown).  These findings indicate that 
the triply phosphorylated peptide binds too tightly to IIa’s surface.  Thus, the transfer of 
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information regarding peptide proton or phosphorous interactions with the protein back to 
the free peptide population does not occur.  The result is a 1D spectrum for the peptide in 
the presence of IIa similar to the free peptide (see Chapter II for further explanation). 
Since the GpIbα (YP276YP278YP279) peptide spectra did not display line broadening, a 
doubly phosphorylated variant was synthesized.  The GpIbα (YP276YP279) peptide still 
interacts with IIa (demonstrated by the two crystal structures (96, 97)), but the absence of 
one phosphotyrosine may sufficiently weaken the interaction for the appearance of 1D 
line broadening.  The spectra in Figure 33 focus on the amide region and do illustrate line 
broadening in the presence of IIa.  Most of the broadening encompasses residues D275-
YP279, while a modest amount of broadening is observed for residues E281-D283.  
However, the line broadening is not extensive, with residues D269-D274 and T284-G286 
appearing unchanged from the free peptide spectrum.  Curiously, the 31P spectra do not 
present evidence of line broadening (data not shown).  These results suggest two 
possibilities.  The peptide may be binding too tightly for the N- and C-terminal residues 
to display line broadening or these residues are not involved in the interaction with IIa. 
A final peptide was synthesized without any phosphotyrosines.  Much more line 
broadening is evident with the unphosphorylated peptide (Figure 33).  The central portion 
of the peptide spanning D274-Y279, E281, and D283 display a significant amount of line 
broadening.  The residues E282 and E285 show a modest amount of broadening.  Finally, 
the N-terminal residues D269-T273 and the C-terminal residues T284 and G286 do not appear 
to be essential for the interaction of GpIbα (269-286) with IIa. 
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Two-Dimensional Transferred Nuclear Overhauser Effect NMR.  For the triply 
phosphorylated peptide, the 2D spectra of the free peptide were indistinguishable from 
the spectrum with the peptide in the presence of the enzyme (data not shown).  For the 
doubly phosphorylated and unphosphorylated GpIbα peptides, the 2D trNOESY spectra 
displayed only nearest neighbor NOEs in the presence of the enzyme.  Appendix A has 
tables for the chemical shift assignments of both the free and bound unphosphorylated 
GpIbα.  Only 2D NMR spectra in the presence of thrombin were collected for GpIbα 
(YP276YP279) and these resonances are compiled in Appendix A. 
Figure 33:  Line broadening spectra for the GpIbα peptides in the presence of thrombin.  All NMR 
samples are in 25 mM H3PO4, 150 mM NaCl, 200 µM EDTA, and 10% D2O, pH 5.6.  A. 1D NMR 
spectrum for 1.5 mM YP276YP279 peptide in solution.  B. 1D NMR spectrum for 1.5 mM YP276YP279 peptide 
in the presence of 0.148 mM IIa.  The amide protons that display the most line broadening are D275-YP279.  
A moderate amount of line broadening is evident for the NHs of E281-D283.  Line broadening is not 
observed for the amide protons of D269-D274 and T284-G286.  C. 1D NMR spectrum for 1.5 mM 
unphosphorylated peptide in solution.  D. 1D NMR spectrum for 1.5 mM unphosphorylated peptide in the 
presence of 0.150 mM IIa.  The amide protons that display the most line broadening are D274-YP279, E281, 
and D283.  A moderate amount of line broadening is evident for the NHs of E282 and E285.  Line broadening 
is not observed for the amide protons of D269-T273, T284, and G286. 
 
A 
B 
C 
D 
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Figure 34 presents some of the key features from the unphosphorylated GpIbα-IIa 
2D trNOESY spectra.  The presence of only nearest neighbor NOEs suggests that the 
peptide adopts an extended conformation when binding to IIa.  In addition, the Y279-P280 
amide bond is in the trans conformation.  With the GpIbα (YP276YP279) peptide, slightly 
fewer inter-residue NOEs are observed in the presence of IIa when compared to 
unphosphorylated GpIbα (data not shown).  With the doubly phosphorylated GpIbα, a 
trans conformation is also evident for the YP279-P280 peptide bond. 
Figure 34:  Representative spectra of GpIbα peptide NOEs in the presence of thrombin.  2D 
trNOESY spectrum of the unphosphorylated GpIbα (1.5 mM) bound to IIa (0.150 mM). The top 
panel illustrates the evidence for a trans Y279-P280 peptide bond.  The bottom panels demonstrate that 
GpIbα exists in an extended structure when bound to IIa due to the presence of only nearest neighbor 
NOEs.  The NOEs are color coded according to the corresponding residue. 
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HDX Experiments (I):  Observing the Effect of the GpIbα (YP276YP278YP279) Peptide 
on Thrombin’s Backbone Amide Solvent Accessibility.  In contrast to the NMR 
experiments, the strong interaction between the GpIbα (YP276YP278YP279) and IIa is an 
important asset when performing HDX (see Chapter III).  Chapter IV describes the 
sequence coverage obtained from a peptic digest of IIa with or without the aid of the 
reducing agent TCEP (Figure 25).  The fourteen fragments contain coverage for ABE-I, 
ABE-II, the autolysis loop, the Na+ site, the A-chain, and residues involved in substrate 
recognition and catalysis.   
The GpIbα (YP276YP278YP279) peptide (1 mM) was incubated with IIa (50 µM) at 
room temperature for one or ten minutes in the presence of 99.99% D2O.  The KD for the 
interaction of the GpIbα (269-286) peptide with IIa has not been determined.  A previous 
study found that GpIbα residues 265-285 bound to IIa with a KD of 5.9 nM (101).  In 
addition, the NMR results suggest that the binding of the GpIbα (269-286) peptide to IIa 
is probably tighter than γ′ peptide (410-427) (KD = 680 nM) (69).  Therefore, similar 
HDX concentrations of the peptide and IIa (20:1) were used as described in Chapter IV.   
The results for deuterium incorporation are compiled in Table 7 and Figure 35.  The 
GpIbα peptide significantly protects fragments spanning residues 85-99 (Figure 36) and 
173-181 from deuterium.  In fact, the protection from solvent, as represented by negative 
% differences in Table 8, increases from one to ten minutes suggesting this peptide is 
binding to ABE-II.  These results are similar in magnitude to the effects of the γ′ peptide 
on deuterium exchange at ABE-II (Table 8).  Within one minute of deuteration, the 
GpIbα peptide protects the fragment 85-99 by 2.7 deuterons (-17.3%) and the γ′ peptide 
by 2.5 deuterons (-16.4%) (Figure 36B, C, and D).  After 10 minutes of deuteration, the 
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GpIbα peptide shields the same fragment from solvent by 3.7 deuterons (-23.9%) and the 
γ′ peptide by 3.4 deuterons (-21.8%) (Figure 36 H, I, and J).  
 As with the γ′ peptide, the GpIbα peptide protects regions within IIa unaffiliated 
with binding at ABE-II.  Most of these peptides are more shielded from deuterium within 
one minute of exchange compared to ten minutes.  These fragments are considered not to 
be completely solvent excluded in the presence of the GpIbα peptide.  The regions 
Figure 35:  Graphs of deuterium incorporation for IIa, GpIbα-IIa, and γ′-IIa at 20:1.  The bars in 
the graph correspond to IIa alone (red), GpIbα-IIa (green) and γ′ peptide-IIa (blue).  Errors 
correspond to the standard deviation of the mean for three independent experiments. 
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affected by GpIbα binding to ABE-II after one minute of deuterium exchange include the 
ABE-I fragments 65-84 (-18.3%), 106-113 (-9.9%), and 106-116 (-7.2%), the A-chain 
residues -13 to -4 (-17.8%) and -3 to 7 (-17.3%) and the nearby B-chain fragment 202-
207 (-15.6%), and finally the W215/Na+ binding site region 212-227 (-5.8%) (Table 8). 
Table 7:  Deuterium Incorporation for IIa, GpIbα-IIa, and γ′-IIa at One and Ten Minutes 
1 Minute 
 20:1 40:1 Residues Theo. Dmax a IIa GpIbα IIa γ′ IIa GpIbα IIa γ′ IIa 
-13 to -4b 
-3 to 7 
46-52 
65-84 
85-94 
85-96 
85-99 
106-113b 
106-116b 
135-149D 
173-180b 
173-181b 
202-207b 
212-227 
8.5 
16.9 
6.6 
21.8 
8.8 
10.9 
15.2 
6.7 
9.8 
19.4 
7.8 
8.8 
6.8 
15.9 
3.7 ± 0.1 
5.3 ± 0.1 
0.4 ± 0.0 
 10.5 ± 0.1 
1.4 ± 0.0 
2.2 ± 0.1 
4.4 ± 0.0 
1.6 ± 0.0 
2.0 ± 0.1 
7.8 ± 0.1 
1.7 ± 0.1 
1.7 ± 0.1 
2.3 ± 0.0 
3.4 ± 0.1 
2.2 ± 0.1 
2.4 ± 0.1 
0.4 ± 0.1 
6.5 ± 0.3 
0.9 ± 0.1 
0.9 ± 0.2 
1.7 ± 0.2 
0.9 ± 0.0 
1.3 ± 0.1 
7.3 ± 0.4 
1.0 ± 0.1 
1.1 ± 0.1 
1.2 ± 0.1 
2.5 ± 0.1 
2.7 ± 0.1 
2.8 ± 0.1 
0.3 ± 0.0 
7.2 ± 0.1 
0.9 ± 0.0 
0.9 ± 0.1 
1.9 ± 0.1 
0.9 ± 0.1 
1.3 ± 0.1 
6.9 ± 0.0 
1.1 ± 0.1 
1.2 ± 0.1 
1.4 ± 0.1 
2.4 ± 0.1 
n/ac 
3.3 ± 0.0 
0.4 ± 0.0 
2.6 ± 0.1 
1.1 ± 0.1 
1.3 ± 0.1 
2.1 ± 0.3 
n/a 
n/a 
3.3 ± 0.1 
n/a 
n/a 
n/a 
2.5 ± 0.1 
2.2 ± 0.0 
2.1 ± 0.3 
0.3 ± 0.0 
5.6 ± 0.1 
0.8 ± 0.1 
0.7 ± 0.1 
1.6 ± 0.2 
0.8 ± 0.1 
1.2 ± 0.1 
6.3 ± 0.0 
1.0 ± 0.1 
1.1 ± 0.1 
1.2 ± 0.1 
2.4 ± 0.1 
10 Minutes 
 20:1 40:1 Residues Theo. Dmax IIa GpIbα IIa γ′ IIa GpIbα IIa γ′ IIa 
-13 to -4b 
-3 to 7 
46-52 
65-84 
85-94 
85-96 
85-99 
106-113b 
106-116b 
135-149D 
173-180b 
173-181b 
202-207b 
212-227 
8.5 
16.9 
6.6 
21.8 
8.8 
10.9 
15.2 
6.7 
9.8 
19.4 
7.8 
8.8 
6.8 
15.9 
    3.6 ± 0.1 
5.3 ± 0.1 
0.4 ± 0.0 
 10.4 ± 0.2 
2.6 ± 0.1 
3.7 ± 0.1 
6.4 ± 0.1 
2.3 ± 0.0 
2.8 ± 0.1 
7.7 ± 0.1 
2.6 ± 0.1 
2.7 ± 0.1 
2.6 ± 0.1 
4.0 ± 0.1 
3.2 ± 0.3 
3.8 ± 0.4 
0.4 ± 0.0 
8.9 ± 0.5 
1.2 ± 0.1 
1.2 ± 0.2 
2.7 ± 0.1 
1.3 ± 0.1 
1.8 ± 0.1 
7.5 ± 0.6 
1.3 ± 0.1 
1.3 ± 0.1 
1.6 ± 0.2 
3.6 ± 0.3 
3.2 ± 0.2 
4.3 ± 0.1 
0.4 ± 0.0 
9.7 ± 0.2 
1.0 ± 0.1 
0.9 ± 0.1 
3.0 ± 0.2 
1.4 ± 0.2 
1.8 ± 0.2 
7.8 ± 0.1 
1.2 ± 0.1 
1.2 ± 0.1 
2.2 ± 0.1 
3.7 ± 0.2 
n/a 
6.6 ± 0.1 
0.6 ± 0.0 
7.6 ± 0.1 
3.1 ± 0.1 
4.0 ± 0.1 
6.2 ± 0.1 
n/a 
n/a 
8.2 ± 0.0 
n/a 
n/a 
n/a 
5.4 ± 0.0 
3.3 ± 0.1 
4.0 ± 0.1 
0.4 ± 0.0 
9.6 ± 0.3 
1.1 ± 0.1 
1.2 ± 0.1 
2.5 ± 0.1 
1.4 ± 0.0 
1.8 ± 0.1 
8.0 ± 0.1 
1.3 ± 0.1 
1.2 ± 0.1 
1.7 ± 0.1 
3.9 ± 0.2 
aThe maximum number of exchangeable protons within the indicated peptide, assuming 100% 
deuteration (Chapter III).  A fully deuterated peptide would theoretically have acquired this 
amount of deuterons.  bThe deuterium uptake for these peptides was quantified from the non-
reducing digests.  All other peptides are from the TCEP digests.  When isotopic clusters appear 
in both the TCEP and non-TCEP digests, the differences in deuteration are negligible when 
comparing similar peptides.  Certain peptides appear exclusively under non-reducing or 
reducing conditions, hence the necessity of performing both types of peptic digests.  cThese 
fragments were not able to be quantified in the non-reducing digest at 40:1 GpIbα to IIa. 
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After ten minutes of deuteration, the two A-chain fragments lose some degree of 
protection from solvent, with -13 to -4 down to -5.2% and -3 to 7 reduced to -8.6%; 
however, the nearby B-chain fragment 202-207 is at a similar level compared to one 
Figure 36:  Mass spectra of residues 85-99 after one and ten minutes of HDX.  All of the 
D-on experiments are in 150 mM NaCl, 25 mM NaH2PO3, pH 6.5.  A and G: the 
undeuterated peak cluster, B and H: IIa spectra in the absence of ligands, C and I: γ′ 
peptide (1 mM) bound to IIa (50 µM) at a 20:1 ratio, D and J: GpIbα peptide (1 mM) 
bound to IIa (50 µM) at a 20:1 ratio, E and K: γ′ peptide (2 mM) bound to IIa (50 µM) at 
a 40:1 ratio, and F and L: GpIbα peptide (2 mM) bound to IIa (50 µM) at a 40:1 ratio.  At 
the ratio of 20:1, both peptides exhibit a similar degree of protection for these ABE-II 
residues; however in spectrum J a small shoulder is present suggesting the presence of 
two IIa populations.  Increasing the amount of peptide completely abrogates protection 
after ten minutes in the presence of the GpIbα peptide, while the γ′ peptide begins to 
display a similar shoulder at ten minutes. 
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minute (-14.1%).  The ABE-I fragment 65-84 (-6.7%) also is reduced in the observed 
amount of deuterium protection.  The segments 106-113 (-13.7%) and 106-116 (-9.5%) 
experience slight increases in protection at ten minutes.  The W215/Na+ binding site 
peptide 212-227 (-2.1%) ceases to be significantly protected from solvent after ten 
minutes of deuteration.  GpIbα binding does not change the dynamics of deuterium 
exchange for the fragments 46-52 and 135-149D (the autolysis loop). 
Table 8:  Changes in % Deuteration for GpIbα-IIa and γ′-IIa at 1 and 10 Minutes Relative to Free IIaa 
20:1 40:1 
GpIbα IIa γ′ IIa GpIbα IIa γ′ IIa Residues Theo. Dmax b 1 min 10 min 1 min 10 min 1 min 10 min 1 min 10 min 
-13 to -4c 
-3 to 7 
46-52 
65-84 
85-94 
85-96 
85-99 
106-113c 
106-116c 
135-149D 
173-180c 
173-181c 
202-207c 
212-227 
8.5 
16.9 
6.6 
21.8 
8.8 
10.9 
15.2 
6.7 
9.8 
19.4 
7.8 
8.8 
6.8 
15.9 
-17.8 d 
-17.3 
0.5 
-18.3 
-5.5 
-12.4 
-17.3 
-9.9 
-7.2 
-2.5 
-8.1 
-6.3 
-15.6 
-5.8 
-5.2 
-8.6 
-0.5 
-6.7 
-15.3 
-22.8 
-23.9 
-13.7 
-9.5 
-1.1 
-17.6 
-15.5 
-14.1 
-2.1 
-11.3 
-15.0 
-0.2 
-15.1 
-5.6 
-12.3 
-16.4 
-10.0 
-6.9 
-4.6 
-7.3 
-5.9 
-13.2 
-6.3 
-5.1 
-6.1 
-0.7 
-3.3 
-17.7 
-25.9 
-21.8 
-13.1 
-10.0 
-0.5 
-18.6 
-16.9 
-6.1 
-1.5 
n/a 
-12.0 
0.8 
-36.2 
-3.4 
-8.2 
-14.8 
n/a 
n/a 
-23.2 
n/a 
n/a 
n/a 
-6.0 
n/a 
7.8 
3.0 
-12.7 
6.3 
2.8 
-1.1 
n/a 
n/a 
2.3 
n/a 
n/a 
n/a 
9.2 
-17.3 
-19.1 
-0.3 
-22.3 
-6.3 
-13.7 
-18.0 
-11.0 
-8.1 
-7.8 
-8.5 
-6.4 
-15.7 
-6.5 
-4.0 
-7.9 
-0.2 
-3.8 
-16.9 
-22.8 
-25.7 
-12.8 
-9.5 
1.0 
-17.6 
-16.5 
-12.2 
-0.7 
aThe % change for a particular peptide is calculated by Equation 7 (Chapter III).  bThe maximum 
number of exchangeable protons within the indicated peptide, assuming 100% deuteration. (Chapter 
III).  A fully deuterated peptide would theoretically have acquired this amount of deuterons.  cThe 
deuterium uptake for these peptides was quantified from the non-reducing digests.  All other peptides 
are from the TCEP digests.  When isotopic clusters appear in both the TCEP and non-TCEP digests, the 
differences in deuteration are negligible when comparing similar peptides.  Certain peptides appear 
exclusively under non-reducing or reducing conditions, hence the necessity of performing both types of 
peptic digests.  dThe values in bold represent significant changes in deuteration of greater than -4.5%.  
eThese fragments were not able to be quantified in the non-reducing digest at 40:1 GpIbα to IIa. 
  
When comparing the amount of deuterium incorporation for these fragments in the 
presence of the GpIbα peptide to the γ′ peptide, very similar trends are observed for the 
segments -13 to -4, -3 to 7, 106-113, 106-116, and 212-227.  Differences do exist for two 
peptides in regard to the amount of protection still present after ten minutes.  The ABE-I 
residues 65-84 (-6.7% for GpIbα vs. -3.3% for γ′) and the peptide 202-207 (-14.1% for 
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GpIbα vs. -6.1% for γ′) are more protected at ten minutes by the GpIbα peptide than the 
γ′ peptide (Table 8).  In addition, the γ′ peptide exhibits protection from solvent for the 
autolysis loop fragment 135-149D (-4.6%) after one minute, whereas the GpIbα peptide 
does not appear to influence this region.  These results suggest that GpIbα binding to IIa 
has subtly different consequences on protein dynamics when compared to the γ′ peptide. 
In Figure 36J, the isotopic cluster for residues 85-99 has an interesting feature not 
observed with the other fragments in the peptic digest.  The cluster appears to be 
expanded with a slight shoulder ending near 2115 m/z.  This larger peak envelope was 
observed consistently in each experiment when the concentration of GpIbα was 1 mM 
and IIa was 50 µM (20:1 molar ratio).  The results suggest the presence of two different 
IIa populations exposed to deuterium during HDX.  In order to test this theory, HDX was 
performed on a higher ratio (40:1) of peptide (2 mM) to IIa (50 µM).  Perhaps the newly 
emerging second population of IIa would eventually dominate the results.  
 HDX Experiments (II):  Examining the Influence of a Higher Peptide Concentration 
on the Dynamics of Thrombin’s Deuterium Incorporation.   In HDX experiments with 
40:1 GpIbα peptide to IIa, only the digests with TCEP presented reliable isotopic clusters 
for quantification.  Thus, the amount of deuteration for the fragments -13 to -4, 106-113, 
106-116, 173-180, 173-181, and 202-207 was unable to be reported at this GpIbα peptide 
concentration (2 mM).  These problems were not encountered with the γ′ peptide and the 
data for all fourteen peptides are presented in Tables 7 and 8.  Figure 37 graphically 
illustrates the data for HDX at 40:1 peptide to thrombin. 
For the γ′ peptide, deuterium incorporation for the fragments representing ABE-II 
residues 85-99 (Figures 36E and K) and 173-181 were similar at 2 mM peptide (40:1) as 
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at 1 mM peptide (20:1) (Table 8).  Interestingly, Figure 36K displays the appearance of a 
similar shoulder on the 85-99 isotopic cluster for 40:1 γ′ peptide-IIa that was observed 
with the GpIbα peptide during the 20:1 experiments (Figure 36I).  In fact, many of the 
other fragments obtained from the non-reducing digests are analogous to the results for 
GpIbα at 20:1.  The A-chain residues -13 to -4 are initially protected to a greater degree 
Figure 37: Graphs of deuterium incorporation for IIa, GpIbα-IIa, and γ′-IIa at 40:1.  These 
results are taken from the digests with the reducing agent TCEP.  The bars in the graph 
correspond to IIa alone (red), GpIbα-IIa (green) and γ′ peptide-IIa (blue).  Errors correspond 
to the standard deviation of the mean for three independent experiments. 
A-Chain 
A-Chain 
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(-17.3% for 40:1 vs. -11.3% for 20:1) and residues 202-207 maintain a steady difference 
in deuterium incorporation over ten minutes (-15.7% at one minute to -12.2% at ten 
minutes) (Table 8).  The ABE-I fragment 106-116 is shielded from deuterium in a similar 
manner at both peptide concentrations.  The only significant difference between 40:1 γ′ 
peptide and 20:1 GpIbα peptide is apparent in the autolysis loop, where the γ′ peptide 
protects residues 135-149D from deuterium after 1 minute of exchange. 
GpIbα binding to IIa at a higher peptide concentration reveals a different 
mechanism for peptide interaction.  Figure 38 illustrates the one minute HDX spectra for 
ABE-I residues 65-84.  At 40:1 and one minute of HDX, the GpIbα peptide imparts a 
dramatic amount of protection for 65-84 amounting to 7.9 deuterons up from 4.0 
deuterons at 20:1 (Figure 38D and F; Tables 7).  Even after ten minutes of deuteration, 
the protection is 2.8 deuterons compared to 1.5 deuterons at 20:1.  The γ′ peptide at both 
HDX concentrations shows a significant amount of initial protection (Figure 38C and E), 
which dissipates after ten minutes of deuteration.  Examining the effect of GpIbα on 
ABE-II, residues 85-94 are not shielded from HDX after one minute (-3.4%); however, 
within ten minutes, these residues are more exposed to solvent (+6.3%).  HDX in 85-96 
and 85-99 reveal protection from solvent within a minute of deuterium exposure, but ten 
minutes of HDX leaves these residues at similar levels to IIa alone (Figure 36H and L).  
Three additional IIa regions display new responses to GpIbα peptide binding.  Both 
the A-chain fragment -3 to 7 and the W215/Na+ binding site peptide (212-227) are 
shielded from deuterium within one minute (-12.0% and -6.0% respectively); however 
ten minutes of deuterium exposure results in both of these regions becoming more 
available for deuterium exchange when compared to IIa alone (+7.8% and +9.2% 
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respectively) (Table 8).  With the autolysis loop, 20:1 GpIbα peptide did not affect the 
amount of deuterium incorporation relative to free IIa.  By increasing the concentration of 
the GpIbα peptide (40:1), the residues 135-149D are now protected by -23.2% within a 
minute of deuterium exchange and that protection is abrogated after ten minutes (+2.3%). 
Analytical Ultracentrifugation.  AUC was employed to determine whether the 
GpIbα peptide or the γ′ peptide induces dimerization of IIa in solution.  In these AUC 
trials, the concentrations of PPACK inhibited IIa spanned 4.7-7.0 µM.  A series of 
sedimentation velocity experiments were executed with a range of peptide to IIa molar 
ratios varying from 1:1 to 20:1.  Two trials with IIa alone were performed for comparison 
to the peptide-IIa experiments.  Table 9 presents the data for the average of two runs.  
Figure 38:  Mass spectra of residues 65-84 
after one minute of HDX.  All D-on 
experiments are in 150 mM NaCl and 25 
mM NaH2PO3, pH 6.5.  Panels:  A. the 
undeuterated peak cluster, B. IIa spectrum 
in the absence of ligands, C. γ′ peptide (1 
mM) bound to IIa (50 µM), D. GpIbα 
peptide (1 mM) bound to IIa (50 µM), E. γ′ 
peptide (2 mM) bound to IIa (50 µM), and 
F. GpIbα peptide (2 mM) bound to IIa (50 
µM). 
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Figures 39 and 40 illustrate the raw SV data used to construct the distribution of 
Svedberg constants (S) for the trial examining the GpIbα peptide and IIa at a 2:1 ratio 
and the γ′ peptide and IIa at 1:1, respectively.  
The Svedberg constant measures the rate of sedimentation, which is related to the 
size and shape of the molecule.  It should be noted that this constant is not additive, 
though molecular weight is additive.  In other words, S values are affected by the amount 
of surface area exposed to solvent.  Thus when two proteins interact, the surface area is 
decreased leading to a non-additive increase in the S constant.  The calculated Svedberg 
constants for the peptide binding to the enzyme range from 3.2-3.3, compared to 3.1 for 
IIa alone.  The slight increase in molecular weight with increasing peptide concentration 
coupled with the slight increase in S values seem to propose that the peptides bind to IIa 
but appear not to instigate protein dimerization. 
Table 9: Analytical Ultracentrifugation Data 
 Sedimentation Coefficient (S) Molecular Weight (kDa) 
IIa alone 3.11 ± 0.00 36.2 ± 0.3 
GpIbα peptide:IIa   
1:1 3.19 ± 0.02 37.3 ± 0.0 
2:1 3.18 ± 0.01 37.5 ± 0.9 
5:1 3.27 ± 0.05 37.9 ± 0.7 
10:1 3.25 ± 0.02 37.2 ± 1.1 
20:1 3.22 ± 0.01 38.1 ± 1.4 
γ′-peptide:IIa   
1:1 3.19 ± 0.02 39.3 ± 1.0 
2:1 3.22 ± 0.03 38.6 ± 0.4 
5:1 3.23 ± 0.03 39.9 ± 0.2 
10:1 3.27 ± 0.01 39.9 ± 0.6 
20:1 3.28 ± 0.01 40.9 ± 0.7 
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Figure 39:  Sedimentation velocity AUC of GpIbα peptide (14 µM) and IIa (7 µM).  
Analysis was performed at 280 nm, 20 °C, and 60,000 rpm in 150 mM NaCl, 25 mM 
phosphate, pH 7.4.  Top Panel: Raw data set for the sedimentation velocity run examining 
this interaction.  Bottom Panel: The apparent Svedberg constant distribution centered at 3.2 
S with the residuals resulting from a global fit of the data using the DCDT+ program. 
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Figure 40:  Sedimentation velocity AUC of γ′ peptide (4.7 µM) and IIa (4.7 µM). 
Analysis was performed at 280 nm, 20 °C and 60,000 rpm in 150 mM NaCl, 25 mM 
phosphate, pH 7.4.  Top Panel:  Raw data set for the sedimentation velocity run 
examining this interaction.  Bottom Panel: The apparent Svedberg constant distribution 
centered at 3.2 S with the residuals resulting from a global fit of the data using the 
DCDT+ program. 
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Discussion 
 GpIbα binds to IIa, however, the literature presents evidence for interactions at both 
anion binding exosites.  Though mutagenesis data strongly suggest that GpIbα binds 
exclusively at ABE-II (23, 68, 92), binding studies display interactions at both exosites 
(68, 93, 95, 98, 101).  Adding to the ambiguity, two crystal structures of GpIbα-IIa 
illustrate similar interactions at ABE-II for one IIa molecule, while a symmetry related 
IIa binds to GpIbα through ABE-I at different GpIbα interfaces (96, 97) (Figure 32).  
The studies described in this chapter use solution NMR, HDX coupled with MALDI-
TOF MS, and AUC to investigate the interaction of the GpIbα peptide with thrombin.  
The results will be described in terms of the crystal structures when applicable (96, 97).        
 Analysis of NMR Data:  the GpIbα Peptide Binds to Thrombin in an Extended 
Conformation.  Initially, NMR experiments were performed with the triply 
phosphorylated GpIbα peptide.  The 1D spectra did not display line-broadening and the 
2D trNOESY lacked the presence of inter-residue NOEs.  These results indicate that the 
koff for this peptide is too slow for these types of NMR experiments (see Chapter II).  In 
order to sufficiently weaken the interaction and observe the trNOESY effect, the GpIbα 
peptide was dephosphorylated, first at Y278, then at all three Y residues.  Conflicting 
accounts exist regarding the interaction of unphosphorylated variants of GpIbα and IIa.  
One report describes unphosphorylated GpIbα as unable to bind to thrombin (252), while 
another group demonstrated competitive inhibition of FVIII hydrolysis by IIa in the 
presence of unphosphorylated GpIbα peptide (residues 268-282) (65).  The present 
investigation supports the observation that unphosphorylated GpIbα can effectively 
interact with IIa. 
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 The NMR results from both GpIbα (YP276YP279) and the unphosphorylated GpIbα 
peptide can be used to describe the two different conformations of the GpIbα residues 
269-277 in both X-ray structures (Figure 41A) (96, 97).  The residues D269-T273 of the 
GpIbα peptide do not display line broadening suggesting that these residues do not 
contribute to IIa binding.  Also, the 2D trNOESY spectra do not support the existence of 
a turn conformation present in the Dumas structure (1P8V) between residues D274-D277 
(96).  Thus, the N-terminus of this peptide probably exists as a flexible portion of the 
GpIbα protein, able to adopt both of the conformations observed in the two structures. 
 Curiously, these results are at odds with a prior study focusing on the inhibition of 
IIa binding to platelets and glycocalicin by GpIbα based peptides (101).  The group 
showed that residues E270-T273 are important for inhibiting platelet and glycocalicin 
interactions with IIa (101).  Yet, both X-ray structures show that D269-T273 does not make 
electrostatic contacts with residues from thrombin (96, 97).  Another study demonstrated 
that residue D269-G271 are not essential for GpIbα binding (98).  The present data and the 
X-ray structures (96, 97) seem to deemphasize D269-T273 as important for binding IIa. 
 The 2D trNOESY data in conjunction with the 1D NMR appear to support the 
Celikel structure (1OOK) more so than the Dumas structure (1P8V).  The Celikel X-ray 
crystal (1OOK) displays the residues 269-284 in an extended conformation sandwiched 
between two thrombin monomers (Figure 41B) with a trans conformation for YP279-P280 
(Figure 41A) (97).  Electrostatic interactions are observed for residues D274-T284 with 
both ABE-I and ABE-II (Figure 42) (97).  Presumably, residues P280-G286 are too 
disordered in the Dumas structure (1P8V) to be effectively modeled (96); yet the NMR 
data displays significant interactions with thrombin for several of the residues within this 
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sequence.  Assuming the Celikel structure (1OOK) is an accurate representation of a 
potential mode of GpIbα-IIa binding (97), the 1D line broadening support the possibility 
of GpIbα binding to both exosites of thrombin in an extended conformation through 
dimerization of the protease.       
Figure 41:  Crystallographic views of GpIbα bound to thrombin (I).  A. Representation of 
the GpIbα peptide isolated from thrombin.  The peptide on the left is from 1OOK and the 
structure on the right is from 1P8V.  The individual amino acids are labeled.  The trans bond 
between YP279-P280 in 1OOK is in light blue.  Residues experiencing line-broadening in the 
1D NMR spectra are in blue.  B. Illustration of GpIbα peptide induced dimerization of 
thrombin in 1OOK.  The data suggests this structure more accurately represents the NMR 
results.  The C-terminus of GpIbα is in an extended conformation and residues D274-T284 
interact with both ABE-II and ABE-I of opposing thrombin monomers. 
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 Analytical Ultracentrifugation: γ′ Peptide and GpIbα Peptide is Unable to Induce 
Dimerization of Thrombin.  To explain the NMR observations (167), dimerization of IIa 
appears to be a necessary requirement. (Figures 29B in Chapter IV and Figure 41B) (97, 
242).  These observations led to AUC being performed with the two peptides and 
PPACK-IIa (PPACK is an active site inhibitor).  It should be noted that the HDX 
experiments demonstrate that the γ′ peptide interacts effectively with PPACK-IIa (Table 
5) (167) and that the GpIbα X-ray structures were solved with PPACK-IIa (96, 97).  The 
AUC results do not depict dimerization of PPACK-IIa by either peptide.  The S values 
calculated for PPACK inhibited bovine IIa (3.1) and PPACK-II in the presence of the 
peptides (3.2-3.3) match those previously determined for the exact same form of IIa (3.3) 
in a similar buffer (253).  The same study shows a fragment of thrombomodulin with a 
similar molecular weight to IIa binding to the serine protease and increasing S from 3.3 to 
4.2 (253).  Thus, IIa dimerization would lead to an increase in the S value. 
An important discrepancy exists between the AUC studies and the NMR/X-ray 
investigations.  For the NMR/X-ray work, higher concentrations of thrombin are required 
(100-150 µM) (96, 97, 167, 242) whereas in the AUC experiments the concentration of 
IIa was much lower in order to avoid saturation of the uv-vis detector.  For example, 4.7 
µM IIa leads to an optical density of 0.41.  Thrombin dimerization by these peptides may 
also have a IIa concentration dependence.  In the future directions section of chapter VII, 
additional experiments are detailed that could independently confirm IIa dimerization by 
the peptides, including the measurement of diffusion coefficients by NMR. 
 Analysis of HDX Results (I):  GpIbα (269-286) Behaves in a Similar Manner to the 
γ′ peptide (410-427) when Binding to Thrombin.  At a ratio of 20:1 GpIbα peptide to IIa, 
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the HDX data illustrate very comparable effects to the γ′ peptide (167) on IIa deuterium 
exchange.  The GpIbα peptide appears to bind to IIa’s ABE-II based on the deuterium 
protection for fragments 85-99 and 173-181 over the course of ten minutes (Figure 42).  
Several residues within these two fragments have been demonstrated to be involved in 
the interaction by mutagenesis and the X-ray crystallography (68, 92, 96, 97).  Two 
residues from the mutagenesis studies are present within 85-99 that reduce GpIbα 
binding when mutated to alanine:  R93 and R97 (68, 92) (Figure 42).  While R97 does not 
appear to interact with GpIbα in the crystal structures, IIa R93 is depicted as being 
prominent residue in binding to YP279 at the C-terminus of both GpIbα crystals (96, 97).  
In addition, the structures display the importance of IIa N179 in binding to GpIbα D277, 
which is within fragment 173-181 (96, 97).  Unfortunately, the coverage from the peptic 
digest does not include a majority of the residues that bind GpIbα at ABE-II, such as 
R101, R126, R165, R233, K235, K236, and K240 (not shown in Figure 42).  
 Several studies have found that GpIbα binding to IIa has consequences on catalysis.  
Increases in the rate of IIa catalysis for FXI (23), PAR-1 (67), and GpV (254) are 
observed when IIa interacts with GpIbα.  Conversely, IIa bound to GpIbα 
noncompetitively inhibits the rate of fibrinopeptide A release and catalysis of small 
chromogenic substrates suggesting an allosteric mechanism transmitted by ABE-II ligand 
binding to the active site (68).  Similar results are described for the ABE-II ligands γ′ 
peptide (113) and the chondroitin sulfate moiety of thrombomodulin (255).  The residues 
R97, E97A, and I174 play important roles orienting and binding FpA for catalysis (248) 
(Figure 42).  These residues are within the fragments 85-99 and 173-181 that contain 
residues involved with binding to GpIbα and display large decreases in % deuteration.  
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Interestingly, R97 does not play a direct role in GpIbα binding to IIa, but when mutated to 
alanine results in an 8-fold increase of KD (92).  Therefore, the binding of GpIbα to ABE-
II is allosterically linked to at least one residue, R97, involved in IIa catalysis of FpA. 
 As with the γ′ peptide, GpIbα is affecting the rate of deuterium exchange for sites 
distant from ABE-II.  Explanations for how allostery is transmitted from ABE-II binding 
to these regions are discussed in Chapter IV (167).  It should be noted that several reports 
have described allostery resulting from glycocalicin binding to ABE-II.  Two ABE-I 
ligands have been demonstrated to display a reduced affinity for IIa when glycocalicin 
binds to ABE-II:  hirudin (256) and PAR-1 (257).  The reduced amount of deuterium 
exchange for the ABE-I regions 65-84 and 106-116 once a ligand binds to ABE-II 
illustrates a linkage between the two exosites and supports the observed non-competitive 
inhibition observed for these ABE-I ligands.   
 A few important differences exist between GpIbα and the γ′ peptide deuterium 
protection at 20:1.  The first variation is that GpIbα does not affect the autolysis loop’s 
(135-149D) rate of HDX after one minute, whereas the γ′ peptide provides a slight 
amount of protection.  In addition, the GpIbα peptide provides slightly more protection 
for the A-chain residues -13 to -4 at one minute.  These two regions are highly flexible.  
The fragment -13 to -4, in addition to being present only in bovine IIa, is not modeled in 
X-ray structures of bovine IIa binding to the ligands FpA and hirudin (258, 259).  Thus, 
these observations for the fragment -13 to -4 may be of little physiologic relevance.  With 
the autolysis loop (135-149D), residue W141 has been postulated to connect ABE-I to the 
active site (233); however the significance of the γ′ peptide’s slight amount of protection 
for this region may just be a result of stabilizing this pliable loop to a small degree. 
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 The most striking variation between the two peptides is the shoulder visible at 
higher m/z for the isotopic cluster representing residues 85-99 when GpIbα interacts with 
IIa (Figure 36K).  This suggests the presence of two different populations of IIa 
exchanging for deuterium.  After ten minutes of deuterium exchange, residues 65-84 still 
show 1.5 deuterons (-6.7%) of protection for GpIbα.  In addition, the fragment 202-207 
does not appear to significantly change in the amount of deuterium incorporation 
compared to one minute of exchange (-15.6% vs. -14.1%).  These longer observed effects 
for these regions coupled with the observation for 85-99 could be a consequence of a 
small fraction of GpIbα binding to ABE-I.  Once bound to ABE-I, the interaction may 
have a negative allosteric effect on ligand binding to ABE-II.  Thus, residues 85-99 are 
no longer protected from deuterium.  Such negative allostery between the exosites has 
been reported in the literature (70, 170).  In order to test this hypothesis, a series of HDX 
experiments at 40:1 peptide to protein were performed.  
Analysis of HDX Results (II):  GpIbα (269-286) Interacts with a Unique Site in 
Thrombin when Compared to the γ′ peptide (410-427).  The HDX results for the γ′ 
peptide at 40:1 demonstrate similar effects on HDX as observed at 20:1 GpIbα.  A 
shoulder begins to appear at higher m/z for 85-99 (Figure 36J).  An increase in protection 
for the A-chain residues -13 to -4 at one minute, coupled with sustained protection for 
202-207 over ten minutes of exchange are also evident in GpIbα (20:1).  However, subtle 
differences are apparent.  Once again, the γ′ peptide slightly protects the autolysis loop 
after one minute of deuteration.  The ABE-I region 65-84 is slightly more protected at 
one minute at 40:1 than at 20:1.  Significant amounts of HDX protection are not observed 
for 65-84 after ten minutes of exchange at both concentrations of the γ′ peptide.   
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Figure 42:  Crystallographic views of GpIbα bound to thrombin (II).  A. The Dumas structure 
(1P8V) and B. the Celikel structure (1OOK).  Regions of HDX coverage are color-coded in both 
structures:  1H-7 (red), 65-84 (blue), 85-99 (orange), 106-116 (yellow), 135-149D (purple), 173-
181 (brown), 202-207 (cyan), and 212-227 (green).  Residues from the GpIbα peptide that interact 
with thrombin are labeled without a colored background.  Residues from thrombin that bind to 
GpIbα or are mentioned in the text are labeled with a corresponding colored background.    
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 These results provide more evidence that these two peptides have slightly different 
consequences on IIa dynamics when binding to ABE-II.  The appearance of a similar 
shoulder for the γ′ peptide at 40:1 as for GpIbα at 20:1 for residues 85-99 suggest that 
perhaps higher concentrations of the γ′ peptide could drive the peptide to ABE-I as well.  
Unfortunately, raising the concentration of the γ′ peptide to 80:1 over IIa significantly 
suppresses peptide ionization in the MALDI-TOF MS.  Therefore, further observing the 
effects of concentration on this interaction was not possible with the HDX technique. 
Eight peptide fragments were quantified at 40:1 GpIbα to IIa.  The non-TCEP 
digests did not yield any peaks in the mass spectra, thus the peptides -13 to -4, 106-116, 
173-181, and 202-207 were unobserved.  These HDX results suggest that the GpIbα 
peptide is now interacting at ABE-I.  Protection for 65-84 is doubled in magnitude from 
20:1 (-18.3%) to 40:1 (-36.2%).  The amount of HDX protection decreases after ten 
minutes (-12.7).  Unexpectedly, the autolysis loop shows quite a dramatic increase in 
HDX protection at one minute of deuteration (-23.2%), disappearing within ten minutes.      
Examining the Celikel X-ray structure illustrates that several residues within 65-84 
and 135-149D are binding to GpIbα in a symmetry related IIa molecule: R73-E282, K145-
E281, and T147- YP279 (Figure 42B) (97).  These autolysis loop interactions suggest 
stabilization of this region that is evident in the HDX results as well as in the Celikel 
structure (97); however, these residues are significantly more disordered in the IIa 
structures with the ABE-I binding thrombomodulin (260) and hirudin (72).  The 
described interactions are not present in the Dumas structure, which only displays ABE-II 
binding for GpIbα (269-286) and is lacking in electron density to model several of the 
residues in the autolysis loop (96).   
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The ABE-II fragment 85-94, with the ABE-II ligand-binding residue R93, is no 
longer protected from HDX after one minute.  The observed protection for residues 95-99 
(within 85-99) may be a result of allostery due to binding at ABE-I, which is also evident 
with thrombomodulin interactions with IIa’s ABE-I (173).  Curiously, fragments -3 to 7 
and 212-227 are initially protected from HDX at one minute, then dramatically increase 
in the amount of HDX at ten minutes.  In fact, the regions -3 to 7, 85-94, and 212-227 are 
more exposed to deuterium at ten minutes when compared to IIa alone.    
The 40:1 HDX studies suggest that GpIbα no longer interacts specifically at ABE-
II, but now binds at a unique interface on IIa, perhaps ABE-I.  The interaction at the new 
interface may be weaker than binding at ABE-II.  Once bound, the GpIbα peptide can no 
longer effectively interact at ABE-II; however, the peptide may retain the ability to bind 
ABE-II through dimerization of IIa.  Therefore, the concentration of IIa and GpIbα may 
have an effect on the type of interaction under study and explain some of the divergent 
results.  The crystal structure reported by Celikel (97) was formed at a total concentration 
of 25 mg/ml while the Dumas structure (96) was reported at 10 mg/ml.  Unfortunately, 
the individual concentrations of IIa and GpIbα within the crystallization solutions were 
not reported.  Regardless, the less concentrated Dumas structure (96) may be reflecting 
the HDX data at 20:1, while the Celikel structure (97) reflective of the 40:1 results.   
The same line of thought becomes more interesting as the competitive binding 
studies determining where GpIbα binds to IIa are considered.  One report declares that 
ABE-I is the destination for GpIbα.  The investigators used IIa at 0.42 nM and GpIbα at 
50 µM to monitor the effect of the peptide on catalytic activity, 100,000 times the amount 
of IIa (93).  Conversely, a study proclaiming ABE-II as GpIbα’s site of interaction 
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implemented much lower ratios of IIa (100 nM) to GpIbα (8 µM) when performing 
competitive binding experiments (68).  These observations suggest that protein/peptide 
concentration plays an important role in determining the destination of GpIbα on IIa.  
Physiologically, IIa interactions with platelets have been characterized by high 
affinity binding (KD = 0.5 nM) and intermediate affinity binding (KD = 50 nM) (261, 
262).  An interesting paradox centers on the presence of 25,000 copies of GpIbα on the 
surface of platelets (263), yet they provide only 105-1050 high affinity binding sites for 
IIa (101, 262).  The 40:1 HDX data suggest a situation where GpIbα no longer targets 
ABE-II and instead binds ABE-I.  In addition, research has shown that low levels of IIa 
activate platelets in a GpIbα dependent manner, whereas higher levels of IIa perform this 
function independent of GpIbα (94, 264).  These studies indicate that the binding 
interface for GpIbα on IIa is concentration dependent.  It should be noted that IIa 
interacts with other proteins on the surface of platelets, including PAR-I through ABE-I.  
As Adam et al. suggests, the relative KD and concentrations of all IIa interacting partners 
must be considered at the site of thrombus formation (265).          
Conclusions.  These studies further characterize peptide binding to IIa’s anion 
binding exosites.  The NMR results suggest that the GpIbα peptide binds to IIa through 
residues D274-E285 in an extended conformation.  These investigations also imply that Y 
phosphorylation is not a requirement for effective interaction with IIa.  HDX data at 20:1 
peptide to IIa demonstrate significant similarities between the GpIbα peptide and the γ′ 
peptide; however, at higher GpIbα concentrations (40:1), the peptide appears to interact 
at a new interface.  These results suggest that the concentration of the ligand and IIa 
dictate where the peptide interacts with IIa as well as the corresponding allosteric effects. 
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CHAPTER VI 
PERTURBATIONS IN FACTOR XIII RESULTING FROM ACTIVATION AND 
INHIBITION EXAMINED BY SOLUTION BASED METHODS AND DETECTED 
BY MALDI-TOF MS 
 
Introduction 
Along with converting fibrinogen to fibrin and activating platelets in preparation for 
clot formation, thrombin also cleaves the activation peptide of Factor XIII (FXIII) 
forming FXIIIa.  FXIIIa is a transglutaminase that catalyzes the creation of covalent 
crosslinks between adjacent fibrin molecules leading to the formation of the hard clot.  
As mentioned in Chapter I, the similarity amongst the X-ray structures of zymogenic 
(119), IIa activated (118), and Ca2+ activated (117) FXIII suggests two distinct 
possibilities.  First, the activated state of FXIII is not favored during the process of 
crystallization (117).  The other potential explanation is that substrate binding induces the 
transition to the active conformation of FXIIIa (117).   
Previous work by Brian Turner focused on implementing solution-based methods to 
probe the conformational dynamics of FXIII activation that may be undetected in static 
crystal structures (174, 175).  Two useful techniques for observing protein dynamics are 
HDX coupled with MALDI-TOF MS and differential chemical modification of C and K 
residues (discussed in Chapter III).  Figure 43 summarizes previous results using these 
techniques.  HDX studies have revealed potential allostery associated with Ca2+ binding 
for both the β sandwich and β barrel 1 domains (174).  Furthermore, activating FXIII was 
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determined to expose regions within the proposed exosite peptides 4 and 7 (145), to 
modify C409 at the A2 dimer interface, and to affect the conformation of β barrel 2 (174, 
175).  These studies highlight the subtle conformational changes that are associated with 
the activation of FXIII.  
Figure 43: Summary of previous results reported on Factor XIII dynamics (174, 175).  Residues 
and peptides experiencing conformational changes upon FXIII activation are highlighted in red.  
The activation peptide is yellow.  β sandwich (blue):  1. 98-104 large decrease in % deuteration 
upon Ca2+ activation.  2. K73 acetylated within peptide 4 upon Ca2+ activation.  3.  K156 acetylated 
upon IIa activation.  Catalytic core (green):  1. 220-230 increase in % deuteration.  2. K221 
acetylated within peptide 7.  3. C314 is alkylated.  4. C409 alkylated at the dimer interface.  β barrel 
1 (cyan):  1. 513-522 small decrease in % deuteration.  2. 526-546 large decrease in % 
deuteration upon Ca2+ activation.  β barrel 2 (orange):  1. C695 is alkylated. 
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The difficulties in crystallizing an active conformer of FXIIIa have led to the 
prospect of designing an inhibitor for the TGase that may potentially trap the enzyme in 
the active state.  Once irreversibly inhibited, perhaps FXIIIa would be more amenable to 
crystallization.  Recently, Hausch et al. have reported inhibition of tissue TGase 2 with 
gluten peptide analogs that replace glutamine with the Q isostere 6-diazo-5-oxo-
norleucine (DON) (176) (Figure 44A).  The DON moiety has now been incorporated into 
the FXIIIa substrate K9, which is a peptide derived from β-casein (177).  By inhibiting 
FXIIIa with a peptide (proposed mechanism in Figure 44B (266)), solution based studies 
could potentially yield clues on how FXIIIa interacts with proteins containing a reactive 
Q and how this TGase prepares for K substrate incorporation.  Currently, a crystal 
structure of an inhibited TGase or a TGase interacting with a ligand has not been solved.  
The focus of this chapter is two-fold.  First, conformational perturbations in FXIII 
dynamics were further examined that result from proteolytic activation by IIa (FXIIIaIIa) 
versus nonproteolytic activation with 50 mM Ca2+ (FXIIIaCa).  IIa activation of FXIII led 
to the increased exposure of residues within peptide 7, a putative FXIIIa exosite.  
Regarding FXIIIaCa, unique changes in the dynamics of the β sandwich and the β barrel 2 
may suggest the presence of additional Ca2+ binding sites.  The second facet of these 
studies concerned FXIIIa inhibition.  For the first time, the FXIIIa inhibitors 
iodoacetamide (IAA) and K9 DON were investigated using the described techniques.  A 
TGase activity assay demonstrated that K9 DON inhibits FXIIIa with an IC50 in the high 
nM range.  HDX reveals that a β sandwich fragment and several regions within the β 
barrel 1 are further stabilized by FXIIIa inhibition.  Chemical modification shows that K9 
DON inhibition impairs the conversion of several residues to the chemically altered state.  
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These investigations have demonstrated the efficacy of the DON moiety as an inhibitor 
specific for FXIIIa.  More importantly, potential regions of plasticity resulting from 
activation and inhibition of FXIIIa have been observed that appear static in the currently 
available crystal structures. 
Figure 44:  K9 DON Inhibition of FXIIIa.  A.  The isosteres glutamine and 6-diazo-5-oxo-
norleucine.  B.  The proposed mechanism of inhibition proceeds through tetrahedral intermediate 
formation resulting from cysteine attack at the carbonyl group.  The methylene carbon then 
abstracts a proton from the active site H373.  Finally, a thioether is formed resulting in the release of 
N2 and irreversible inhibition of FXIIIa (266).   
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Materials and Methods 
Factor XIII Preparation and Synthetic Peptides.  Recombinant human cellular 
factor XIII (FXIII) was a generous gift from Dr. Paul Bishop  (ZymoGenetics, Inc., 
Seattle, WA) (267).  Lyophilized FXIII was reconstituted in 18 MΩ dI water.  The 
concentration of FXIII was determined with a Cary 100 uv-vis spectrophotometer 
monitoring absorbance at 280 nm and using the FXIII extinction coefficient of 1.49 
mL/mg-cm.  Aliquots of 40 µM FXIII were stored at -70 °C. 
K9 is a peptide substrate for FXIIIa that is derived from β-casein (177).  The 
sequence of K9 is Ac-LGPGQSKVIG-OMe and was synthesized by Peptides 
International (Louisville, KY).  The active site inhibitor Ac-LGPG-(DON)-SLVIG-OMe 
(K9 DON) was custom synthesized by N-Zyme BioTec GmbH.  The K9 DON inhibitor 
is most soluble at high concentrations in DMSO, therefore this solvent was used to 
prepare stock solutions.  Experiments where K9 DON is absent contain an equivalent 
amount of DMSO.  Peptide concentrations were determined by quantitative amino acid 
analysis (AAA Service Laboratory, Inc., Boring, OR). 
TGase Assay.  The Dade-Behring Berichrom Assay (177) utilizes coupled reactions 
involving FXIIIa and glutamate dehydrogenase (GDH).  As FXIIIa reacts with Q from 
the peptide K9, NH3 is released.  Next, the primary amine glycine ethyl ester (GEE) 
concludes the TGase reaction through formation of an isopeptide bond with the K9 
peptide.  GDH converts α-ketoglutarate and NH3 into glutamate with the aid of reducing 
equivalents from NADH.  Thus, FXIIIa activity is directly related to NADH oxidation, 
which results in decreasing absorbance at 340 nm.   
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The FXIII activation mix consisted of 6.9 µM FXIII, 30 nM bovine IIa (purified as 
described in (243)) , 1 mM CaCl2, in 20 mM borate, pH 8.3.  After 12 min at 37 °C, IIa 
activity was inhibited by 376 nM PPACK to prevent further proteolysis of FXIIIa.  An 
additional 12 min at 37 °C elapsed after which 19 µL aliquots of FXIIIaIIa were made and 
stored at -70 °C.  
Inhibition of FXIIIaIIa with 
either K9 DON or iodoacetamide 
(IAA) was monitored with a modified 
version of the Berichrom assay (200).  
Figure 45 displays the mass spectrum 
indicating K9 DON modification of 
C314 (266).  Irreversible inhibition is a 
time and concentration dependent 
phenomenon.  Throughout each trial, the volumes of the detector reagent (250 µL) and 
the activator reagent (163 µL), as well as FXIIIaIIa (218 nM) and K9 peptide (313 µM), in 
100 mM bicine pH 8.3 were held constant.  The amount of the inhibitor K9 DON or IAA 
ranged from 0 to 5000 nM, resulting in inhibitor to FXIIIa active site molar ratios of 1:1 
to 23:1.  The assay contents were incubated in a Cary 100 uv-vis spectrophotometer for 5 
min at 37 °C, then the substrate K9 was added.  NADH oxidation was monitored for 10 
min at 340 nm.  Since 4% DMSO is present in the assay mix, a series of control 
experiments were performed demonstrating that FXIIIaIIa in 4% DMSO possesses 
identical activity to FXIIIaIIa with an equal amount of dI water (data not shown).   
Figure 45:  Mass spectrum of the K9 DON 
modified C314 from a tryptic digest. 
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FXIIIaIIa activity was measured by determining the slope for the steepest part of the 
curve.  The slope represents the velocity of the reaction (Δabs/min).  The resultant slope 
of FXIIIaIIa activity in the absence of the inhibitor was assigned as 0% inhibition or 100% 
activity.  All reaction velocities calculated in the presence of K9 DON or IAA were 
normalized with respect to the slope observed with 0% inhibition.  As described in 
Rajagopal et al. (268), IC50 values for inhibition of FXIIIaIIa were determined by plotting 
the % inhibition versus the log of the inhibitor concentration, which produced an apparent 
sigmoidal curve.  Equation 8 was used to fit the sigmoidal with SigmaPlot and calculate 
an IC50.  In this equation, a represents the minimal curve asymptote, b equals the 
maximal curve asymptote, and c is the Hill slope which is an indicator of the steepness of 
the inhibitor-response curve. 
Activation and Inhibition of FXIII for HDX and NEM Experiments.  IIa activation 
of FXIII proceeded as described for the TGase assay.  Ca2+ activation of FXIII was 
carried out in 50 mM CaCl2, 20 mM borate pH 8.3.  The activation mix incubated for 2 
hrs at 37 °C.  The inhibitors K9 DON or IAA were added at a ten-fold molar excess to 
FXIIIa and incubated at 37 °C for 30 min.  The amount of inhibitor to FXIIIa (10:1) was 
chosen based on the results of the TGase assay.  Furthermore, the Berichrom assay 
verified FXIIIa activation and inhibition.  As with uninhibited FXIIIa, K9 DON and IAA 
FXIIIa exhibited limited solubility.  For the described experiments, enough FXIIIa is 
present in solution to gather reliable and reproducible results.  
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HDX Sample Preparation.  FXIIIa was exchanged into 6.67 mM borate, 0.33 mM 
CaCl2, pH 8.3, removing excess inhibitor and/or Ca2+.  The exception was the standard 
for comparison, zymogenic FXIII without Ca2+, which was buffer exchanged into 6.67 
mM borate, pH 8.3.  The concentration of FXIII(a) (the (a) is shorthand for all forms of 
Factor XIII:  unactivated, activated, and inhibited) for all HDX preparations varied from 
10-13 µM.  Aliquots (36 µL) of the buffer-exchanged FXIII(a) were evaporated to 
dryness using a SpeedVac (Savant) and stored at -70 °C.  
HDX Experiments.  The HDX protocol is described in more detail in Chapter III.  
Dry aliquots of FXIII(a) were allowed to come to room temperature before beginning the 
experiment.  12 µL of 99.996% D2O (Cambridge Isotope Laboratories) was added to the 
aliquot yielding 30-36 µM FXIII(a), 1 mM CaCl2, in 20 mM borate pH 8.3.  The samples 
were incubated in a desiccator at room temperature for 1 or 10 min.  Adding 120 µL of 
chilled 0.1% TFA pH 2.5 quenched HDX.  Immediately, the entire quenched solution 
was transferred to a tube of activated pepsin bound to 6% agarose (Pierce Chemical).  
Digestion occurred on ice for 10 min.  Centrifugation at 4 °C separated the digest from 
the pepsin and 10 µL aliquots were immediately frozen in liquid N2 and stored at –70 °C.  
Each time point was performed three times. 
HDX Analysis.  A HDX aliquot of FXIII(a) was thawed, immediately mixed with 
an equal volume of 10 mg/mL α-cyano-hydroxycinnamic acid matrix (α-CHCA) 
(Aldrich) in 1:1:1 ethanol/CH3CN/0.1% TFA, pH 2.2, and 0.5 µL spotted onto a chilled 
stainless steel MALDI plate.  The spotted MALDI plate was dried within a SpeedVac 
unit and then inserted into the MALDI-TOF MS (Voyager DE-Pro, Applied Biosystems).  
The entire procedure took about 5 min, limiting the amount of back exchange.  Spectra 
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were collected in the reflector mode over a mass range of 800-3500 m/z with 256 laser 
shots per spectrum.  All peptides in the peptic digest were previously identified by Brian 
T. Turner, Jr. (174) (Figure 46).  Data Explorer (Applied Biosystems) was used to 
analyze the spectra.  Calibration of the spectra involved two singly protonated reference 
peptides, the monoisotopic mass of 850.4787 Da (residues 535-541) and the 
quadraisotopic mass of 1375.7097 Da (residues 220 -230).  The amount of deuterium 
uptake by each peptide and the % difference in deuteration relative to zymogenic FXIII 
was quantified as described by Sabo et al. (167) and discussed in Chapter III.  
Cysteine Modification with NEM.  FXIII(a) at 10 µM was incubated with 50 µM 
NEM (stock in 50% CH3CN) for 60 min at room temperature.  The reaction was 
quenched with the addition of dithiothreitol.  In either trypsin buffer (100 mM NH4HCO3, 
pH 8) or chymotrypsin buffer (100 mM Tris-HCl, 10 mM CaCl2, pH 7.4), the quenched 
samples were digested with 2 µL of 1 mg/mL chymotrypsin (25 °C) or 1 mg/mL trypsin 
Figure 46: Sequence Coverage Map of FXIII.  Pepsin fragments monitored during HDX 
experiments are underlined (45% sequence coverage).  Residues highlighted in red 
represent trypsin coverage (68%), in blue indicates chymotrypsin coverage (48%), and in 
green displays regions where the proteases overlap (81%). 
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(37 °C) for at least 4 hr.  Proteolysis was quenched by acidification with 5% TFA.  
Chymotrypsin cleaves primarily after the aromatic residues W, Y, and F.  Trypsin 
hydrolysis occurs primarily after the positively charged R and K residues.   
Lysine Acetylation and Limited Proteolysis Experiments.  In 10 mM NH4HCO3 pH 
7.4, FXIII at 10 µM was either activated with Ca2+ or with IIa.  Inhibition of FXIIIa 
occurred concurrently with the activation process in the presence of 20 µM IAA or K9 
DON in DMSO.  Ca2+ activation occurred in 50 mM CaCl2 for 2 hr at 37 °C.  IIa 
activation took place with 42 nM IIa and 1 mM CaCl2 for 12 min at 37 °C.  PPACK was 
used to inhibit IIa activity and the FXIIIa mix incubated for an additional 108 min.   
After 2 hours, 5 µL of 600 mM acetic anhydride (AA) in DMF was added to 
FXIII(a) and allowed to incubate for 1 hr.  The acetylation mix was acidified with 1% 
TFA.  Residual AA and the byproduct acetic acid were removed by drying in a SpeedVac 
concentrator device.  When performing limited proteolysis, AA was not added but 
FXIII(a) was handled in a similar manner.  The dry protein was reconstituted in dI water.  
The modified protein was then split in half and addition of buffer yielded 10 µM FXIII(a) 
in 100 mM NH4HCO3 pH 8.0 (trypsin) or in 100 mM Tris-HCl, 10 mM CaCl2 pH 7.4 
(chymotrypsin).  To 25 µL of the modified protein in digestion buffer, 2 µL of 1 mg/ml 
trypsin (37 °C) or chymotrypsin (25 °C) was added and proteolysis occurred for 4 hr.  
With limited proteolysis, the digest was quenched after 30 min with 5 % TFA. 
MALDI-TOF Mass Spectrometry for Chemical Modification and Limited 
Proteolysis.  C18 ZipTips (Microcon) were used to concentrate and clean up the digested 
FXIII(a) samples with elution into 50% CH3CN.  The eluted peptides were mixed with 5 
µL of either α-CHCA or ferulic acid MALDI matrix.  The samples were spotted on a 
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stainless steel MALDI plate and acquired in reflector mode using MALDI-TOF MS.  The 
mass range was from 550-4000 m/z and 256 shots per spectrum were collected.  At least 
three separate trials were performed for each state of FXIII(a) monitored and at least two 
spectra collected for each trial.  All spectra were analyzed as described by Turner et al 
(175) and the FXIII sequence coverage produced with chymotrypsin and trypsin is 
presented in Figure 46.  For limited proteolysis, the intensity of a monoisotopic peak 
representing FXIII(a) digest fragments was normalized with respect to the most intense 
(abundant) monoisotopic peak.  Differences in relative peak intensities greater than 20% 
were considered significant for the limited proteolysis studies based on a comparative 
standard employed by Ansong et al. (218). 
Results 
TGase Assay with FXIIIaIIa.  A modified version of the Dade-Behring Berichrom 
assay was performed to determine the potency of the irreversible inhibitor K9 DON for 
FXIIIaIIa and the results compared to IAA.  Figure 47A displays a series of progress 
curves for inhibition of FXIIIaIIa with increasing concentrations of K9 DON and Figure 
47B presents a plot of the data fitted to the Equation 8.  The calculated IC50 was 816 ± 32 
nM.  The small molecular inhibitor IAA was slightly more effective with an IC50 of 539 ± 
74 nM.  The p value comparing the two inhibitors was p= 0.03.  Briefly, the p value is a 
statistical tool gauging the probability that the observed difference between two values 
can be attributed to chance alone.  Typically, p values less than 0.05 are considered to 
reflect significant variance amongst two data sets.   
Hydrogen Deuterium Exchange Coupled with MALDI-TOF Mass Spectrometry.  
The solvent accessibility of IAA or K9 DON inhibited FXIIIa was compared to the 
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zymogen, FXIIIaCa, and FXIIIaIIa.  Table 10 contains the % differences in HDX for 
FXIIIa relative to the zymogen.  The table groups the data according to the activation 
method observed.  The amount of deuterium incorporated at each time point is presented 
in Figure 48 (FXIIIaCa) and Figure 49 (FXIIIaIIa) as well as in Table 11.   
The β-sandwich residues 98-104 were only present in the FXIIIaCa spectra, 
presumably due to pepsin’s inability to produce this peptide from FXIIIaIIa.  Inhibition of 
FXIIIaCa with K9 DON resulted in differences in the deuteration profiles for this peptide 
at one and ten minutes.  Whereas FXIIIaCa displayed an increase in solvent accessibility 
after 10 minutes (from -24.3% at one minute to -15.3% after ten minutes), K9 DON 
FXIIIaCa was observed to acquire less deuterium over a similar time span (from -15.5% at 
one minute to -30.1% after ten minutes).  As for IAA FXIIIaCa, inhibition with the small 
molecular inhibitor leads to sustained stabilization over ten minutes of HDX (-31.9% at 
one minute to -35.0% after ten minutes).   
Figure 47:  TGase Assay and FXIIIa inhibition 
by K9 DON.  A.  Eight separate trials were 
performed at varying inhibitor concentrations:  
FXIIIa in the absence of K9 DON (navy blue); 
250 nM K9 DON (red); 400 nM K9 DON 
(orange); 700 nM K9 DON (pink); 900 nM K9 
DON (purple); 1500 nM K9 DON (brown); 
2500 nM K9 DON (cyan); and 5000 nM K9 
DON (blue).  The assay components, FXIIIa, 
and the indicated amount of inhibitor were 
incubated for 5 min at 37 °C, at which point 
the substrate K9 was introduced to the assay 
mix.  The graph depicts the oxidation of 
NADH as a function of time.  B.  A plot of % 
inhibition versus the log of inhibitor 
concentration.  Open and filled in circles 
represent IAA and K9 DON, respectively.  
Three separate trials were performed and the 
plot was fit to equation 8.  The IC50 was 
determined as 815.5 ± 31.9 nM for K9 DON 
and 538.8 ± 74.3 nM for IAA. 
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Within the catalytic core, several fragments were observed as displaying similar 
differences in deuterium exchange, regardless of the FXIIIa state monitored.  For residues 
220-230, deuterium incorporation varied from 4.5-7.0% more exposure relative to the 
zymogen at one minute and at ten minutes the range was 6.2-9.7%.  The only exception 
was with IAA FXIIIaCa where one minute of exposure to deuterium did not yield a 
significant difference in deuteration when compared to the zymogen (1.7%).  Similarly, 
the results for residues 240-247 were within the standard deviation for all FXIIIa 
conditions examined:  one minute, 6.0-7.3% and ten minutes, 5.9-10.4%.  Only FXIIIaIIa 
presented reliable isotopic clusters for quantification of 248-264.  Once again, the type of 
inhibition when compared to FXIIIaIIa had little effect on deuterium exchange.  In this 
case, significant protection was observed initially at one minute (5.9%-6.7%) and within 
ten minutes, the exchange began to approach zymogenic FXIII (2.2%-3.1%).   
Table 10:  Changes in % Deuteration for Factor XIII-Inhibitor Complexes at One and Ten Minutes 
Relative to Unactivated Factor XIIIa 
FXIIIaCa K9 DON FXIIIaCa IAA FXIIIaCa 
Residues 
Theo. 
  Dmax b 
1m 10m 1m 10m 1m 10m 
98-104 
220-230 
240-247 
513-522 
526-546 
535-541 
6.5 
10.8 
7.5 
9.7 
21.2 
6.5 
 -24.3c 
5.4 
6.0 
-11.6 
-24.1 
1.8 
-15.3 
9.7 
7.1 
-10.6 
-25.8 
2.4 
-15.5 
7.0 
7.2 
-10.0 
 n/ad 
2.6 
-30.1 
7.3 
5.9 
-11.4 
-32.7 
2.7 
-31.9 
1.7 
6.9 
-15.6 
n/a 
1.3 
-35.0 
6.2 
8.5 
-15.6 
n/a 
4.2 
FXIIIaIIa K9 DON FXIIIaIIa IAA FXIIIaIIa 
Residues 
Theo. 
  Dmax 
1m 10m 1m 10m 1m 10m 
220-230 
240-247 
248-264 
513-522 
526-546 
535-541 
10.8 
7.5 
15.9 
9.7 
21.2 
6.5 
4.5 
6.0 
6.0 
-5.4 
-2.6 
1.8 
7.2 
6.8 
3.1 
-5.3 
-2.4 
4.2 
5.9 
6.5 
5.9 
-7.3 
-10.0 
2.8 
6.3 
6.7 
2.2 
-10.3 
-11.8 
4.9 
6.6 
7.3 
6.7 
-8.0 
-4.0 
2.3 
7.5 
10.4 
n/a 
-9.4 
-9.0 
5.1 
aThe % change for a particular peptide is calculated by Equation 7 (Chapter III).  bThe maximum 
number of exchangeable protons within the indicated peptide, assuming 100% deuteration. 
(Chapter III).  A fully deuterated peptide would theoretically have acquired this amount of 
deuterons.  cThe values in bold represent significant changes in deuteration of greater than ± 4.5%.  
dn/a refers to a peptide that was either not observed in the peptic digest or was not of sufficient 
intensity to quantify. 
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 The final region of FXIII investigated with HDX was the β barrel 1.  Considering 
all FXIIIaCa states, two of the three regions observed, 513-522 (-10.0% to -15.6%), and 
535-541 (1.3% to 4.2%), were similar in regard to the dynamics of deuterium exchange at 
one and ten minutes.  However, the presence of the K9 DON peptide protects the 
fragment 526-546 by 6.9% after ten minutes of HDX (-25.8% for FXIIIaCa and -32.7% 
for K9 DON FXIIIaCa).  Unfortunately, this region was unable to be observed in the IAA 
FXIIIaCa spectra (Tables 10 and 11).   
Figure 48: Graphs of deuterium incorporation for FXIIIaCa.  A. 1 min and B. 10 min of HDX.  
The bars in the graph correspond to the following conditions:  zymogenic FXIII (red), FXIIIaCa 
(orange), K9 DON FXIIIaCa (yellow), and IAA FXIIIaCa (pink).  Errors correspond to standard 
deviation of the mean for three independent trials. 
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Table 11:  Deuterium Incorporation for FXIII 
One Minute 
Peptide Theo. Dmaxa 
Zymogen FXIIIaCa K9 DON FXIIIaCa 
IAA 
FXIIIaCa FXIIIa
IIa K9 DON FXIIIaIIa 
IAA 
FXIIIaIIa 
98-104 
220-230 
240-247 
248-264 
513-522 
526-546 
535-541 
6.5 
10.8 
7.5 
15.9 
9.7 
21.2 
6.5 
4.4 ± 0.0 
2.4 ± 0.1 
1.2 ± 0.0 
2.9 ± 0.0 
3.8 ± 0.0 
12.8 ± 0.1 
0.6 ± 0.0 
2.9 ± 0.1 
2.9 ± 0.1 
1.7 ± 0.1 
n/ab 
2.7 ± 0.0 
7.7 ± 0.2 
0.7 ± 0.1 
3.4 ± 0.1 
3.1 ± 0.1 
1.7 ± 0.0 
n/a 
2.9 ± 0.0 
n/a 
0.8 ± 0.1 
2.4 ± 0.1 
2.5 ± 0.1 
1.7 ± 0.1 
n/a 
2.3 ± 0.1 
n/a 
0.7 ± 0.1 
n/a 
2.8 ± 0.1 
1.6 ± 0.0 
3.8 ± 0.0 
3.3 ± 0.1 
12.3 ± 0.1 
0.7 ± 0.1 
n/a 
3.0 ± 0.0 
1.7 ± 0.0 
3.8 ± 0.0 
3.1 ± 0.0 
10.7 ± 0.3 
0.8 ± 0.1 
n/a 
3.1 ± 0.1 
1.7 ± 0.1 
3.9 ± 0.1 
3.1 ± 0.2 
12.0 ± 0.5 
0.8 ± 0.1 
Ten Minutes 
Peptide Theo. Dmaxa 
Zymogen FXIIIaCa K9 DON FXIIIaCa 
IAA 
FXIIIaCa FXIIIa
IIa K9 DON FXIIIaIIa 
IAA 
FXIIIaIIa 
98-104 
220-230 
240-247 
248-264 
513-522 
526-546 
535-541 
6.5 
10.8 
7.5 
15.9 
9.7 
21.2 
6.5 
4.8 ± 0.1 
2.9 ± 0.1 
1.4 ± 0.0 
3.5 ± 0.0 
3.9 ± 0.0 
13.0 ± 0.1 
0.7 ± 0.0 
3.8 ± 0.1 
3.9 ± 0.3 
1.9 ± 0.1 
n/a 
2.8 ± 0.1 
7.5 ± 0.2 
0.8 ± 0.0 
2.8 ± 0.1 
3.7 ± 0.1 
1.8 ± 0.0 
n/a 
2.7 ± 0.0 
6.1 ± 0.3 
0.8 ± 0.0 
2.5 ± 0.0 
3.6 ± 0.2 
2.0 ± 0.1 
n/a 
2.3 ± 0.2 
n/a 
0.9 ± 0.1 
n/a 
3.7 ± 0.0 
1.9 ± 0.0 
4.0 ± 0.1 
3.3 ± 0.0 
12.5 ± 0.2 
0.9 ± 0.0 
n/a 
3.6 ± 0.1 
1.9 ± 0.1 
3.9 ± 0.0 
2.9 ± 0.3 
10.5 ± 0.8 
1.0 ± 0.0 
n/a 
3.7 ± 0.1 
2.1 ± 0.2 
n/a 
2.9 ± 0.0 
11.0 ± 0.2 
1.0 ± 0.1 
aThe maximum number of exchangeable protons within the indicated peptide, assuming 100% 
deuteration (Chapter III).  A fully deuterated peptide would theoretically have acquired this amount of 
deuterons.  bThese clusters were unable to be quantified under these conditions. 
 
When considering the various forms of FXIIIaIIa (Tables 10 and 11), residues 513-
522 experience slightly more protection from solvent in both inhibited forms of FXIIIaIIa.  
At ten minutes, FXIIIaIIa had incorporated 3.3 deuterons (-5.3%) and both types of 
inhibited FXIIIaIIa integrated 2.9 deuterons (-9.4% and -10.3%).  The amount of 
deuteration in FXIIIaIIa for 526-546 was comparable to FXIII (-2.4% to -2.6%).  For the 
same span of residues, K9 DON FXIIIaIIa exhibited an immediate decrease in solvent 
accessibility after 1 minute (-10.0%); conversely, IAA FXIIIaIIa affected the dynamics of 
HDX in a gradual manner, reaching a statistically significant difference following ten 
minutes of HDX (-9.0%).  Lastly, the fragment 535-541 became more exposed to solvent 
at ten minutes in all forms of FXIIIaIIa (4.2% to 5.1%).  
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The isotopic clusters representing 526-546 for FXIIIaCa and K9 DON FXIIIaCa were 
of an uneven distribution with a small rise in peak intensity toward higher m/z (Figure 
50).  This observation led to a separate series of HDX experiments to be performed on 
the zymogen in the presence of 1 mM Ca2+.  The rationale for these HDX trials was to 
differentiate the effects of Ca2+ concentration on deuterium exchange.  Figure 50 shows 
an expanded isotopic cluster for FXIII in 1 mM Ca2+, intermediate between the zymogen 
and FXIIIaCa, as well as, the spectra for the states of FXIIIaIIa in the same region.     
Figure 49: Graphs of deuterium incorporation for FXIIIaIIa.  A. 1 min and B. 10 min of 
HDX.  The bars in the graph correspond to the following conditions:  zymogenic FXIII 
(red), FXIIIaIIa (blue), K9 DON FXIIIaIIa (green), and IAA FXIIIaIIa (cyan).  Errors 
correspond to standard deviation of the mean for three independent trials. 
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N-ethylmaleimide Modification of FXIII.  Digesting FXIII with the proteases trypsin 
and chymotrypsin provided a total of 81% sequence coverage (Figure 46).  As previously 
reported (175), seven of the nine cysteine residues were able to be observed in the tryptic 
digests of FXIII:  C152, C188, C238, C314, C327, C409, and C695.  Unfortunately, chymotrypsin 
did not produce additional proteolytic peptides containing C374 or C423.  All NEM 
modification experiments are summarized in Table 12.   
The only consistently unmodified cysteine was C152 within the β-sandwich.  For the 
zymogen, C188 was the lone residue to react with NEM.  Once FXIII was activated, NEM 
Figure 50:  Mass spectra of FXIII residues 526-546 after ten minutes of HDX.  All D-on 
experiments are in 20 mM borate and 1 mM CaCl2 pH 8.3, except the zymogen in the absence of 
Ca2+ where the buffer was 20 mM borate pH 8.3.  The FXIII state illustrated in each spectrum is 
listed in the figure.  This peak cluster contains β-barrel 1 residues and displays drastically 
varying degrees of deuteration between FXIIIaCa and FXIIIaIIa.  In both types of activation states, 
inhibition provides protection from solvent amounting to around 1-2 deuterons.   
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modified the active site residue C314.  Regarding the inhibited forms of FXIIIa, IAA 
modified C314 was observed in the mass spectra (data not shown) and a weak peak for K9 
DON covalently linked to C314 was infrequently apparent at 2900 m/z (Figure 45), 
probably due to difficulties in ionization.   
Table 12:  Cysteine Alkylation Results at pH 8.3 
Cysteine Residues 152a 188 238 314c 327 374 409 423 695 
Zymogen  Xb        
FXIIIaCa  X  X     X 
IAA FXIIIaCa  X  IAA   X  X 
K9 DON FXIIIaCa  X weak K9 DON     X 
FXIIIaIIa   X X X  X   
IAA FXIIIaIIa   X IAA X  X   
K9 DON FXIIIaIIa  X X K9 DON X  weak  X 
aA blank space indicates that the modified peaks were not observed in the mass spectra.  
bNEM modification of cysteine was identified.  cCysteine 314 in the activated state reacted 
with NEM in the uninhibited forms.  The presence of the inhibitor covalently linked to 
cysteine 314 prevented NEM from modifying the active site and the NEM peak was 
unobserved in the mass spectra.   
 
In the β-sandwich, C188 was altered by NEM in all three FXIIIaCa states.  Moving to 
the catalytic core, the residue C238 was weakly modified in K9 DON FXIIIaCa, while C409 
reacted with NEM only when IAA inhibited FXIIIaCa.  C327 remained unmodified after 
Ca2+ activation.  The β-barrel 2 residue C695 was available to NEM in all three forms of 
FXIIIaCa.  Turning to IIa activation, K9 DON FXIIIaIIa was the only form of FXIIIaIIa to 
display modification of the β-sandwich residue C188 and the β-barrel 2 residue C695.  Two 
cysteine residues located near the activation peptide, 238 and 327, were consistently 
labeled in all forms of FXIIIaIIa.  Finally, the catalytic core C409 was modified in FXIIIaIIa 
and IAA FXIIIaIIa, but K9 DON FXIIIaIIa severely weakened chemical modification.   
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Acetic Anhydride Modification of FXIII.  There are 38 lysine residues in FXIII 
spanning all four domains.  Only 10 of the 38 lysine residues were unable to be observed 
as acetylated in the mass spectra:  K61, K269, K363, K366, K418, K445, K446, K462, K467, and 
K657.  Residues always accessible to acetic anhydride included K54, K133, K534, K623, K635, 
and K704.  Additional labeling of the zymogen involved K129, K583, K584, and K621.  Lysine 
residues K73, K113, K156, K199, K221, K257, and K531, were exposed to acetic anhydride only 
after activation of FXIII.  The modifications recorded from both trypsin and 
chymotrypsin digests will be combined and the data separated into tables concerning 
FXIIIaCa (Table 13) and FXIIIaIIa (Table 14).   
Table 13:  Lysine Acetylation Results for FXIIIaCa 
β sandwich Catalytic Core 
Residues 54a 68 73 113 129 133 151 156 199 221 257 482 503 504 513 
Zymogen  Xb   ?c X X        ? ? 
FXIIIaCa X  X X  X ? X X X X X ? ? ? 
IAA 
FXIIIaCa X  X X  X ? X X X X X ? ?  
K9 DON 
FXIIIaCa X  X X  X ? X X X X   ? ? 
β barrel 1 β barrel 2 
Residues 531 534 565 569 570 583 584 621 623 635 677 678 704 
Zymogen ? X    X X X X X ? ? X 
FXIIIaCa X X X  X X X X X X ? ? X 
IAA 
FXIIIaCa X X ? ? X X X X X X ? ? X 
K9 DON 
FXIIIaCa X X X ? ? X X X X X ? ? X  
aResidues displaying modification regardless of FXIII activation or inhibition are referred to as always 
solvent exposed.  bThe letter X represents lysine modification of the indicated residue.  cA question 
mark denotes ambiguous data and the possibility exists for modification of the lysine residue.  The first 
possibility is when two peptides have similar masses and both possess lysine residues.  Alternatively, a 
peptide with two or three lysine residues may be observed as acetylated once, thus presenting ambiguity 
in assigning the modified lysine.   
 
In the β sandwich, K68 and K129 were not accessible to acetic anhydride 
modification in all forms of FXIIIaCa.  Interestingly, the catalytic core K482 was labeled in 
FXIIIaCa and IAA FXIIIaCa, yet unmodified in K9 DON FXIIIaCa.  For all three states of 
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FXIIIaCa, the β barrel 1 residues K583, K584 and K621 were modified, while both K565 and 
K570 could not be unambiguously assigned as always labeled.  Acetylation results 
revealed that six residues spanning the β sandwich and catalytic core displayed consistent 
labeling in FXIIIaIIa:  K68, K129, K482, K503, K504, and K513 (Table 14).  Like FXIIIaCa, 
K565, could not be unambiguously assigned.  K583 and K584 did not react with acetic 
anhydride when IIa activated FXIII, however, general inhibition of FXIIIaIIa resulted in 
protection from acetic anhydride for the β barrel 1 residue K621. 
Table 14:  Lysine Acetylation Results for FXIIIaIIa 
β sandwich Catalytic Core 
Residues 54a 68 73 113 129 133 151 156 199 221 257 482 503 504 513 
Zymogen  Xb   ?c X X        ? ? 
FXIIIaIIa X X X X X X ? X X X X X X X X 
IAA 
FXIIIaIIa X X
 X X X X ? X X X X X X X X 
K9 DON 
FXIIIaIIa X X X X X X ? X X X X X X X X 
β barrel 1 β barrel 2 
Residues 531 534 565 569 570 583 584 621 623 635 677 678 704 
Zymogen ? X    X X X X X ? ? X 
FXIIIaIIa X X X ? ?   X X X ? ? X 
IAA 
FXIIIaIIa X X X      X X ? ? X 
K9 DON 
FXIIIaIIa X X ? ? ?    X X ? ? X  
aResidues displaying modification regardless of FXIII activation or inhibition are referred to as always 
solvent exposed.  bThe letter X represents lysine modification of the indicated residue.  cA question 
mark denotes ambiguous data and the possibility exists for modification of the lysine residue.  The first 
possibility is when two peptides have similar masses and both possess lysine residues.  Alternatively, a 
peptide with two or three lysine residues may be observed as acetylated once, thus presenting 
ambiguity in assigning the modified lysine.   
 
Limited Proteolysis of FXIII.  Variations within the mass spectra of FXIII(a) 
provide insight into subtle alterations in conformational dynamics that affect 
chymotrypsin’s ability to hydrolyze backbone amide bonds of the TGase.  For example, 
during IIa activation of FXIII, the amide bond between R36-G37 is cleaved and a 
chymotryptic digest of FXIIIaIIa does not produce the fragment Q32-F44.  Proteolysis of 
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FXIIIaIIa by chymotrypsin produces a significant amount of the activation peptide 
residues G9-L31.  By contrast, the digests of the zymogen and FXIIIaCa displayed the 
peptide Q32-F44 and less G9-L31.  In our studies with FXIII(a), significant variation within 
thirty minutes of trypsin proteolysis was not observed (data not shown), thus the focus 
was centered on chymotryptic digests of FXIII(a).  Selected data for chymotrypsin 
proteolysis is summarized in Figure 51.  Within the β-sandwich, two peptides were 
cleaved more effectively with FXIIIaCa:  75-83 and 104-125.  FXIIIaIIa displayed a large 
abundance of the catalytic core fragment 207-214.   Finally, two fragments in the β barrel 
2, 681-691 and 692-698, were more susceptible to chymotrypsin in FXIIIaCa.  The 
inhibitor K9 DON did not significantly affect the chymotryptic digests profiles. 
Discussion 
At the present time, an X-ray structure of FXIIIa interacting with a substrate or 
inhibitor has not been solved.  Furthermore, limited evidence exists on how Q containing 
substrates access the active site, interact with the catalytic core, and alter the dynamics of 
FXIIIa in preparation for the K containing substrate.  An effective peptide inhibitor for 
Figure 51: Graph of limited chymotryptic proteolysis of FXIII.  Only 
differences in proteolysis larger than ±20% were considered significant.  The 
colored bars refer to the zymogen (red), FXIIIaCa (orange), K9 DON FXIIIaCa 
(yellow), FXIIIaIIa (blue), and K9 DON FXIIIaIIa (green).  Errors correspond to 
standard deviation of the mean for three independent trials. 
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FXIIIa has now been developed that incorporates the Q isostere 6-diazo-5-oxo-norleucine 
into the FXIIIa substrate peptide K9.  The focus of the work has proceeded to observe in 
solution the conformational changes associated with inhibition by K9 DON compared to 
IAA (178).  In addition to probing FXIIIa inhibition, new insight has also been obtained 
regarding the conformational features associated with the activation of FXIIIa by Ca2+ 
and by IIa, thus augmenting our previous investigations (174, 175).  The current studies 
thus provide valuable information about events occurring to the β sandwich, the 
activation peptide, the dimer interface, the catalytic core, and β barrels 1 and 2 (178).  
DON Inhibition of FXIIIaIIa.  A modified version of the Dade-Behring Berichrom 
assay (177) was used to determine that K9 DON is a slightly less potent inhibitor of 
FXIIIaIIa as compared to IAA.  A longer peptide derived from the natural substrate α2-
antiplasmin has been reported to be an even better FXIIIa substrate model.  α2AP (1-15) 
shows improved kinetic parameters, maintains a preference for Q2 over Q4, and suggests 
the existence of additional substrate specificity determinants within the active site (137).  
Incorporation of DON into such a longer peptide sequence could later offer more potent 
inhibition of FXIIIa as well as contribute to further understanding FXIIIa-ligand 
interactions.  The research with K9 DON provides our first successful application of such 
a peptide inhibitor to probe changes occurring to FXIIIa conformation in solution.   
The β sandwich and Proteolytic Versus Non-proteolytic Activation.  The β 
sandwich residues 72-97, also known as peptide 4, are hypothesized to be involved in Q 
substrate recognition (Figure 52A) since synthetic peptides derived from this sequence 
compete for Q substrate binding to FXIIIa (145).  An earlier report demonstrated that K73 
was acetylated in FXIIIaCa only (175).  The present results confirm this finding as well as 
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showing that FXIIIaIIa is also modified at this position.  The current research further 
indicates that FXIIIaCa exhibits increased chymotryptic proteolysis of residues 75-83 
within this peptide 4 region.  Together these results suggest increased exposure of 73-83 
upon activation, especially for FXIIIaCa.  These events could signal FXIIIa preparation 
for Q substrate interaction with the β sandwich (145).   
Figure 52: Correlating results with X-ray structure of Factor XIII (I) (1FIE).  A.  β sandwich 
region:  Depicted are the activation peptide (cyan), peptide 4 fragments 72-74/84-97 and K73 (blue), 
limited proteolysis fragments 75-83 (pink) and 104-125 (yellow), L125-Q126 (purple),  K129 (orange), 
the HDX fragment 98-104 (red), and C152/C188 (yellow).  B.  Activation peptide/dimer interface:  
residues N18/S19/N20/A21 (cyan), K156 (pink), D243 (red), R252 (dark green), M242 (green), C238/C327 
(orange), the HDX fragments 240-247 and 248-264 (purple), K113/K257/R260 (yellow), D367′ (green), 
and E401′/D404′ (blue).  C.  Zymogen crystal structure 1GGT displaying activation peptide (red) 
extending away from the dimer.  D.  FXIIIaIIa crystal structure 1FIE  (orange) displaying activation 
peptide resting across the surface of the dimer. 
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Other unique properties related to FXIIIaCa include an increase in proteolysis of the 
104-125 segment, a loss of the ability to acetylate K129, and a protection from solvent for 
residues 98-104.  As the L125-Q126 peptide bond becomes more accessible to 
chymotrypsin, it may be at the expense of K129 solvent exposure.  Between peptide 4 (72-
97) and the chymotryptic cleavage region (104-125) is the segment 98-104.  Previous 
HDX studies have demonstrated that residues 98-104 of FXIIIaCa exhibited a significant 
decrease in deuteration that may be localized to L98 and F99 (Figure 52A) (174).  IAA 
inhibition of FXIIIaCa further stabilizes this short segment from deuteration.  K9 DON 
FXIIIaCa requires more time to achieve significant stabilization of this fragment 
conceivably due to allostery related to peptide binding within the catalytic core.  
Interestingly, residues 98-104 are not observed peptic digests of FXIIIaIIa. 
The differences in proteolysis observed for FXIIIaCa versus FXIIIaIIa are important 
to consider.  With both chymotrypsin and pepsin, fewer cleavages are detected within the 
β sandwich region of FXIIIaIIa.  Cleavage of the activation peptide by IIa may thus 
protect certain regions within the β sandwich.  Alternatively, the potential presence of 
low affinity Ca2+ binding site(s) within this domain could aide in creating a more 
accessible environment for the proteases to cleave FXIIIaCa.  An earlier study ascertained 
that IAA FXIIIaIIa possessed a higher affinity for fibrin II than IAA FXIIIaCa (269).  
Another investigation found that FXIIIaCa was unable to crosslink fibrin α chains, while 
retaining the ability to crosslink fibrin γ chains (270).  Perhaps several fibrin-binding sites 
are located in or influenced by the β sandwich and only cleavage of the activation peptide 
is able to properly orient or expose residues related to fibrin α chain binding.   
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FXIII Activation Peptide and the Dimer Interface.  Located in close proximity to 
the activation peptide (AP) and the dimer interface, FXIIIa fragments 240-247 and 248-
264 became more exposed to deuterium when compared to FXIII (Figure 52B).  In 
addition, acetylation of K113, K156, and K257 only occurred when FXIII was activated.  
Several electrostatic and water mediated interactions are apparent between the AP 
residues N18-A21 and main chain residues K156, D243, and R252.  The crystal structures of 
FXIII (1GGT) (119) and FXIIIaIIa (1FIE) (118) display the AP in similar conformations 
except for one key stretch.  The N-terminus of the zymogen (F8-P16) is extended away 
from the dimer, while in FXIIIaIIa these same residues are depicted as resting on the 
dimer’s surface (Figure 52C and D).  Perhaps this emphasizes the importance of N18-A21 
in anchoring the AP to FXIII through interactions with K156, D243, and R252.   
Alkylation of the adjacent residues C238 and C327 occurred only with FXIIIaIIa 
(Figure 52B).  C238 is involved in main chain H-bonding with M242, adjacent to D243.  
Cleavage of the activation peptide could conceivably weaken the aforementioned 
electrostatic interactions involving residues within 240-264 and the activation peptide, 
essentially perturbing the dynamics of this region.  In fact, limited proteolysis of FXIIIaIIa 
shows a large abundance of the fragment 9-31.  As stated in the previous section, these 
observations could signal FXIIIaIIa preparation for efficient interaction with the α chains 
of fibrin.  The FXIII mutations M242T, R252I, and G262E further highlight the structural 
and functional importance for this stretch of catalytic core residues (271-273).  
Intersubunit H-bonding among K113-D367′, K257-E401′, and R260-D404′ emphasize the 
role these residues play in maintaining dimer integrity (Figure 7B and 52B).  Acetylation 
of K113 and K257 and the increased exposure of 248-264 insinuate an opening of the dimer 
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space.  Yee et al. predict a possible mode of the K substrate accessing the active site 
through the opening of the dimer interface (119).  Our results suggest activation of FXIII 
weakens the interactions between residues at the dimer interface.  These observations are 
consistent with K-containing substrates accessing the active site from the dimer interface, 
where, as previously suggested, the acyl acceptor is directed to the active site by residue 
D343 and the H342/E434 diad (119).  Three reported mutations resulting in congenital FXIII 
deficiency, R260L, R260C, and R260H, signify the essential nature of the R260-D404′ 
interaction for proper FXIII functioning (274-277).   
Cis-trans Isomerization Within the Catalytic Core and the Secondary IIa Cleavage 
Site.  NEM modification of C409 was severely impaired by the covalent linkage of K9 
DON to C314 in FXIIIaCa and FXIIIaIIa (Figure 53B).  Two non-prolyl cis bonds, Q425-F426 
and R310-Y311, reside near C314 and C409.  These unusual cis peptide bonds may possess 
ample potential energy that FXIIIa could use to fuel catalysis and/or open access for 
substrates within the active site (278).  The Ahvazi group, through molecular modeling 
studies on the related species tissue TGase 1 and 3, suggest that Ca2+ binding stabilizes 
the non-prolyl cis bonds in preparation for catalysis and that Q substrate binding results 
in the cis-trans isomerization (279, 280).  C409 may no longer be available for alkylation 
due to Q425-F426 isomerization, which resides about 6.5 Å from C409.  Another explanation 
could be that K9 DON interacts near or with C409.  The distance from C314 to C409 is ~13 
Å indicating that the 5 C-terminal residues (SLVIG) of K9 DON would have to exist in 
an extended conformation (~20 Å in length) toward the dimer interface.  This hypothesis 
is supported by trNOESY data that suggest the K9 peptide and an α2-antiplasmin peptide 
adopted extended conformations within the active site of FXIIIaIIa (137). 
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Another interesting observation was that K482 and K503 were not modified in K9 
DON FXIIIaCa.  K482 is located near the Ca2+ binding site and K503 resides on a fragment 
leading to β barrel 1 near the FXIIIa secondary cleavage site (K513-S514).  Unfortunately, 
fragments resulting from tryptic proteolysis of K513-S514 rarely appeared in the mass 
spectra after a thirty minute digest.  Nevertheless, the acetylation results suggest that K9 
DON inhibition may act in concert with Ca2+ binding to protect against further proteolysis 
at the secondary cleavage site by IIa. 
Figure 53: Correlating results with X-ray structure of Factor XIII (II) (1FIE).  A.  β barrel 2:  
the 5A2 binding epitope (red), the limited proteolysis fragment 681-698 (blue), W691-E692 
(cyan), and C695 (red).  B.  Catalytic Core I:  the activation peptide (cyan), D342/H343/E434 
(blue), Y560 (light blue), C314/H373/D396 (red), C409 (yellow), and the non-prolyl cis bonds R310-
Y311 (red) and Q425-F426 (orange).  C.  β barrel 1:  The HDX fragments 526-534/542-546 
(green), 535-541 (red), and 513-522 (orange), K583/K584 (blue), K565/K621 (yellow), Y560 (light 
blue), 561-564 (red), and the Ca2+ binding site (pink).  D.  Catalytic Core II:  HDX fragment 
220-230 (red), limited proteolysis fragment 207-214 (orange), and residues K199 (green), K221 
(purple), K68 (red), T206 (yellow), Y204/R333 (yellow), and 466-472 (blue).  
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FXIIIaIIa:  the Peptide 7 Region and Catalytic Core.  The fragment 220-230 within 
the potential Q substrate recognition site known as peptide 7 (190-230) (145) experienced 
similar levels of deuterium incorporation upon inhibition, as also seen with activation.  
Furthermore, acetylation of both K221 and K199 only occurs in FXIIIa.  Inhibition of 
FXIIIa did not result in hindering the modification of these residues.  These findings are 
consistent with any of the following conclusions:  residues 220-230, K199, and K221 are 
not involved in substrate recognition, ten residues are not long enough to reach peptide 7, 
and/or Q containing substrates do not lead to allosteric effects within these regions.   
Unique to FXIIIaIIa was the increased proteolysis of the peptide 7 residues 207-214 
by chymotrypsin and acetylation of K68 (Figure 53D).  The distance from the K68 side 
chain to the backbone carbonyl of L206 is 3.8 Å suggesting H-bond disruption concurrent 
with IIa activation.  A highly conserved loop amongst all TGases exists between residues 
467-472 which appear to shield a portion of peptide 7.  The previous observation that 
K467 was acetylated upon activation (175) indicates a possible rearrangement of this loop.   
Curiously, Fox et al. noticed a highly conserved water at a fork between two β 
strands (117), which is situated within a pocket formed by the conserved residues Y204, 
R333, T466, and K467.  The same group also observed that the strand containing R333 runs 
anti-parallel to the strand with H373 and that T466/K467 are downstream of A457 a Ca2+ 
binding site residue (117).  This potential K467 loop repositioning could be associated 
with the increased exposure of peptide 7 and proper orientation of residues involved in 
catalysis.  A study examining the consequences of TGase 1 mutations resulting in rare 
skin disorders commented on the significance of an R395L  (R333 in FXIII) mutant on 
impairing TGase 1 activity (281).  Also, the FXIII polymorphism Y204F leads to higher 
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occurrences of recurrent miscarriage, probably due to conformational changes resulting 
from the disruption of Y204-R333 H-bonding (282).   
Ca2+ Concentration and FXIIIa Inhibition Affect Dynamics of β barrel 1.  The 
current HDX results confirm an earlier report of Ca2+ protecting the fragments 513-522 
and 526-546 from deuterium exchange (174), however FXIIIaCa displayed significantly 
more protection from solvent within this region than FXIIIaIIa.  Fragment 535-541 
remained at similar deuterium levels compared to the zymogen, which enabled the 
observed changes in dynamics to be localized to the two flanking loops, 526-534 and 
542-546 (Figure 53C).  The isotopic cluster for FXIII residues 526-546 exposed to 1 mM 
Ca2+ appears to be an amalgam of the zymogen and FXIIIaCa (Figure 50).  This isotopic 
cluster possibly illustrates a concentration of Ca2+ where the cation binding site(s) is not 
fully occupied.  Analysis of these results could be interpreted to signify allostery within 
the TGase.  Ca2+ binding could potentially direct β barrel 1 to “roll away” from the 
catalytic core to allow Q substrate access, as previously hypothesized (118). 
Interestingly, the presence of K9 DON results in increased protection for 526-546 
from solvent after ten minutes in both FXIIIaCa and FXIIIaIIa .  Even residues 513-522, 
though only in FXIIIaIIa, were slightly more protected in the presence of either K9 DON 
or IAA.  Both these inhibitors also blocked lysine acetylation of K621 in FXIIIaIIa.  These 
results suggest that Q substrate binding further stabilizes β barrel 1, perhaps restricting 
access to additional Q substrates in preparation for covalent crosslinking to the acyl 
acceptor. 
Is the β barrel 2 the Location of a Lysine Containing Substrate Recognition Site?  
Within β barrel 2, chemical modification studies have provided evidence for the C695 
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exposure concurrent with activation (175).  In the current work, only FXIIIaCa was 
always alkylated at C695 regardless of inhibition, while FXIIIaIIa alkylation occurred when 
K9 DON was present at the active site.  The discrepancy in our results is likely due to the 
amount of NEM used in our earlier report (200 mM versus 50 mM) (175).  Further 
supporting this finding was the limited proteolysis studies demonstrating that FXIIIaCa 
resulted in increased chymotryptic proteolysis (chymotrypsin cleaves after W, F, and Y) 
of W691-E692, which may be related to C695 exposure (Figure 53A).   
As illustrated in Mitkevich et al., the antibody 5A2 that targets the FXIIIa epitope 
646-658 displays uncompetitive inhibition toward the Q substrate and competitive 
inhibition against the K substrate (146).  In fact, 5A2 binding is enhanced when the acyl 
donor binds to the active site (146).   The K9 DON FXIIIaIIa results suggest that the Q 
substrate creates a more solvent accessible region within the β barrel 2, potentially 
involved in K substrate recognition.  This hypothesis is in line with competitive inhibition 
of the acyl acceptor reaction when 5A2 binds to the FXIIIa epitope 646-658 (146).   
Conclusions 
The main objectives of this project were to demonstrate the applicability of DON 
based peptides in FXIIIa inhibition and to explore perturbations associated with 
activation and inhibition on FXIIIa dynamics.  For the first time, our chemical 
modification and newly implemented limited proteolysis studies utilized the protease 
chymotrypsin in addition to trypsin.  These results corroborate and further augment 
previous FXIII studies from our lab (174, 175). 
New insight was obtained into the conformational variance amongst FXIIIaCa and 
FXIIIaIIa.  Chymotrypsin proteolysis supplied evidence of additional peptide 7 exposure 
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resulting from IIa activation:  the fragment 207-214 is cleaved more efficiently and K68 is 
acetylated in FXIIIaIIa.  Also with FXIIIaIIa, increased proteolysis of 9-31 and alkylation 
of the nearby residues C238/C327 suggest unique events associated with activation peptide 
cleavage.  FXIIIaCa revealed amplification in proteolysis of the peptide bond L125-Q126 
and suppression of nearby K129 acetylation.  The β barrel 2 peptide bond W691-E692 and 
C695 in FXIIIaCa were more solvent accessible than with FXIIIaIIa.  These results perhaps 
indicate allostery associated with Ca2+ binding or the presence of additional Ca2+ binding 
sites within these domains.  General activation of FXIII led to an increase in deuteration 
for 240-268, as well as acetylation at K113, K156, and K257.  These events could indicate 
opening of the dimer interface for K substrate access to the active site.  
 With regard to FXIIIa inhibition, the results demonstrate that K9 DON is an 
effective inhibitor of FXIIIaIIa.  Furthermore, the solution studies reveal potential 
conformational features of FXIIIa trapped in the active state by K9 DON and IAA.  
Specific to K9 DON inhibition was the cessation of C409 alkylation within the active site, 
unique perturbations in HDX for 98-104 within the β sandwich of FXIIIaCa, increased 
accessibility of C695 with FXIIIaIIa, and blocked K482/K503 acetylation in FXIIIaCa.  
General inhibition resulted in FXIIIaIIa residue K621 no longer being available for 
acetylation and β barrel 1 fragments 513-522 and 526-546 becoming more protected from 
deuteration.  These observations provide subtle glimpses into how substrate bound FXIIIa 
prepares for the incoming lysine containing substrate.  The current work focuses on the 
consequences of interactions at the active site of FXIIIa.  Future endeavors into FXIII 
dynamics will examine larger more physiologically based substrates potentially evoking 
greater conformational changes and further targeting of putative binding exosites.  
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CHAPTER VII 
 
RESEARCH SUMMARY AND FUTURE DIRECTIONS 
 
The primary focus of this dissertation has been ligand-protein interactions.  For the 
research projects, two blood coagulation enzymes with very divergent catalytic activities 
were studied to enhance understanding of the consequences of ligand binding on protein 
dynamics.  Chapters IV and V describe work performed on the serine protease thrombin 
and peptide interactions at the anion binding exosites.  The peptides represent binding 
sites for thrombin found in fibrinogen and in the platelet receptor GpIbα.  Thrombin 
hydrolyzes peptide bonds, converting fibrinogen to fibrin and activating platelets.  
Another substrate for thrombin is Factor XIII.  Instead of catalyzing proteolysis, the 
transglutaminase FXIIIa serves to crosslink adjacent proteins through the formation of a 
covalent bond between a glutamine and lysine residue.  The studies in chapter VI 
illustrate the effects of an irreversible peptide inhibitor on the conformational dynamics 
of the transglutaminase.   
Two types of instrumental approaches were employed as the primary methods for 
examining ligand binding to proteins in these projects:  nuclear magnetic resonance 
(NMR) and matrix-assisted laser desorption-ionization mass spectrometry (MALDI-TOF 
MS).  In the studies with thrombin, NMR experiments described details regarding which 
protons within the peptide interact with a protein and secondary structural elements the 
peptide assumes when bound to protein.  MALDI-TOF MS proved to be an indispensable 
tool when investigating ligand binding from the perspective of thrombin and FXIIIa.  
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Hydrogen deuterium exchange can yield information concerning sites of peptide-protein 
interactions.  The technique can also probe the perturbations in the conformational 
dynamics of a protein resulting from peptide binding to a site unaffiliated with the 
binding interface.  Two methods that provide similar information as the HDX 
experiments are differential chemical modification and limited proteolysis.  These two 
techniques elucidated some of the subtle conformational transitions resulting from the 
activation and inhibition of FXIII. 
The following sections in this chapter summarize the findings described in chapters 
IV, V, and VI.  In addition, some preliminary work with isothermal calorimetry (ITC) has 
been performed to thermodynamically characterize the interactions of thrombin with the 
GpIbα peptide.  Based on these results and conclusions, new avenues will be discussed 
for investigating ligand binding to thrombin and the mechanisms of FXIII activation and 
substrate recognition. 
γ′ Peptide (410-427) Binding to Thrombin 
NMR and HDX coupled with MALDI-TOF MS were utilized to describe the 
structural and conformational features associated with ligand binding to IIa anion binding 
exosite-II (ABE-II) (167).  In the absence of a crystal structure, the main impetus for 
these investigations was to gain insight into the mode and consequences of γ′ peptide 
interactions at ABE-II.  Many observations discussed in chapter IV correlate extremely 
well with the recently reported X-ray structure of the γ′ peptide bound to thrombin (242). 
The research employed 1D and 2D NMR to characterize the structural features of 
the bound γ′ peptide (410-427) and to evaluate the requirement of sulfonation for 
effective thrombin interaction.  The results indicate the γ′ residues 414-427 make 
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significant contact with thrombin; however, removing one phosphate from either tyrosine 
lessens the amount of observed line broadening.  Interestingly, the unphosphorylated 
peptide does not show any 1D line broadening suggesting that at least one tyrosine must 
be phosphorylated to bind thrombin.  The 2D trNOESY spectra illustrate the presence of 
a turn structure involving YP422-D425 and a trans configuration for the YP422-P423 that are 
only evident when bound to thrombin.  Once again, these structural elements require at 
least one phosphotyrosine.  Further evidence for the turn structure at the C-terminus of 
the peptide is provided by the abundance of inter-residue long range NOEs, 
predominately centered at the aromatic rings of both phosphotyrosines. 
The NMR data (167) predict many of the features depicted in the solved X-ray 
crystal structure (242).  Only residues 413-426 were modeled in the X-ray structure, 
supporting the NMR data suggesting that the first few N-terminal residues were not 
necessary for interacting with thrombin.  Finally, the two structural elements predicted 
from the 2D trNOESY, the turn structure YP422-D425 and the trans YP422-P423 bond are 
both present in the X-ray structure. 
HDX coupled with MALDI-TOF MS was implemented to examine the location of 
the γ′ peptide-thrombin interface and to screen for changes in solvent exposure at distant 
sites.  The HDX results indicate that residues within the thrombin fragments 85-99 and 
173-181 interact with the γ′ peptide.  The binding of the γ′ peptide also protects other 
regions of thrombin from deuterium exchange.  Affected regions include segments of 
ABE-I, the autolysis loop, the W215/Na+ binding site fragment, and the A-chain.  The 
investigation also determined that thrombin forms a ternary complex with the γ′ peptide 
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and the active site inhibitor PPACK.  This interaction generates an enzyme whose 
solvent-exposed regions are even further stabilized from backbone amide HDX. 
When comparing the data (167) to the reported crystal structure (242), the ABE-II 
regions 85-99 and 173-181 that were predicted to engage with γ′ peptide contain two 
residues (R93 and N179) that appear to bind the peptide.  These observed interactions in the 
X-ray structure serve to further expand the interpretations of the HDX data.  The crystal 
structure depicts electrostatic interactions involving R93T-S420γ′ and N179T-D419γ′.  
Furthermore, the γ′ peptide appears to dimerize thrombin with many of the described 
secondary features observed in the NMR data forming as a result of this dimerization.  In 
the X-ray structure, R93 of a symmetry related thrombin molecule interacts with two 
residues in the γ′ peptide:  D425 and D426.  The N-terminus of the γ′ peptide fits into a 
hydrophobic pocket formed by several thrombin residues, one of which is F181 and 
several neighboring residues of the HDX protected fragment 173-181.  
Another aspect of peptide interactions with thrombin’s ABE-II revealed by the 
HDX studies concerns allostery connected to ligand binding.  Quite a few residues that 
participate in substrate binding are contained in the coverage from a peptic digest of 
thrombin.  In particular, residues L99, I174, and W215 are present in segments that are 
significantly protected from deuterium incorporation after one minute.  These results 
support a connection from ABE-II to the active site that has been previously described 
from kinetic studies (113).  The reduced rate of HDX for residues at ABE-I advocates the 
presence of an interexosite linkage.  Similar conclusions were reached in HDX studies 
with ABE-I ligand binding (172, 173) and fluorescent work (70, 170). 
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GpIbα Peptide (269-286) Binding to Thrombin 
Two crystal structures have been published illustrating the GpIbα-IIa interaction 
(96, 97).  Whereas the γ′ peptide-IIa interface has been localized to ABE-II, the binding 
site for GpIbα is more ambiguous and may be at ABE-II or ABE-I.  The C-terminal tail 
of GpIbα (269-286) shares similar sequence elements with the γ′ peptide.  Both GpIbα 
X-ray structures (96, 97) display comparable ABE-II interactions for the C-terminal tail; 
however, the Celikel structure (1OOK) shows the C-terminal tail dimerizing thrombin 
through binding with ABE-I in a symmetry related thrombin molecule (97).  Curiously, 
the γ′ peptide-IIa structure (242) also illustrates ligand-induced dimerization of thrombin, 
but in this instance the γ′ peptide binds to both thrombin molecules through ABE-II 
interactions.  
The research performed in chapter V further characterizes the features of peptide 
binding to thrombin, building upon similar work in chapter IV on fibrin(ogen)’s γ′ 
peptide.  Peptides were synthesized based on the C-terminal GpIbα residues 269-286.  
Utilizing the same techniques as in chapter IV, perhaps the elements that distinguish γ′ 
peptide versus GpIbα peptide binding to thrombin can be discerned in more detail.  
Furthermore, an additional study employed analytical ultracentrifugation to determine the 
behavior of thrombin in the presence of both the GpIbα and γ′ peptides.  
1D line broadening and 2D trNOESY NMR spectra indicate that GpIbα (269-286) 
YP276YP278YP279 binds too tightly to thrombin for structural information to be obtained 
from these techniques.  Removing phosphorylation from Y278 weakens the interaction to 
a certain extent and line broadening begins to be observed for the GpIbα YP276/YP279 
peptide.  The largest degree of line broadening and of NOEs in the 2D trNOESY appears 
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with the unphosphorylated GpIbα peptide.  The NMR results indicate that the N-terminal 
residues 269-273 and the C-terminal residues 284-286 are not essential for binding 
thrombin.  Furthermore, the GpIbα peptide interacts with thrombin in an extended 
conformation, without significant secondary structural features.   
As with the γ′ peptide, the NMR data compares very well to the X-ray structures.  
The residues 269-273 in the two reported GpIbα crystal structures are in two different 
conformations, which correlates to the lack of line broadening for these residues in the 
1D spectra.  Additionally, the extended conformation predicted by the 2D trNOESY data 
is also evident for the C-terminal residues in both X-ray structures.  Interestingly, the line 
broadening observed for residues Y279-D283 and E285 may exist due to dimerization of 
thrombin and peptide interactions with ABE-I.  The NMR data compared with the crystal 
structures of both GpIbα and the γ′ peptide indicate that these thrombin ligands possess 
unique modes of binding to the serine protease.  
For the HDX experiments, the GpIbα YP276YP278YP279 peptide was used because the 
triply phosphorylated peptide binds tighter to thrombin.  At a ratio of 20:1 peptide to 
enzyme, the results compare well with the data from the γ′ peptide study, suggesting that 
the GpIbα binds primarily to ABE-II.  More protection is observed for the ABE-I 
residues 65-84, perhaps stemming from ABE-I interactions with dimerized thrombin.  
Strikingly, after ten minutes of deuteration with the GpIbα peptide, the appearance of a 
mixed isotopic cluster for ABE-II residues 85-99 is evident.  Increasing the ratio of the 
GpIbα peptide to thrombin (40:1) during the HDX experiment leads to ABE-II fragment 
85-99 experiencing a drastic reduction in protection, while ABE-I residues are now 
significantly protected from solvent.  These results indicate that the GpIbα peptide is now 
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binding exclusively to ABE-I.  The new binding interface leads to different consequences 
on the dynamics of HDX for other fragments observed in the HDX experiments when 
compared to ABE-II binding. 
The studies with analytical ultracentrifugation were performed to screen for 
peptide-induced dimerization of thrombin.  The concentration of IIa was kept between 
4.5-7 µM to avoid saturation of the uv-vis absorbance.  Both the GpIbα peptide and the γ′ 
peptide (4.5-140 µM) did not exhibit dimerization of thrombin at the concentrations 
employed for the experiments. It should be noted that the NMR and HDX results were 
performed at higher concentrations of protein (50-150 µM) and peptide (1-2 mM).   
These studies suggest a concentration dependent binding scheme for the GpIbα and 
IIa.  This observation is not surprising given the low number of high affinity GpIbα 
binding sites on platelets (105-1050) (101, 262) compared to the amount GpIbα present 
on the surface of platelets (~25,000 copies) (263).  In addition, low levels of IIa activate 
platelets in a GpIbα dependent manner, while high levels of IIa can perform this task 
without GpIbα (94, 264).  One possibility could be that GpIbα binding to ABE-II serves 
the function of activating platelets at the initiation of blood coagulation.  After the burst 
of IIa generation, GpIbα may no longer be needed to recruit IIa to the surface of platelets 
to effectively interact with substrates like PAR-1.  In the following sections, ongoing and 
future studies are described to better understand the consequences of ligand binding to 
ABE-II.    
Preliminary Results from Isothermal Calorimetry of GpIbα Binding to Thrombin 
Isothermal calorimetry (ITC) was performed to thermodynamically analyze the 
GpIbα-IIa interaction.  A significant advantage of this technique rests in the ability to 
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directly measure ligand-protein interactions without the need for extraneous labeling, 
such as fluorophores or chromophores (283).  By titrating a ligand into a cell containing 
an interacting partner, i.e. protein, heat will be either released to the environment or 
absorbed from the surroundings (283, 284).  The calorimeter measures the heat effect 
upon binding, which can be used to calculate the dissociation constant (KD), the enthalpy 
(ΔH) and the stoichiometry of interaction.  The Gibbs free energy of an interaction 
determines the binding affinity: ΔG = RT ln KD = ΔH - TΔS.  For an optimal interaction, 
ΔH must be negative and/or the entropy, ΔS, must be positive.  Thus, these types of 
experiments can provide insight into the thermodynamic driving force for the interaction.  
When analyzing the results from ITC experiments, careful consideration must be 
given to the interpretation of the thermodynamic parameters.  Deviations in the value of 
ΔH may not be directly correlated with changes in ΔG (284).  Enthalpy/entropy 
compensation (285) is evident in a study of glycocalicin binding to thrombin (256).  
Glycocalicin (140 kDa) is the extracellular fragment of GpIbα resulting from proteolysis 
of the receptor near the cell membrane by a protease, such as calpain (286, 287).  By 
performing ITC on glycocalicin at a range of temperatures, the authors found that at 
lower temperatures (4-10°C) the dominant driving force was entropic, while at higher 
temperatures (20-37°C) the reverse was observed with enthalpy the major contributor to 
binding (256).  All the while, the ΔG remained relatively constant from -8.6 to -9.6 
kcal/mol (256).  The authors concluded that binding was favored due to the removal of 
non-polar surface area from the solvent, termed the hydrophobic effect (288).  
Another contribution to favorable ligand-protein interactions could be exclusively 
entropic in nature.  In the case of thrombomodulin binding to thrombin, the interaction 
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has a favorable ΔG of -11.9 kcal/mol; however, ITC experiments demonstrated that ΔH 
did not contribute to the favorable binding event (289).  Thus, entropy was driving the 
interaction, through an increase in protein mobility and/or the release of solvent 
molecules from the binding interface.  The authors found that 1H-15N HSQC NMR work 
predicted a restriction in the configurational entropy once thrombomodulin bound to 
thrombin (290).  The increase in entropy was primarily assigned to the displacement of 
water from the surface of the protein to the bulk solvent (289). 
As mentioned previously, ITC has also characterized the interaction of glycocalicin 
and IIa (256).  The authors demonstrated that the favorable binding affinity results from 
the burial of nonpolar surface area (256).  The residues of GpIbα and glycocalicin 
targeted by thrombin are located within the segment 269-286 (as discussed in Chapter V).  
In an attempt to understand the thermodynamic contribution of residues 269-286 when 
binding IIa, ITC was performed with the GpIbα (YP276YP278YP279) peptide and IIa.   
The active site inhibitor PPACK was allowed to inhibit IIa for 30 min at a 2:1 ratio.  
An assay involving the chromogenic substrate S2238 was employed to ensure that IIa 
was inactive.  PPACK-IIa was then subjected to dialysis in 150mM NaCl, 25mM 
phosphate, pH 7.4.  The GpIbα peptide was lyophilized and reconstituted in the excess 
buffer from dialysis.  The ITC experiment attempted to characterize both the KD and ΔH, 
with the GpIbα peptide at 450 µM and PPACK-IIa at 26.1 µM.  PPACK-IIa was in the 
cell and the peptide was titrated in as 5 µL aliquots every 5 minutes.  The experiments 
were carried out at 25°C in a VP-ITC from Microcal.  The following controls were also 
performed:  buffer titrated into buffer, GpIbα peptide (450 µM) titrated into buffer, and 
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buffer titrated into IIa (36.4 µM).  The data was analyzed with the ORIGIN software 
supplied by MicroCal. 
The data from the first ITC experiment in Figure 54A shows that the GpIbα 
(YP276YP278YP279) peptide binding saturated thrombin too quickly to accurately observe 
the full sigmoidal titration curve.  Thus, accurate modeling of the data by the program 
Origin was not possible due to the absence of the initial plateau that represents the 
enthalpy of binding.  The experiment did indicate that GpIbα peptide binding to thrombin 
was endothermic.   
Figure 54:  Isothermal calorimetry of the GpIbα peptide and thrombin.  A.  Top panel is the raw data 
showing the measured heat change of GpIbα peptide titrated into IIa.  Bottom panel is the integrated 
heat of binding for GpIbα peptide-IIa without subtraction of the heat measured from the controls.  B.  
Top panel is the raw data from the “model free” ITC experiment with GpIbα peptide titrated into 
thrombin.  The bottom panel is the uncorrected integrated heat of binding for GpIbα peptide-IIa.  The 
experiments were conducted at 298 K in 150 mM NaCl, 25 mM H3PO4, pH 7.4. 
A B 
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The second type of ITC experiment was performed in order to assess the enthalpy 
of interaction in a “model free” manner where saturation of PPACK-IIa (30.1 µM) by the 
GpIbα peptide (30 µM) is not achieved (291).  In order to calculate the ΔH, the GpIbα 
peptide was titrated into thrombin at much lower concentrations (Figure 54B), where 
each injection yields an independent “model-free” measurement of the ΔH.  The results 
indicate that the average ΔH for the interaction is about +5.4 kcal/mol (291).  The 
controls measuring buffer into buffer and buffer into thrombin did not display any heat 
evolution or absorption, discounting these possible contributors to the observed ΔH (data 
not shown).  The heat of dilution for the GpIbα peptide into IIa was around -0.5 kcal/mol, 
thus ΔH for GpIbα peptide binding to IIa is closer to +4.9 kcal/mol (data not shown). 
The data from the ITC experiments indicate that the binding of the triply 
phosphorylated GpIbα peptide is endothermic with ΔH of +4.9 kcal/mol.  Bothrojaracin 
is a thrombin inhibitor found in snake venom that binds to both ABE-I and ABE-II (292).  
ITC studies measuring the thermodynamics of bothrojaracin binding to ABE-I in 
prothrombin described a positive value for the enthalpy (13.5 kcal/mol) (293).  It should 
be noted that ABE-II is not available in prothrombin due to binding by prothrombin 
fragment II (169).  The report concluded that the interaction was entropically driven, but 
the reasons why were unclear.  The authors suggested that either the release of water 
from a non-polar binding interface or an increase in conformational mobility of 
prothrombin leads to the observed positive enthalpy (293).   
Both of these proposals from the bothrojaracin work seem to be unlikely 
explanations for the GpIbα peptide studies (293).  First, the electrostatic nature of the 
glycocalicin interaction with thrombin was measured by Li et al. giving a Γsalt = -4.2 (68).  
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In addition, the GpIbα peptide is highly anionic and, as demonstrated by the crystal 
structures, interacts with a complementary cationic binding exosite on the IIa surface (96, 
97).  Thus, these observations seem to indicate that the GpIbα peptide is not releasing 
water from a non-polar binding interface.  Second, the HDX results at 20:1 GpIbα to 
thrombin indicate that the protein is quite protected from HDX when compared to 
thrombin alone (chapter V).  These results suggest a restriction of the conformational 
ensembles sampled by IIa and a restriction of protein mobility, at least for the regions of 
HDX coverage.   
Curiously, the ΔH of glycocalicin binding to IIa at 25 °C was found to be -11.10 
kcal/mol (256).  At the present time, the discrepancy between the thermodynamic 
behavior of glycocalicin and the GpIbα peptide is unknown.  A possible explanation may 
be that the GpIbα peptide, at the concentrations employed for ITC, dimerizes thrombin.  
This dimerization is observed in the Celikel crystal structure and may result in the burial 
of solvent accessible non-polar residues at the thrombin dimer interface (97).   
Future ITC work will endeavor to further characterize the GpIbα peptide-IIa 
interaction thermodynamically.  The data from Figure 54 suggests that the top and bottom 
of the sigmoidal binding isotherm has been observed during the course of the two 
experiments.  By using the concentrations employed in these experiments, perhaps an 
experiment can be designed to generate the whole binding isotherm.  If successful, these 
experiments could yield more detailed thermodynamic information, such as the 
stoichiometry of binding and the binding affinity.  In addition, performing ITC 
experiments with the γ′ peptide could provide important clues as to whether the positive 
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enthalpies associated with the GpIbα peptide are a general feature of ABE-II association 
and possible dimerization of thrombin. 
Future Directions for the Study of Ligand Binding to Thrombin 
As with any endeavor, important discoveries and insights regarding the system 
under study generate more paths for investigation.  In this section, new NMR, HDX, and 
AUC experiments will be suggested to help further elucidate the effects of ligand binding 
to thrombin.  More than likely, these potential studies will lead to even more questions to 
be addressed in the future. 
An unresolved issue from chapters IV and V (and further probed in the new ITC 
data of this chapter) has been whether the GpIbα or γ′ peptides dimerize thrombin.  The 
crystal structures of these ligands bound to IIa display dimerization through a symmetry 
related thrombin molecule.  In addition, the NMR data appear to require thrombin 
dimerization in order to explain the observed effects.  Unfortunately, peptide induced 
dimerization has not been independently confirmed by another solution-based method.   
An NMR technique was developed in 1965 to measure the diffusion constants, 
termed NMR pulsed field-gradient (PFG) spin-echo technique (294).  Briefly, as 
discussed by Stejskal and Tanner (294), during a 1D NMR spin-echo experiment, two 
additional gradient pulses are applied that surround the 180° spin echo pulse.  The first 
pulse dephases the transverse magnetization along the z-axis and the second pulse 
rephases the magnetization.  While the nuclear spins are dephased, the molecules will 
diffuse along the z-axis.  The speed of diffusion will determine the degree of attenuation 
required to refocus the resonances once the second pulse rephases the magnetization.  
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Translational self-diffusion is related to measurable NMR parameters as described by 
Stejskal and Tanner (294).  
The method has been used to distinguish between RNA in a duplex or RNA 
forming a hairpin turn and thus monomeric (295).  Also, the aggregation state of the 
protein myosin light chain 2 has been determined employing this technique (296).  By 
comparing the diffusion of an NMR sample of IIa alone with IIa in the presence of both 
peptides, the pulsed field-gradient (PFG) spin-echo technique (294) could help determine 
if peptide induced IIa dimerization is occurring in the NMR tube. 
Another method for determining thrombin dimerization is analytical 
ultracentrifugation.  AUC experiments were described in chapter V at significantly lower 
thrombin concentrations than required for NMR and crystallization.  A less accurate 
AUC experiment could utilize the absorbance of proteins at 300-310 nm, where 
saturation of the signal at 280 nm can be avoided when analyzing high concentrations of 
protein.  In this case, an AUC experiment can be performed at 150 µM IIa just for the 
express purpose of determining if two macromolecular species are dimerizing in solution.  
Concerning the work with HDX, the leech derived inhibitor hirudin is known to 
bind to ABE-I of thrombin with a tight affinity.  The 40:1 HDX results with GpIbα 
suggest that the peptide is binding presumably at ABE-I.  By performing HDX with a 
peptide that targets ABE-I, perhaps the results from studies with hirudin will mirror the 
results with GpIbα at 40:1, further supporting the concept of ABE-I binding.  At the same 
time, the allosteric consequences of ligand binding to ABE-I can also be observed and 
compared to work performed with fragments of the ABE-I binding protein 
thrombomodulin.  The HDX results in chapter V imply that simultaneous occupation of 
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both ABE-II and ABE-I by the GpIbα peptide is not possible.  Negative allostery 
between the two exosites is supported by fluorescent work (70, 170).  Thus, an HDX 
experiment could be designed at lower GpIbα peptide concentrations (i.e. 20:1) in the 
presence of hirudin to observe whether protection is observed at both exosites. 
An additional HDX experiment would study full-length protein-thrombin 
interactions.  The peptides GpIbα and γ′ are derived from the larger parent proteins.  By 
attaching fibrinogen with the γ′ chain or GpIbα (1-290) to an agarose bead, HDX can be 
performed to examine the effects on thrombin dynamics resulting from protein-protein 
binding.  An E.coli expression system has been recently developed for the γ′ chain 
residues 148-427 (297).  As for GpIbα, residues 1-290 have been expressed in D. 
melanogaster (97) and residues 1-288 have been expressed in Chinese hamster ovary 
cells (96).  Glycocalicin, the extracellular portion of GpIbα, could also be studied by 
using a protease to cleave GpIbα at the platelet surface and then the extracellular portion 
could be purified (287, 298).    
For fibrinogen, the HDX projects could examine the effects of the whole fibrinogen 
γ′ homodimer (AαBβγ′)2 versus the heterodimer (Aα)2(Bβ)2(γAγ′).  Within the HDX 
protocol, one more step would be added to separate the thrombin from the protein 
attached to the agarose bead, perhaps involving an acidic quench (0.1% TFA) in a solvent 
of lower polarity (i.e. propanol) to disrupt the interaction (299).  This would be followed 
by centrifugation, then peptic digestion.  Finally, the binding could be studied from the 
perspective of GpIbα (1-290), with IIa attached to the bead.  Both of these proteins are of 
similar length.  In this case, the fragments from a peptic digest of GpIbα would have to 
be identified by PSD and carboxypeptidase Y sequencing.  HDX work has been 
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performed with a similar leucine rich repeat protein IκBα, which is involved in 
transcriptional regulation of NF-κB (300). 
FXIII Activation and Inhibition Studies 
Another important substrate for thrombin is the transglutaminase Factor XIII.  To 
date, crystallography has been unable to accurately model the conformational transition 
that occurs once FXIII is activated by thrombin (117-119).  Therefore, solution based 
techniques have been performed to characterize some of the subtle changes in FXIII 
dynamics that results from activation.  MALDI-TOF MS was utilized to observe the 
effects of activation and inhibition on FXIII dynamics through HDX, differential 
chemical modification, and limited proteolysis (178).   
The work described in chapter VI further builds upon research performed by Brian 
T. Turner, Jr. (174, 175) by increasing FXIII sequence coverage with the protease 
chymotrypsin and by binding the irreversible peptide inhibitor K9 DON to the active site.  
Previous HDX experiments demonstrated that FXIII activation protects regions within 
the β sandwich (98-104) and the β barrel 1 (526-546) from deuterium, while exposing the 
potential Q substrate recognition site (220-230) to deuteration (174).  Differential 
chemical modification indicated the availability of several residues upon activation 
including K73, K221, C314, and C409 (175).  These initial forays into FXIII dynamics 
supported the notion that conformational changes occur after FXIII activation that are 
currently undetected in the crystal structures of the transglutaminase (117-119). 
In the current work (178), activations of FXIII by thrombin and calcium were 
further examined.  New findings unique to FXIIIaIIa (thrombin activated FXIII) included 
additional evidence for the exposure of peptide 7 with the acetylation of K68 and 
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increased proteolysis of 207-214.  Peptide 7 is hypothesized to be a potential substrate 
recognition site accessible after FXIII activation (145).  Thrombin cleavage of the 
activation peptide exposed resides C238 and C327 to alkylation by NEM, as well as 
enhanced proteolysis of 9-31.  By contrast, FXIIIaCa (calcium activated FXIII) led to 
increased proteolysis of the β sandwich fragments 75-83 and 104-125 and a loss of K129 
acetylation.  In addition, several residues within the β barrel 2 were more solvent exposed 
in FXIIIaCa including the peptide bond W691-E692 and C695.  These observations may be 
connected to the allosteric transmission of calcium binding at undiscovered sites 
proposed by two independent groups (131, 132).  Finally, activating FXIII with either 
thrombin or calcium appeared to increase access within the dimer interface, as evidenced 
by the enhancement of deuterium incorporation for residues 240-268 and acetylation of 
K113, K156, and K257.    
The investigation also examined FXIIIa inhibition by the K9 DON peptide (with the 
glutamine isostere 6-diazo-5-oxo-norleucine) compared with the nonspecific alkylating 
agent iodoacetamide (IAA).  The results illustrate, for the first time, irreversible 
inhibition of FXIIIa with a peptide-derived inhibitor.  K9 DON prevented alkylation of 
C409 within the catalytic core perhaps a result of the inhibitor interacting near this residue 
within the active site.  Other observations related to K9 DON inhibition may signal 
preparation for the incoming lysine containing substrate, including alkylation of C695 in 
FXIIIaIIa and the cessation of K482-K503 acetylation in FXIIIaCa.  Both inhibitors promoted 
even greater protection from deuteration for the β sandwich (98-104) and the β barrel 1 
(513-522 and 526-546).  The solution-based approaches reveal that activation and 
inhibition lead to local and long range perturbations in the conformational dynamics of 
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the transglutaminase.  Important glimpses are being provided on FXIIIa allostery and the 
presence of putative FXIIIa exosites. 
Future Research for the Study of FXIII Activation and Substrate Recognition 
The development of a peptide-based inhibitor of FXIIIa has created new 
possibilities for studying the conversion of FXIII to FXIIIa.  The glutamine isostere 6-
diazo-5-oxo-norleucine may be incorporated into a better peptide substrate for FXIIIa α2-
antiplasmin (1-15) (137).  Since the reactive glutamine is at position 2 in this 15-residue 
peptide, inhibition of FXIIIa with α2-antiplasmin (1-15) DON will allow the C-terminal 
13 residues to interact with a larger interface within the catalytic core than the four C-
terminal residues of the K9 DON peptide.  Similar HDX and chemical modification 
experiments as described in chapter VI could be performed to assess the effects of a 
different inhibitor on the dynamics of FXIIIa.  Crystallization of DON peptide inhibited 
FXIIIa should also be attempted.  As has been already hypothesized, the binding of an 
inhibitor to FXIIIa could favor crystallization of the transglutaminase in the active state, 
revealing aspects of the FXIIIa conformation previously unobserved. 
Non-proteolytic activation of FXIII by metals is another area that lends itself to 
further exploration.  An investigation could be conducted examining the activity of FXIII 
in high concentrations (~50 mM) of divalent metals such as Mg2+, Mn2+, and Sr2+.  A 
question to be addressed is whether these metals can activate FXIII without the presence 
of calcium, in the presence of 1 mM calcium (where the known Ca2+ binding site is 
occupied), or substitute for 1 mM Ca2+ in thrombin activated FXIII.  Since the secondary 
reporter reactions typically used to study FXIIIa involve glutamate dehydrogenase, the 
presence of a variety of metals may interfere with the catalytic activity of the reporter 
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enzyme.  A new fluorometric assay has been recently developed to study the kinetics of 
the second part of the FXIII crosslinking reaction (lysine crosslinking to glutamine) 
(301).  The reported method may be better suited to study the effects of divalent metals 
on FXIIIa activity since it does not rely on a secondary reporter enzyme (301). 
Another aspect of FXIII that could be investigated by HDX and chemical 
modification is the interaction of the regulatory B-subunits of plasma FXIII with the A-
subunits and with the fibrinogen γ′ peptide.  Research has shown that the B subunits of 
plasma FXIII binds to the γ′ chain of fibrinogen (116).  In addition, the binding interface 
for the B dimer has not been identified on the A dimer.  The catalytic A-subunits could 
also be attached to agarose beads and HDX performed to study the effects of B-subunit 
binding to the A-subunits.  As with GpIbα (1-290), the fragments from a peptic digest of 
the B subunits would have to be identified with PSD and carboxypeptidase Y sequencing.  
Final Thoughts on the Investigations into Blood Coagulation Protein Interactions 
The projects described in the preceding chapters have delved into further 
understanding the dynamics of ligand-protein interactions.  The binding of two peptides 
with very similar sequences to thrombin leads to conformational differences in peptide 
structure and affects thrombin dynamics in subtly unique ways.  Important insight 
regarding FXIIIa substrate recognition and activation has been reported with the advent 
of a peptide with a moiety that irreversibly inhibits FXIIIa.  In the future, the specific 
details of these peptide interactions could perhaps be exploited to develop drugs that 
specifically target thrombin or Factor XIIIa in treatments for stroke, wound healing, and 
coronary artery disease.  
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APPENDIX A  CHEMICAL SHIFT TABLES 
(All Samples in Aqueous Solution and Referenced to EDTA) 
 
Table A:  1H Resonance Assignments (ppm) of the γ′peptide (YP418 YP422) at 15°C. 
 
 
 
 
 
Table B: 1H Resonance Assignments (ppm) of the γ′peptide (YP418 YP422) bound to IIa at 15°C.  The 
assignments for this peptide bound to γ-IIa are not significantly different. 
 
Residue NH CαH CβH CγH CδH CεH 
P410  4.40 2.45 2.07, 2.00 3.42, 3.38  
E411 8.86 4.25 1.96, 1.88 2.25, 2.20   
H412 8.66 4.99 3.23, 3.13  7.31  
P413  4.43 2.31 2.02, 1.98 3.76, 3.58  
A414 8.61 4.32 1.42    
E415 8.57 4.34 2.11, 1.98 2.32   
T416 8.19 4.32 4.17 1.13   
E417 8.49 4.28 1.96, 1.86 2.21, 2.13   
YP418 8.25 4.60 3.14, 2.93  7.18 7.08 
D419 8.36 4.59 2.70, 2.61    
S420 8.26 4.35 3.83, 3.79    
L421 8.29 4.28 1.52 1.38 0.88, 0.81  
YP422 8.26 4.86 3.14, 2.85  7.23 7.11 
P423  4.42 2.29 2.03, 1.99 3.72, 3.62  
E424 8.73, 8.70 4.32 2.11, 1.97 2.35   
D425 8.35 4.63 2.71, 2.65    
D426 8.34 4.67 2.76, 2.61    
L427 7.79 4.17 1.64 1.57 0.91, 0.86  
 
 
 
Residue NH CαH CβH CγH CδH CεH 
P410  4.40 2.45 2.07, 2.01 3.42, 3.39  
E411 8.86 4.25 1.95, 1.88 2.26, 2.20   
H412 8.64 5.00 3.22, 3.13  7.31  
P413  4.43 2.32 2.02, 1.98 3.76, 3.58  
A414 8.61 4.31 1.43    
E415 8.57 4.35 2.11, 1.99 2.32   
T416 8.18 4.33 4.17 1.13   
E417 8.49 4.28 1.96, 1.86 2.20, 2.15   
YP418 8.26 4.59 3.13, 2.94  7.19 7.14 
D419 8.35 4.60 2.70, 2.60    
S420 8.28 4.36 3.84, 3.79    
L421 8.29 4.25 1.52 1.38 0.88, 0.81  
YP422 8.26 ? 3.13, 2.86  7.23 7.13 
P423  4.42 2.29 2.03, 1.99 3.72, 3.62  
E424 8.72, 8.65 4.31 2.10, 1.96 2.36   
D425 8.38 4.63 2.71, 2.64    
D426 8.36 4.67 2.76, 2.62    
L427 7.80 4.17 1.62 1.58 0.92, 0.86  
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Table C:  1H Resonance Assignments (ppm) of the γ′peptide (YP418) at 15°C. 
 
Residue NH CαH CβH CγH CδH CεH 
P410  4.40 2.47 2.10, 2.03 3.43, 3.39  
E411 8.86 4.25 1.97, 1.88 2.24, 2.18   
H412 8.64 5.02 3.23, 3.13  7.30  
P413  4.43 2.34 2.02 3.76, 3.57  
A414 8.61 4.31 1.43    
E415 8.57 4.35 2.12 2.32, 2.00   
T416 8.19 4.33 4.17 1.14   
E417 8.50 4.28 1.99, 1.88 2.20, 2.15   
YP418 8.27 4.59 3.13, 2.96  7.18 7.11 
D419 8.34 4.60 2.70, 2.60    
S420 8.21 4.36 3.84, 3.79    
L421 8.20 4.24 1.48 1.31 0.87, 0.79  
Y422 8.18 4.86 3.08, 2.83  7.15 6.82 
P423  4.42 2.28 2.00 3.69, 3.57  
E424 8.61 4.31 2.12, 1.96 2.36   
D425 8.36 4.63 2.74, 2.65    
D426 8.34 4.66 2.76, 2.61    
L427 7.79 4.16 1.57 1.63, 1.60 0.92, 0.86  
 
 
 
 
Table D:  1H Resonance Assignments (ppm) of the γ′peptide (YP418) bound to IIa at 15°C. 
 
Residue NH CαH CβH CγH CδH CεH 
P410  4.40 2.45 2.08, 2.03 3.42, 3.38  
E411 8.86 4.25 1.96, 1.89 2.21, 2.26   
H412 8.66 4.99 3.22, 3.13  7.30  
P413  4.43 2.32 2.03, 1.99 3.77, 3.58  
A414 8.61 4.33 1.43    
E415 8.58 4.36 2.11, 1.99 2.32   
T416 8.20 4.36 4.17 1.14   
E417 8.50 4.29 1.97, 1.87 2.21, 2.14   
YP418 8.25 4.60 3.13, 2.95  7.18 7.09 
D419 8.34 4.60 2.70, 2.62    
S420 8.21 4.36 3.85, 3.79    
L421 8.20 4.24 1.47 1.32 0.87, 0.79  
Y422 8.19 4.86 3.09, 2.81  7.14 6.80 
P423  4.42 2.28 2.01, 1.98 3.69, 3.57  
E424 8.63 4.31 2.10, 1.96 2.36   
D425 8.35 4.64 2.72, 2.67    
D426 8.33 4.68 2.75, 2.62    
L427 7.79 4.17 1.62 1.57 0.92, 0.86  
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Table E:  1H Resonance Assignments (ppm) of the γ′peptide (YP422) at 15°C. 
 
Residue NH CαH CβH CγH CδH CεH 
P410  4.40 2.45 2.07, 2.00 3.42, 3.39  
E411 8.85 4.25 1.96, 1.88 2.25, 2.20   
H412 8.65 5.01 3.24, 3.14  7.32  
P413  4.43 2.32 2.02, 1.95 3.76, 3.58  
A414 8.61 4.31 1.43    
E415 8.57 4.36 2.11, 1.99 2.33   
T416 8.18 4.32 4.16 1.13   
E417 8.47 4.28 1.96, 1.87 2.20, 2.15   
Y418 8.21 4.56 3.09, 2.92  7.11 6.82 
D419 8.32 4.59 2.71, 2.62    
S420 8.17 4.34 3.85, 3.79    
L421 8.20 4.23 1.51 1.34 0.87, 0.80  
YP422 8.18 4.85 3.13, 2.84  7.21 7.12 
P423  4.42 2.27 2.01, 1.96 3.67, 3.59  
E424 8.64 4.32 2.10, 1.96 2.36   
D425 8.38 4.63 2.74, 2.66    
D426 8.36 4.66 2.77, 2.63    
L427 7.80 4.18 1.64 1.57 0.91, 0.87  
 
 
 
 
Table F:  1H Resonance Assignments (ppm) of the γ′peptide (YP422) bound to IIa at 15°C. 
 
Residue NH CαH CβH CγH CδH CεH 
P410  4.40 2.45 2.08, 2.00 3.43, 3.39  
E411 8.86 4.25 1.95, 1.88 2.24, 2.19   
H412 8.66 5.00 3.23, 3.14  7.32  
P413  4.43 2.32 2.02, 1.95 3.76, 3.58  
A414 8.61 4.32 1.42    
E415 8.57 4.35 2.11, 1.98 2.32   
T416 8.20 4.33 4.18 1.14   
E417 8.47 4.26 1.97, 1.88 2.19, 2.13   
Y418 8.20 4.58 3.08, 2.90  7.11 6.78 
D419 8.30 4.58 2.72, 2.62    
S420 8.20 4.32 3.84, 3.79    
L421 8.22 4.21 1.50 1.31 0.84, 0.74  
YP422 8.15 4.86 3.12, 2.82  7.20 7.11 
P423  4.42 2.27 2.01, 1.95 3.68, 3.61  
E424 8.68 4.31 2.11, 1.96 2.36   
D425 8.36 4.64 2.73, 2.67    
D426 8.33 4.68 2.75, 2.61    
L427 7.80 4.18 1.64 1.59 0.90, 0.86  
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Table G:  1H Resonance Assignments (ppm) of the γ′peptide (No Phosphorylation) at 17°C.  In the 
presence of IIa, the peptide does not experience significant deviations in chemical shift. 
 
Residue NH CαH CβH CγH CδH CεH 
P410  4.41 2.46 2.08, 2.00 3.42, 3.39  
E411 8.84 4.25 1.94, 1.88 2.25, 2.19   
H412 8.64 5.00 3.23, 3.13  7.32  
P413  4.42 2.32 2.02, 1.95 3.74, 3.57  
A414 8.60 4.32 1.42    
E415 8.55 4.34 2.08, 1.98 2.31   
T416 8.19 4.31 4.16 1.13   
E417 8.46 4.26 1.96, 1.87 2.19, 2.14   
Y418 8.19 4.53 3.08, 2.92  7.13 6.81 
D419 8.30 4.57 2.68, 2.61    
S420 8.15 4.34 3.85, 3.80    
L421 8.15 4.19 1.45 1.27 0.87, 0.78  
YP422 8.10 ? 3.07, 2.81  7.14 6.81 
P423  4.42 2.26 2.00, 1.97 3.65, 3.55  
E424 8.59 4.28 2.08, 1.94 2.33   
D425 8.32 4.62 2.70, 2.64    
D426 8.32 4.66 2.74, 2.60    
L427 7.78 4.15 1.61 1.58 0.91, 0.86  
 
 
 
 
Table H:  1H Resonance Assignments (ppm) of the GpIbα peptide (YP276 YP279) bound to IIa at 17°C. 
 
 
 
 
 
 
 
Residue NH CαH CβH CγH CδH CεH 
D269 ? ? ?    
E270 8.95 4.27 2.30 2.06, 1.99   
G271 8.67 4.03, 3.96     
D272 8.14 4.69 2.75, 2.73    
T273 8.22 4.27 4.24 1.17   
D274 8.44 4.61 2.71, 2.63    
L275 8.13 4.25 1.52 1.44 0.87, 0.80  
YP276 8.14 4.50 2.99, 2.89  7.19 7.11 
D277 8.23 4.55 2.60, 2.54    
Y278 7.97 4.49 2.86  7.06 6.78 
YP279 8.20 4.75 3.05, 2.83  7.20 7.18 
P280  4.34 2.26 1.95 3.47  
E281 8.56 4.29 2.35 2.07, 1.97   
E282 8.49 4.31 2.29 2.05, 1.95   
D283 8.55 4.72 2.79, 2.66    
T284 8.22 4.37 4.29 1.22   
E285 8.46 4.36 2.31 2.13, 1.98   
G286 8.11 3.78     
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Table I:  1H Resonance Assignments (ppm) of the GpIbα peptide (No Phosphorylation) at 17°C. 
 
 
 
 
 
Table I:  1H Resonance Assignments (ppm) of the GpIbα peptide (No Phosphorylation) bound to IIa at 
17°C. 
 
 
 
 
Residue NH CαH CβH CγH CδH CεH 
D269 ? ? ?    
E270 8.94 4.28 2.31 2.07, 1.98   
G271 8.65 4.02, 3.96     
D272 8.13 4.68 2.75, 2.73    
T273 8.21 4.30 4.25 1.20   
D274 8.39 4.60 2.67, 2.64    
L275 8.04 4.25 1.47 1.40 0.87, 0.78  
Y276 8.05 4.52 3.00, 2.83  ? ? 
D277 8.15 4.54 2.57, 2.53    
Y278 7.82 4.47 2.88, 2.81  ? ? 
Y279 8.09 4.72 3.00, 2.77  ? ? 
P280  4.32 2.25 1.94 3.48, 3.43  
E281 8.48 4.27 2.34 2.07, 1.95   
E282 8.44 4.31 2.28 2.06, 1.93   
D283 8.51 4.72 2.79, 2.66    
T284 8.20 4.37 4.28 1.21   
E285 8.44 4.36 2.30 2.11, 1.97   
G286 8.08 3.77     
Residue NH CαH CβH CγH CδH CεH 
D269 ? ? ?    
E270 8.94 4.28 2.31 2.07, 1.98   
G271 8.64 4.04, 3.96     
D272 8.13 4.68 2.75, 2.73    
T273 8.19 4.30 4.25 1.20   
D274 8.39 4.60 2.67, 2.64    
L275 8.01 4.25 1.47 1.40 0.87, 0.78  
Y276 8.01 4.52 3.00, 2.83  7.04 6.77 
D277 8.15 4.54 2.57, 2.53    
Y278 7.82 4.47 2.88, 2.81  7.02 6.77 
Y279 8.02 4.72 3.00, 2.77  7.09 6.79 
P280  4.32 2.25 1.94 3.48, 3.43  
E281 8.47 4.27 2.34 2.07, 1.95   
E282 8.42 4.31 2.28 2.06, 1.93   
D283 8.48 4.72 2.79, 2.66    
T284 8.17 4.37 4.28 1.21   
E285 8.38 4.36 2.30 2.11, 1.97   
G286 8.07 3.77     
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APPENDIX B  INTER-RESIDUE NOE TABLE 
Table J:  Inter-residue NOEs for the γ′peptide (YP418YP422) bound to IIa at a mixing time of 400ms + 15°C. 
 
  Inter-Residue NOE 
Residue Proton NH CαH CβH CγH CδH CεH 
P410 CαH E411      
NH  P410     
CαH H412      E411 
CβH H412      
NH  E411 P413 E411  P413  
CαH     P413  
CβH A414    P413  H
412 
CδH     P413  
CαH H412 A414 E415  A414    
CγH A414      P413 
CδH H412A414 H412 H412  H412  
NH  P413 H412 E415 P413 E415 P413  
CαH E415      A414 
CβH E415 P413 E415 E415   
NH T416 P413 A414 A414    
CβH A414 T416  A414 T416   E415 
CγH A414 T416  A414 T416   
NH E415 E417  E415 E415   
CαH E417    YP418  
CβH E417      
T416 
CγH E417 YP418  E415 E415 YP418  
NH T416 YP418 T416 T416 T416   
CαH YP418  YP418  YP418  
CβH YP418    YP418  
E417 
CγH YP418    YP418  
NH E417 D419 E417 E417 T416 E417   
CβH D419 E417     YP418 
CδH D419 T416 E417 E417 D419 T416 E417 L421  
NH YP418  YP418  YP418  D419 CβH S420    YP418  
NH   D419    
CαH L421  L421 YP422  L421 YP422 YP422 S420 
CβH L421    YP422 YP422 
NH  S420 S420 YP422  YP422 YP422 
CαH YP422    YP422 YP422 
CβH  S420   YP422 YP422 
CγH     YP422 YP422 
L421 
CδH  S420   YP418 YP422 YP422 
NH  L421     
CβH L421 D425 S
420 P423 
E424  P
423 P423  
CδH L421 S
420 L421 
P423 D425 
S420 L421 
E424 
L421 P423 
E424 L
421 P423  
YP422 
CεH L421 S
420 L421 
P423 D425 S
420 L421 L421 L421 P423  
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Table J:  Inter-residue NOEs for the γ′peptide (YP418YP422) bound to IIa at a mixing time of 400ms + 15°C 
(continued). 
 
  Inter-Residue NOE 
Residue Proton NH CαH CβH C
γ
H C
δH CεH 
CαH E424 D425  YP422 E424  YP422 YP422 
CβH E424 D425      
CγH   YP422  YP422  
P423 
CδH   YP422  YP422 YP422 
NH D425 P423 P423    
CαH D425  YP422D425L427 
L42
7 L
427  
CβH D425 P423   YP422  
E424 
CγH D425    YP422  
NH E424 P423 E424 YP422 P423 E424 
E42
4   
CαH     YP422 YP422 
D425 
CβH  E424     
NH L427      
CαH L427  L427 L
42
7   D
426 
CβH L427      
NH D426 D426 D426    
CβH  E424D426     
CγH  E424D426     
L427 
 
CδH  E424     
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Table K:  Inter-residue NOEs for the γ′peptide (YP418) bound to IIa at a mixing time of 400ms + 15°C. 
 
  Inter-Residue NOE 
Residue Proton NH CαH CβH CγH CδH CεH 
P410 CαH E411      
NH  P410     
CαH H412      E411 
CβH H412      
NH  E411 P413 E411  P413  
CαH     P413  
CβH A414    P413  
H412 
CδH     P413  
CαH H412A414 E415  A414    P413 
CδH H412A414 H412 H412  H412  
NH  P413 H412  P413  
CαH E415      A414 
CβH E415 P413     
NH T416 P413 A414 A414 T416   
CβH T416      E415 
CγH T416      
NH E415 E417  E415 E415   
CαH E417    YP418 YP418 
CβH E417    YP418 YP418 
T416 
CγH E415E417YP418    YP418  
NH T416 YP418 T416 T416 T416 YP418  
CαH YP418  YP418  YP418 YP418 
CβH YP418    YP418  
E417 
CγH YP418    YP418  
NH E417 D419 E417 E417 T416 E417   
CβH D419 S420 E417     
CδH E417 D419 L421 T416 E417 T
416E417 D419 
S420 
T416 E417 
L421 L
421  
YP418 
CεH D419 T416E417 T416 S420    
NH YP418 S420  YP418  YP418 YP418 
CαH S420      D419 
CβH S420    YP418  
NH D419 D419 YP418D419    
CαH   L421 L421 L421 Y422 Y422 S420 
CβH L421    YP418Y422 
YP418
Y422 
NH   S420  YP418Y422 Y422 
CαH Y422    Y422 Y422 
CβH  S420 Y422   Y422 Y422 
CγH  S420   YP418 Y422 Y422 
L421 
CδH  S420   YP418 Y422 Y422 
NH  L421   P423  
CβH E424D425 L421P423   P423  
CδH L421 E424 D425 S
420L421 
P423E424D425 
S420 L421 
P423E424 L
421 P423  L421 P423  
Y422 
CεH L421 D425 S420L421E424  S420 L421 L421 L421 P423  
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Table K:  Inter-residue NOEs for the γ′peptide (YP418) bound to IIa at a mixing time of 400ms + 15°C 
(continued). 
 
  Inter-Residue NOE 
Residue Proton NH CαH CβH CγH CδH CεH 
CαH E424 D425  Y422 E424  Y422  
CβH E424 D425    Y422  
CγH     Y422  
P423 
CδH E424Y422  Y422  Y422 Y422 
NH D425 P423 Y422 P423  Y422 P423  
CαH D425  D425L427 L427 Y422L427  
CβH D425 P423   Y422  
E424 
CγH D425      
NH E424 P423 E424 Y422 P423 E424 E424 Y422 Y422 D425 CβH L427 E424   Y422  
NH L427      
CαH L427  L427 L427   D426 
CβH L427      
NH D426 D426 D425D426    
CβH  E424D426     
CγH  E424D426     L
427 
CδH  E424     
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Table L:  Inter-residue NOEs for the γ′peptide (YP422) bound to IIa at a mixing time of 400ms + 15°C. 
 
  Inter-Residue NOE 
Residue Proton NH CαH CβH CγH CδH CεH 
P410 CαH E411      
NH  P410     
CαH H412      E411 
CβH H412      
NH  E411 P413 E411  P413  
CαH     P413  
CβH A414    P413  H
412 
CδH     P413  
CαH H412 A414 E415  A414    
CγH A414      P413 
CδH H412A414 H412 H412  H412  
NH  P413 H412 E415 P413 E415 P413  
CαH E415      A414 
CβH E415 P413  E415   
NH T416 P413 A414 A414 T416   
CβH A414 T416   T416   E415 
CγH A414 T416  A414 T416   
NH E415 E417  E415 E415   
CαH E417    Y418 Y418 
CβH E417      
T416 
CγH E415 E417  E417 E415 E415 Y418 Y418 
NH T416  T416 T416 T416 Y418  
CαH Y418   T416 Y418 Y418 
CβH Y418    Y418 Y418 E
417 
CγH Y418    Y418 Y418 
NH D419 E417 E417 E417   
CβH D419      
CδH E417D419 T416 E417 E417 D419 T416 E417 L421  Y
418 
CεH D419 T416 E417 E417 T416 E417 L421  
NH Y418  Y418  Y418 Y418 
CαH S420      D419 
CβH S420    Y418  
NH  D419 D419    
CαH   L421 L421 L421 YP422  S420 
CβH L421    YP422 YP422 
NH   S420  YP422 YP422 
CαH     YP422  
CβH  S420   YP422 YP422 
CγH  S420   YP422 YP422 
L421 
CδH  S420   Y418 YP422 
Y418 
YP422 
CβH E424D425 P423   P423 P423  
CδH L421 E424D425 S
420 L421 
P423 D425 
S420 L421 
E424 
L421 P423 
E424 L
421 P423  YP422 
CεH L421 E424D425 P423  S420 L421 L421 L421 P423  
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Table L:  Inter-residue NOEs for the γ′peptide (YP422) bound to IIa at a mixing time of 400ms + 15°C 
(continued). 
 
  Inter-Residue NOE 
Residue Proton NH CαH CβH CγH CδH CεH 
CαH E424 D425  YP422E424  YP422 YP422 
CβH E424 D425      
CγH E424  YP422  YP422  
P423 
CδH   YP422  YP422 YP422 
NH D425 P423 YP422 P423 P423 YP422  YP422 
CαH D425  D425L427 L427 L427  
CβH D425 P423   YP422  
E424 
CγH D425    YP422  
NH E424 P423 E424 YP422 P423 E424 E424 YP422 YP422 
CαH     YP422  D425 
CβH L427 E424     
NH L427 D425 D425   YP422 
CαH L427  L427 L427   D426 
CβH L427      
NH D426 D426 D425D426    
CβH  E424D426     
CγH  E424D426     
L427 
CδH  E424     
 
Table M:  Inter-residue NOEs for 1). free γ′peptides and 2.) unphosphorylated γ′peptide in the presence of 
IIa at a mixing time of 400ms + 17°C.  There are not many significant differences in NOE assignments 
across this series of NMR experiments. 
 
  Inter-Residue NOE 
Residue Proton NH CαH CβH CγH CδH CεH 
E411 CαH H412      
NH  E411 P413     H412 
CαH     P413  
CαH H412 A414      P413 
CδH  H412     
NH  P413 P413    
CαH E415      A414 
CβH E415      
NH T416 A414 A414    E415 CβH T416      
NH E415  E415    
CαH E417      
CβH E417      T
416 
CγH E417      
NH Y418 T416 T416 T416   
CαH Y418      E417 
CβH Y418      
NH E417 E417 E417    
CαH D419      Y418 
CβH D419      
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Table M:  Inter-residue NOEs for 1). free γ′peptides and 2.) unphosphorylated γ′peptide in the presence of 
IIa at a mixing time of 400ms + 17°C.  There are not many significant differences in NOE assignments 
across this series of NMR experiments (continued). 
 
  Inter-Residue NOE 
Residue Proton NH CαH CβH CγH CδH CεH 
NH  Y418 Y418    
CαH S420      D419 
CβH S420      
NH  D419 D419    
CαH L421      S420 
CβH L421      
NH  S420 S420    
CαH Y422      
CβH Y422      L
421 
CγH Y422      
Y422 NH  L421 L421 L421   
CαH E424      P423 
CδH E424      
NH D425 P423  P423   
CαH D425      E424 
CβH D425      
NH E424 E424 E424    D425 CαH D426      
NH L427 D425     D426 CαH L427      
L427 NH D426 D426     
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APPENDIX C LIST OF FRAGMENTS FROM PEPTIC DIGESTS OF FXIII(a) and IIa 
 
Table N:  Peak listing of fragments from a peptic digest of human FXIII(a). 
 
Residues Theo. m/z Sequence Theo. Dmaxa 
4-20 1800.92 SRTAFGGRRAVPPNNSN 17.1 
19-33 1558.77 SNAAEDDLPTVELQG 13.6 
27-36 1038.58 PTVELQGVVP 7.4 
31-41 1151.69 LQGVVPRGVNL 9.5 
73-90 2212.24 KLIVRRGQSFYVQIDFSR 18.2 
75-84 962.55 IVRRGQSK 7.5 
88-99 1568.80 FSRPYDPRRDLF 11.9 
89-99 1421.73 SRPYDPRRDLF 10.9 
98-104 925.51 LFRVEYV 6.5 
100-111 1508.79 RVEYVIGRYPQE 11.8 
117-132 1680.93 IPVPIVSELQSGKWGA 13.5 
125-136 1317.74 LQSGKWGAKIVM 11.6 
133-145 1588.90 KIVMREDRSVRLS 13.0 
137-144 1030.58 REDRSVRL 7.9 
138-156 2101.13 EDRSVRLSIQSSPKCIVGK 18.1 
171-180 1176.56 RTSRNPETDT 8.9 
178-184 872.44 TDTYILF 6.4 
207-218 1339.65 NDIGVIFYGEVN 11.5 
220-230 1372.70 IKTRSWSYGQF 10.8 
240-247 1013.45 YVMDRAQM 7.5 
248-264 1712.94 DLSGRGNPIKVSRVGSA 15.9 
298-305 980.54 ILLEYRSS 7.5 
328-338 1216.70 LGIPARIVTNY 9.5 
364-372 1125.62 PVPIVSELQSG 8.4 
380-389 1132.58 MTRPDLPVGF 7.5 
380-391 1246.68 MTRPDLPVGFGG 9.5 
511-521 1281.59 VMKSRSNVDMD 10.7 
513-522 1198.55 KSRSNVDMDF 9.7 
526-546 2431.30 NAVLGKDFKLSITFRNNSHN 21.2 
535-541 850.48 LSITFRN 6.5 
576-592 1844.05 TLEPLSFKKEAVLIQAG 15.6 
607-614 949.51 FVTARINE 7.5 
607-619 1533.84 FVTARINETRDVL 12.8 
617-624 888.52 DVLAKQKS 7.5 
632-645 1484.88 IIIKVRGTQVVGSD 13.5 
632-646 1615.92 IIIKVRGTQVVGSDM 14.7 
aThe maximum number of exchangeable protons within the indicated peptide, assuming 100% 
deuteration.  This value accounts for all exchangeable backbone amide protons and a slight 
fraction of N-terminal, C-terminal, and side chain exchangeable protons that are dependent on 
the final percentage of D2O in solution under quench conditions (approximately 4.5%).  A fully 
deuterated peptide would theoretically have acquired this amount of deuterons.  All peaks were 
previously identified by Turner and Maurer (174). 
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Table O:  Peak listing of fragments from a peptic digest of bovine IIa. 
 
Residuesa Theo. m/z Sequence Theo. Dmaxb TCEPc 
-13 to -4 1254.54 TSEDHFQPFF 8.5 n 
-3 to 7 1924.92 NEKTFGAGEADCGLRPLF 16.9 y 
46-52 888.49 (L)ISDRNV(L) 6.6 n 
65-84 2586.48 LVRIGKHSRTRYERKVEKISM 21.8 n 
85-94 1317.78 LDKIYIHPRY 8.8 y 
85-96 1617.87 LDKIYIHPRYNW 10.9 y 
85-99 2102.12 LDKIYIHPRYNWKENL 15.2 n 
106-113 996.66 (L)KLKRPIE(L) 6.7 n 
106-116 1311.80 LKLKRPIELSD 9.8 n 
135-149D 2162.12 KGRVTGWGNRRETWTTSVA 19.4 n 
173-180 1018.55 RIRITDNM 7.8 n 
173-181 1165.62 RIRITDNMF 8.8 n 
202-207 1064.53 KSPYNNRW 6.8 n 
212-227 1788.80 IVSWGEGCDRDGKYGF 15.9 y 
aResidues are numbered according the chymotrypsin numbering scheme described in Chapter I.  
bThe maximum number of exchangeable protons within the indicated peptide, assuming 100% 
deuteration.  This value accounts for all exchangeable backbone amide protons and a slight fraction 
of N-terminal, C-terminal, and side chain exchangeable protons that are dependent on the final 
percentage of D2O in solution under quench conditions (approximately 4.5%).  A fully deuterated 
peptide would theoretically have acquired this amount of deuterons.  cIndicates whether IIa 
reduction by TCEP is required to observe fragment in mass spectrum.  Non-TCEP fragments were 
identified by Croy et al. (233) and TCEP fragments were identified by both Sabo et al. (167) and 
Koeppe and Komives (234). 
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APPENDIX D ABBREVIATIONS  
(In order of appearance) 
 
Shorthand notation for blood coagulation proteins: FXIII = Factor XIII, etc. 
Shorthand notation for activated blood coagulation proteins: FXIIIa=Factor XIIIa, etc 
 
TF Tissue Factor 
Gla γ-carboxyglutamic acid 
IIa Thrombin 
TFPI Tissue Factor Pathway Inhibitor 
vWF von Willebrand Factor 
PAR Protease Activated Receptor 
HK High Molecular Weight Kininogen 
PK Prekallikrein 
TAFI Thrombin Activatable Fibrinolysis Inhibitor 
PC Protein C 
GAG Glycosaminoglycan 
tPA Tissue-type Plasminogen Activator 
Gp Glycoprotein 
KD Dissociation Equilibrium Constant 
ABE Anion Binding Exosite 
LRR Leucine Rich Repeat 
Mac-I Macrophage Antigen-I 
FpA Fibrinopeptide A 
YS Sulfotyrosine 
TGase Transglutaminase 
NMR Nuclear Magnetic Resonance 
FXIIIaIIa Thrombin Activated FXIII 
FXIIIaCa Calcium Activated FXIII 
AT Antithrombin 
MALDI Matrix-Assisted Laser Desorption-Ionization 
TOF Time-of-Flight 
MS Mass Spectrometry 
1D One Dimensional 
2D Two Dimensional 
trNOESY Transferred Nuclear Overhauser Effect Spectroscopy 
HDX Hydrogen Deuterium Exchange 
DON 6-diazo-5-oxo-norleucine 
IAA Iodoacetamide 
FID Free Induction Decay 
T1 Spin-lattice Relaxation 
T2 Transverse Relaxation 
ω Resonance Frequency 
τc Rotational Correlation Time 
koff Dissociation Rate Constant 
TOCSY Total Correlation Spectroscopy 
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DE Delayed Extraction 
m/z Mass to Charge ratio 
α-CHCA α-cyano-4-hydroxycinnamic acid 
NEM N-ethylmaleimide 
AA Acetic Anhydride 
ku Unfolding Rate Constant 
kf Folding Rate Constant 
kop Local Unfolding Rate Constant 
kcl Local Folding Rate Constant 
kobs Observed Rate Constant 
TCEP Tris (2-carboxyethyl) phosphine 
PSD Post Source Decay 
YP Phosphotyrosine 
BSE Barium sulfate eluate 
EDTA Ethylenediaminetetraacetate 
MWCO Molecular Weight Cut-Off 
PPACK D-Phe-Arg-Pro-chloromethyl ketone 
TFA Trifluoroacetic acid 
AUC Analytical Ultracentrifugation 
KI Inhibition Equilibrium Constant 
IC50 Concentration Resulting in 50% Inhibition 
SV Sedimentation Velocity 
S Svedberg Constant 
DMSO Dimethylsulfoxide 
GDH Glutamate Dehydrogenase 
GEE Glycine ethyl ester 
NADH Nicotinamide adenine dinucleotide 
FXIII(a) Unactivated, Activated and Inhibited Factor XIII 
DMF Dimethyl formamide 
α2AP α2-antiplasmin 
AP Activation Peptide 
ITC Isothermal Calorimetry 
ΔH Enthalpy 
ΔG Gibbs Free Energy 
ΔS Entropy 
R Gas Constant 
T Absolute Temperature 
HSQC Heteronuclear Single Quantum Coherence 
PFG Pulsed Field-Gradient 
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